<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">mSystems</journal-id><journal-id journal-id-type="iso-abbrev">mSystems</journal-id><journal-id journal-id-type="pmc-domain-id">3105</journal-id><journal-id journal-id-type="pmc-domain">msys</journal-id><journal-id journal-id-type="publisher-id">msystems</journal-id><journal-title-group><journal-title>mSystems</journal-title></journal-title-group><issn pub-type="epub">2379-5077</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10134813</article-id><article-id pub-id-type="pmcid-ver">PMC10134813.1</article-id><article-id pub-id-type="pmcaid">10134813</article-id><article-id pub-id-type="pmcaiid">10134813</article-id><article-id pub-id-type="pmid">36861991</article-id><article-id pub-id-type="doi">10.1128/msystems.00927-22</article-id><article-id pub-id-type="publisher-id">00927-22</article-id><article-id pub-id-type="publisher-id">msystems.00927-22</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="article-attributes"><compound-subject><compound-subject-part content-type="code">editors-pick</compound-subject-part><compound-subject-part content-type="label">Editor's Pick</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="sss-taxonomy"><compound-subject><compound-subject-part content-type="code">special-series-ersars</compound-subject-part><compound-subject-part content-type="label">Special Series: Evolving Reviews on SARS-CoV-2 and COVID-19</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">host-microbial-interactions</compound-subject-part><compound-subject-part content-type="label">Host-Microbial Interactions</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Application of Traditional Vaccine Development Strategies to SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="no"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7688-1770</contrib-id><name name-style="western"><surname>Rando</surname><given-names initials="HM">Halie M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="no"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9668-3368</contrib-id><name name-style="western"><surname>Lordan</surname><given-names initials="R">Ronan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0208-3730</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="AJ">Alexandra J.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Naik</surname><given-names initials="A">Amruta</given-names></name><xref rid="aff7" ref-type="aff">
<sup>g</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8955-7582</contrib-id><name name-style="western"><surname>Wellhausen</surname><given-names initials="N">Nils</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Sell</surname><given-names initials="E">Elizabeth</given-names></name><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Kolla</surname><given-names initials="L">Likhitha</given-names></name><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><collab>COVID-19 Review Consortium</collab></contrib><contrib contrib-type="author" equal-contrib="no"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5324-9833</contrib-id><name name-style="western"><surname>Gitter</surname><given-names initials="A">Anthony</given-names></name><xref rid="aff8" ref-type="aff">
<sup>h</sup>
</xref><xref rid="aff9" ref-type="aff">
<sup>i</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="no"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8713-9213</contrib-id><name name-style="western"><surname>Greene</surname><given-names initials="CS">Casey S.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref><xref rid="aff10" ref-type="aff">
<sup>j</sup>
</xref><email>casey.s.greene@cuanchutz.edu</email></contrib><aff id="aff1">
<label>a</label>
<addr-line>Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA</addr-line>
</aff><aff id="aff2">
<label>b</label>
<addr-line>Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA</addr-line>
</aff><aff id="aff3">
<label>c</label>
<addr-line>Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, USA</addr-line>
</aff><aff id="aff4">
<label>d</label>
<addr-line>Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA</addr-line>
</aff><aff id="aff5">
<label>e</label>
<addr-line>Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA</addr-line>
</aff><aff id="aff6">
<label>f</label>
<addr-line>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA</addr-line>
</aff><aff id="aff7">
<label>g</label>
<addr-line>Children&#8217;s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA</addr-line>
</aff><aff id="aff8">
<label>h</label>
<addr-line>Department of Biostatistics and Medical Informatics, University of Wisconsin&#8212;Madison, Madison, Wisconsin, USA</addr-line>
</aff><aff id="aff9">
<label>i</label>
<addr-line>Morgridge Institute for Research, Madison, Wisconsin, USA</addr-line>
</aff><aff id="aff10">
<label>j</label>
<addr-line>Childhood Cancer Data Lab, Alex&#8217;s Lemonade Stand Foundation, Philadelphia, Pennsylvania, USA</addr-line>
</aff></contrib-group><contrib-group><contrib contrib-type="collab"><collab>The COVID-19 Review Consortium includes</collab></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Bansal</surname><given-names initials="V">Vikas</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Barton</surname><given-names initials="JP">John P.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Boca</surname><given-names initials="SM">Simina M.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Boerckel</surname><given-names initials="JD">Joel D.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Brueffer</surname><given-names initials="C">Christian</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Byrd</surname><given-names initials="JB">James Brian</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Capone</surname><given-names initials="S">Stephen</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Das</surname><given-names initials="S">Shikta</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Dattoli</surname><given-names initials="AA">Anna Ada</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Dziak</surname><given-names initials="JJ">John J.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Field</surname><given-names initials="JM">Jeffrey M.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ghosh</surname><given-names initials="S">Soumita</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Gitter</surname><given-names initials="A">Anthony</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Goel</surname><given-names initials="RR">Rishi Raj</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Greene</surname><given-names initials="CS">Casey S.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Guebila</surname><given-names initials="MB">Marouen Ben</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Himmelstein</surname><given-names initials="DS">Daniel S.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Hu</surname><given-names initials="F">Fengling</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Jadavji</surname><given-names initials="NM">Nafisa M.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Kamil</surname><given-names initials="JP">Jeremy P.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Knyazev</surname><given-names initials="S">Sergey</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Kolla</surname><given-names initials="L">Likhitha</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lee</surname><given-names initials="AJ">Alexandra J.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lordan</surname><given-names initials="R">Ronan</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lubiana</surname><given-names initials="T">Tiago</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lukan</surname><given-names initials="T">Temitayo</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>MacLean</surname><given-names initials="AL">Adam L.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Mai</surname><given-names initials="D">David</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Mangul</surname><given-names initials="S">Serghei</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Manheim</surname><given-names initials="D">David</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>McGowan</surname><given-names initials="LD">Lucy D&#8217;Agostino</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Meyer</surname><given-names initials="JG">Jesse G.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Mundo</surname><given-names initials="AI">Ariel I.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Naik</surname><given-names initials="A">Amruta</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Park</surname><given-names initials="Y">YoSon</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Perrin</surname><given-names initials="D">Dimitri</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Qi</surname><given-names initials="Y">Yanjun</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Rafizadeh</surname><given-names initials="DN">Diane N.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ramsundar</surname><given-names initials="B">Bharath</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Rando</surname><given-names initials="HM">Halie M.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ray</surname><given-names initials="S">Sandipan</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Robson</surname><given-names initials="MP">Michael P.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Rubinetti</surname><given-names initials="V">Vincent</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Sell</surname><given-names initials="E">Elizabeth</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Shinholster</surname><given-names initials="L">Lamonica</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Skelly</surname><given-names initials="AN">Ashwin N.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Sun</surname><given-names initials="Y">Yuchen</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Sun</surname><given-names initials="Y">Yusha</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Szeto</surname><given-names initials="GL">Gregory L.</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Velazquez</surname><given-names initials="R">Ryan</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jinhui</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wellhausen</surname><given-names initials="N">Nils</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Gilbert</surname><given-names initials="JA">Jack A.</given-names></name><aff>University of California San Diego</aff></contrib></contrib-group><author-notes><fn fn-type="COI-statement"><p>The authors declare a conflict of interest. Anthony Gitter filed a patent application with the Wisconsin Alumni Research Foundation related to classifying activated T cells.</p></fn><fn fn-type="equal"><p>Alexandra J. Lee, Amruta Naik, and Nils Wellhausen contributed similarly to this work. Author order was determined alphabetically.</p></fn></author-notes><pub-date publication-format="electronic" date-type="pub"><day>2</day><month>3</month><year>2023</year></pub-date><pub-date publication-format="electronic" date-type="collection"><season>Mar-Apr</season><year>2023</year></pub-date><volume>8</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">434448</issue-id><elocation-id>e00927-22</elocation-id><pub-history><event event-type="pmc-release"><date><day>02</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-17 12:25:42.567"><day>17</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Rando et al.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Rando et al.</copyright-holder><ali:free_to_read start_date="2023-03-02"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="msystems.00927-22.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="msystems.00927-22.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="ArXiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC9413721"><article-title>Application of Traditional Vaccine Development Strategies to SARS-CoV-2</article-title><date><day>23</day><month>1</month><year>2023</year></date><elocation-id>arXiv:2208.08907v2</elocation-id><source>ArXiv</source><pub-id pub-id-type="pmcid">PMC9413721</pub-id><pub-id pub-id-type="pmid">36034485</pub-id></related-article><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" xlink:title="review-article" journal-id="mSystems" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10134841"><article-title>The Coming of Age of Nucleic Acid Vaccines during COVID-19</article-title><volume>8</volume><issue>2</issue><date><day>2</day><month>3</month><year>2023</year></date><elocation-id>e00928-22</elocation-id><source>mSystems</source><pub-id pub-id-type="doi">10.1128/msystems.00928-22</pub-id><pub-id pub-id-type="pmcid">PMC10134841</pub-id><pub-id pub-id-type="pmid">36861992</pub-id></related-article><abstract><title>ABSTRACT</title><p>Over the past 150&#8201;years, vaccines have revolutionized the relationship between people and disease. During the COVID-19 pandemic, technologies such as mRNA vaccines have received attention due to their novelty and successes. However, more traditional vaccine development platforms have also yielded important tools in the worldwide fight against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A variety of approaches have been used to develop COVID-19 vaccines that are now authorized for use in countries around the world. In this review, we highlight strategies that focus on the viral capsid and outwards, rather than on the nucleic acids inside. These approaches fall into two broad categories: whole-virus vaccines and subunit vaccines. Whole-virus vaccines use the virus itself, in either an inactivated or an attenuated state. Subunit vaccines contain instead an isolated, immunogenic component of the virus. Here, we highlight vaccine candidates that apply these approaches against SARS-CoV-2 in different ways. In a companion article (H. M. Rando, R. Lordan, L. Kolla, E. Sell, et al., mSystems 8:e00928-22, 2023, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1128/mSystems.00928-22" ext-link-type="uri">https://doi.org/10.1128/mSystems.00928-22</ext-link>), we review the more recent and novel development of nucleic acid-based vaccine technologies. We further consider the role that these COVID-19 vaccine development programs have played in prophylaxis at the global scale. Well-established vaccine technologies have proved especially important to making vaccines accessible in low- and middle-income countries. Vaccine development programs that use established platforms have been undertaken in a much wider range of countries than those using nucleic acid-based technologies, which have been led by wealthy Western countries. Therefore, these vaccine platforms, though less novel from a biotechnological standpoint, have proven to be extremely important to the management of SARS-CoV-2.</p><p><bold>IMPORTANCE</bold> The development, production, and distribution of vaccines is imperative to saving lives, preventing illness, and reducing the economic and social burdens caused by the COVID-19 pandemic. Vaccines that use cutting-edge biotechnology have played an important role in mitigating the effects of SARS-CoV-2. However, more traditional methods of vaccine development that were refined throughout the 20th century have been especially critical to increasing vaccine access worldwide. Effective deployment is necessary to reducing the susceptibility of the world&#8217;s population, which is especially important in light of emerging variants. In this review, we discuss the safety, immunogenicity, and distribution of vaccines developed using established technologies. In a separate review, we describe the vaccines developed using nucleic acid-based vaccine platforms. From the current literature, it is clear that the well-established vaccine technologies are also highly effective against SARS-CoV-2 and are being used to address the challenges of COVID-19 globally, including in low- and middle-income countries. This worldwide approach is critical for reducing the devastating impact of SARS-CoV-2.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>live attenuated virus</kwd><kwd>review</kwd><kwd>subunit vaccines</kwd><kwd>vaccine equity</kwd><kwd>vaccines</kwd><kwd>virus-like particle</kwd><kwd>whole-virus vaccines</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award1"><funding-source id="GS1"><institution-wrap><institution>NIH Medical Scientist Training Program T32</institution></institution-wrap></funding-source><award-id>GM07170</award-id><principal-award-recipient><name name-style="western"><surname>Kolla</surname><given-names>Likhitha</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award2"><funding-source id="GS2"><institution-wrap><institution>John W. and Jeanne M. Rowe Center for Research in Virology</institution></institution-wrap></funding-source><principal-award-recipient><name name-style="western"><surname>Gitter</surname><given-names>Anthony</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award3"><funding-source id="GS3"><institution-wrap><institution>Gordon and Betty Moore Foundation (GBMF)</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000936</institution-id></institution-wrap></funding-source><award-id>GBMF 4552</award-id><principal-award-recipient><name name-style="western"><surname>Greene</surname><given-names>Casey S.</given-names></name></principal-award-recipient><principal-award-recipient><name name-style="western"><surname>Rando</surname><given-names>Halie M.</given-names></name></principal-award-recipient><principal-award-recipient><name name-style="western"><surname>Lee</surname><given-names>Alexandra J.</given-names></name></principal-award-recipient></award-group><award-group award-type="grant" id="award4"><funding-source id="GS4"><institution-wrap><institution>HHS | NIH | National Human Genome Research Institute (NHGRI)</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000051</institution-id></institution-wrap></funding-source><award-id>R01 HG010067</award-id><principal-award-recipient><name name-style="western"><surname>Greene</surname><given-names>Casey S.</given-names></name></principal-award-recipient><principal-award-recipient><name name-style="western"><surname>Rando</surname><given-names>Halie M.</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="0" count-type="supplementary-material"/><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="314"/><page-count count="32"/><word-count count="26800"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March/April 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>REVIEW</title><p>The development of vaccines is widely considered one of the most important medical advances in human history. Over the past 150&#8201;years, several approaches to vaccination have been developed and refined (<xref rid="B1" ref-type="bibr">1</xref>). The COVID-19 pandemic has produced unusual circumstances compared to past health crises, leading to differences in vaccine development strategies. As of 10 January 2023, there have been over 665,112,541 SARS-CoV-2 cases, and the virus has taken the lives of at least 6,711,446 people globally (E. Dong, H. Du, and L. Gardner, Lancet Infect Dis 20:533&#8211;534, 2020, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1016/S1473-3099(20)30120-1" ext-link-type="uri">https://doi.org/10.1016/S1473-3099(20)30120-1</ext-link>). One way in which the COVID-19 pandemic differs from prior global health crises is that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome was sequenced, assembled, and released very early in the course of the pandemic (January 2020). This genomic information has informed the biomedical response to this novel pathogen across several dimensions (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). All the same, vaccines have been developed since long before the concept of a virus or a viral genome was known, and as early as September 2020, there were over 180 vaccine candidates against SARS-CoV-2 in development, many of which employed more traditional vaccine technologies (<xref rid="B4" ref-type="bibr">4</xref>). However, public attention in the United States and elsewhere has largely focused on vaccine development platforms that use new technologies, especially mRNA vaccines. We review vaccine technologies used for SARS-CoV-2 in two parts: here, the application of established vaccine development platforms to SARS-CoV-2, and separately, novel nucleic acid-based approaches (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Understanding vaccine development programs that are using well-established technologies is important for a global perspective on COVID-19. As of 2 December 2022, 50 SARS-CoV-2 vaccines have been approved for use in at least one country (<xref rid="B6" ref-type="bibr">6</xref>). A resource tracking the distribution of 28 vaccines indicates that as of 10 January 2023, 13.0 billion doses have been administered across 223 countries (<xref rid="B7" ref-type="bibr">7</xref>). Many of these vaccines use platforms that do not require information about the viral genome, with 20 developed using subunit and 11 using whole-virus approaches (<xref rid="B6" ref-type="bibr">6</xref>). The types of vaccines available vary widely throughout the world, as the process of developing and deploying a vaccine is complex and often requires coordination between government, industry, academia, and philanthropic entities (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Another difference between prior global health crises and the COVID-19 pandemic is the way that vaccines are evaluated. A vaccine&#8217;s success is often discussed in terms of vaccine efficacy (VE), which describes the protection conferred during clinical trials (<xref rid="B9" ref-type="bibr">9</xref>). The real-world protection offered by a vaccine is referred to as its effectiveness (<xref rid="B9" ref-type="bibr">9</xref>). Additionally, protection can mean different things in different contexts. In general, the goal of a vaccine is to prevent disease, especially severe disease, rather than infection itself. As a proxy for VE, vaccine developers often test their candidates for serum neutralizing activity, which has been proposed as a biomarker for adaptive immunity in other respiratory illnesses (<xref rid="B10" ref-type="bibr">10</xref>). The duration and intensity of the COVID-19 pandemic have made it possible to test multiple vaccines in phase III trials, in which the effect of the vaccines on a cohort&#8217;s likelihood of contracting SARS-CoV-2 can be evaluated, whereas this has not always been feasible for other infectious diseases. In some cases (e.g., SARS), the pathogen has been controlled before vaccine candidates were available, while in others (e.g., Middle East respiratory syndrome [MERS]), the scale of the epidemic has been smaller. Vaccine development is traditionally a slow process, but the urgency of the COVID-19 pandemic created an atypical vaccine development ecosystem in which fast development and production were prioritized. Estimates of VE have been released for many vaccine candidates across a number of technology types based on phase III trial data.</p><p>However, efficacy is not a static value, and both trial efficacy and real-world effectiveness can vary across location and over time. Shifts in effectiveness in particular have been an especially heightened topic of concern since late 2021 given the potential for variants of SARS-CoV-2 to influence VE. Due to viral evolution, vaccine developers are in an arms race with a pathogen that benefits from mutations that reduce its susceptibility to adaptive immunity. The evolution of several variants of concern (VOC) presents significant challenges for vaccines developed based on the index strain identified in Wuhan, China, in late 2019. We discuss these variants in depth elsewhere (<xref rid="B11" ref-type="bibr">11</xref>). To date, the most significant VOC identified are Alpha (2020), Beta (2020), Gamma (2020), Delta (2021), and Omicron (2021), with various subvariants of Omicron being the most recently identified (2022). The relative timing of studies relative to dominant VOC in the region where participants are recruited is important context for a complete picture of efficacy. Therefore, the efficacy and/or effectiveness of vaccines in the context of these variants is discussed where information is available.</p><p>Beyond the variability introduced by time and geography, efficacy within a trial and effectiveness in the real-world setting can also differ due to cohort differences. Patients participating in a clinical trial are likely to receive more medical oversight, resulting in better follow-up, adherence, and patient engagement (<xref rid="B12" ref-type="bibr">12</xref>). Additionally, the criteria for participant inclusion in a trial often bias trials toward selection of younger, healthier individuals (<xref rid="B13" ref-type="bibr">13</xref>). The ability of an randomized controlled trial (RCT) to accurately assess safety can be biased by the fact that a clinical trial might not reveal rare adverse events (AEs) that might become apparent on a larger scale (<xref rid="B13" ref-type="bibr">13</xref>). Therefore, while clinical trials are the gold standard for evaluating vaccines for COVID-19, the results of these trials must be considered in a broader context when real-world data are available.</p><p>While the relationship between a vaccine and a pathogen is not static, the data clearly demonstrate that a variety of efficacious vaccines have been developed against SARS-CoV-2. Here, we discuss a selection of programs that use well-established vaccine biotechnologies. These programs have been undertaken worldwide, in complement to the more cutting-edge approaches developed and distributed in the United States, the European Union, the United Kingdom, and Russia (<xref rid="B5" ref-type="bibr">5</xref>). In this review, we discuss vaccine development using two well-established technologies, whole-virus vaccination and subunit vaccination, and the role these technologies have played in the global response to the COVID-19 pandemic.</p></sec><sec id="s2"><title>WHOLE-VIRUS VACCINES</title><p>Whole-virus vaccines have the longest history among vaccine development approaches. Variolation, which is widely considered the first vaccination strategy in human history, is one example (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Famously, variolation was employed against smallpox when healthy individuals were exposed to pus from an individual infected with what was believed to be either cowpox or horsepox (<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">&#8211;</xref><xref rid="B17" ref-type="bibr">17</xref>). This approach worked by inducing a mild case of a disease. Therefore, while whole-virus vaccines confer adaptive immunity, they also raise safety concerns (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>). As of 2005, most vaccines still used whole-virus platforms (<xref rid="B20" ref-type="bibr">20</xref>), and these technologies remain valuable tools in vaccine development today (<xref rid="B1" ref-type="bibr">1</xref>). Whole-virus vaccine candidates have been developed for COVID-19 using both live attenuated viruses and inactivated whole viruses (IWVs).</p><sec id="s2-1"><title>Live attenuated virus vaccines.</title><p>Live attenuated virus vaccines (LAVs), also known as replication-competent vaccines, use a weakened, living version of a disease-causing virus or a version of a virus that is modified to induce an immune response (<xref rid="B4" ref-type="bibr">4</xref>). Whether variolation is the first example of a LAV being used to induce immunity is debated (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B18" ref-type="bibr">18</xref>). The first deliberate (albeit pathogen-naive) attempt to develop an attenuated viral vaccine dates back to Louis Pasteur&#8217;s efforts in 1885 to inoculate a child against rabies (<xref rid="B21" ref-type="bibr">21</xref>). The next intentional LAVs were developed against the yellow fever virus in 1935 and influenza in 1936 (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>Early efforts in LAV development relied on either the identification of a related virus that was less virulent in humans (e.g., cowpox/horsepox or rotavirus vaccines) or the culturing of a virus <italic toggle="yes">in vitro</italic> (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Today, a virus can be attenuated by passaging it in a foreign host until, due to selection pressure, the virus loses its efficacy in the original host. Alternatively, selective gene deletion or codon deoptimization can be utilized to attenuate the virus (<xref rid="B4" ref-type="bibr">4</xref>), or foreign antigens can be integrated into an attenuated viral vector (<xref rid="B23" ref-type="bibr">23</xref>). LAVs tend to be restricted to viral replication in the tissues around the location of inoculation (<xref rid="B22" ref-type="bibr">22</xref>), and some can be administered intranasally (<xref rid="B4" ref-type="bibr">4</xref>).</p><p>Today, LAVs are used globally to prevent diseases caused by viruses such as poliovirus and measles, mumps, rubella, influenza, varicella-zoster, and yellow fever viruses (<xref rid="B24" ref-type="bibr">24</xref>). There were attempts to develop LAVs against both SARS-CoV-1 and MERS-CoV (<xref rid="B25" ref-type="bibr">25</xref>), but no vaccines were approved. It is generally recognized that LAVs induce an immune response similar to natural infection, and they are favored because they induce long-lasting and robust immunity that can protect from disease. This strong protective effect is induced in part by the immune response to the range of viral antigens available from LAVs, which tend to be more immunogenic than those from nonreplicating vaccines (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>).</p></sec><sec id="s2-2"><title>LAVs and COVID-19.</title><p>To date, LAVs have not been widely deployed against SARS-CoV-2 and COVID-19. All the same, there are several COVID-19 LAV candidates in the early (preclinical/phase I) stages of investigation. These candidates utilize different approaches. Interestingly, several candidates (Meissa Vaccines&#8217; MV-014-212 and Codagenix&#8217;s COVI-VAC, specifically) are administered intranasally, potentially improving accessibility by eliminating the need for sterile needles and reducing manufacturing costs, targeting conferring mucosal immunity, and reducing some issues related to vaccine hesitancy (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Additionally, although no phase III trial data are available for LAV candidates, some manufacturers have proactively sought to respond to the emergence of VOC. Therefore, the original approach to vaccination may still prove extremely advantageous in the high-tech landscape of COVID-19 vaccine development.</p><p><bold>(i) YF-S0.</bold> One candidate in the preclinical stage is YF-S0, a single-dose LAV developed at Belgium&#8217;s Katholieke Universiteit Leuven that uses live attenuated yellow fever virus 17D (YF17D) as a vector for a noncleavable prefusion conformation of the spike (S) antigen of SARS-CoV-2 (<xref rid="B23" ref-type="bibr">23</xref>). YF-S0 induced a robust immune response in three animal models and prevented SARS-CoV-2 infection in macaques and hamsters (<xref rid="B23" ref-type="bibr">23</xref>). Additionally, the protective effect of YF-S0 against VOC has been investigated in hamsters (<xref rid="B29" ref-type="bibr">29</xref>). Even for a small number of hamsters that developed breakthrough infections after exposure to the index strain or the Alpha variant, viral loads were very low (<xref rid="B29" ref-type="bibr">29</xref>). However, much higher rates of breakthrough infection and higher viral loads were observed when the hamsters were exposed to the Beta variant (<xref rid="B29" ref-type="bibr">29</xref>). Reduced seroconversion and neutralizing antibody (nAb) titers were also observed against the Beta and Gamma variants (<xref rid="B29" ref-type="bibr">29</xref>). As a result, a modified version of YF-S0, called YF-S0*, was developed to include a modified spike protein intended to increase immunogenicity by including the full spectrum of amino acids found in the Gamma VOC as well as stabilizing the S protein&#8217;s conformation (<xref rid="B29" ref-type="bibr">29</xref>). The updated vaccine was again tested in Syrian golden hamsters (<xref rid="B29" ref-type="bibr">29</xref>). No breakthrough infections were observed following vaccination with YF-S0* and exposure to the index strain and the Alpha, Beta, Gamma, and Delta variants (<xref rid="B29" ref-type="bibr">29</xref>). YF-S0* also reduced the infectious viral load in the lungs of several VOC (Alpha, Beta, Gamma, and Delta) relative to a sham comparison (<xref rid="B29" ref-type="bibr">29</xref>), and the likelihood of the Delta variant spreading to unvaccinated cohoused hamsters was significantly reduced by YF-S0* (<xref rid="B29" ref-type="bibr">29</xref>). The updated vaccine was also associated with the increased production of nAbs against the Omicron variant compared to YF-S0 (<xref rid="B29" ref-type="bibr">29</xref>).</p><p><bold>(ii) COVI-VAC.</bold> Other programs are developing codon-deoptimized LAV candidates (<xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">&#8211;</xref><xref rid="B32" ref-type="bibr">32</xref>). This approach follows the synthetic attenuated virus engineering (SAVE) strategy to select codon substitutions that are suboptimal for the virus (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). New York-based Codagenix and the Serum Institute of India reported a successful preclinical investigation (<xref rid="B32" ref-type="bibr">32</xref>) of an intranasally administered deoptimized SARS-CoV-2 LAV known as COVI-VAC, and COVI-VAC entered phase I human trials and was used to dose the first participants in January 2021 (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B34" ref-type="bibr">34</xref>). This vaccine is optimized through the removal of the furin cleavage site (see reference <xref rid="B2" ref-type="bibr">2</xref> for a discussion of this site&#8217;s importance) and deoptimization of 283 codons (<xref rid="B35" ref-type="bibr">35</xref>). The results of the COVI-VAC phase I human trials are expected soon (<xref rid="B34" ref-type="bibr">34</xref>).</p><p>Other results suggest both potential benefits and risks to the COVI-VAC vaccine candidate. Preclinical results suggest that the vaccine candidate may confer some protection against VOC even though it was designed based on the index strain: a poster reported that Syrian golden hamsters who received COVI-VAC were significantly less likely to lose weight following viral challenge with the Beta VOC (<xref rid="B35" ref-type="bibr">35</xref>). On the other hand, some concerns have arisen about the possibility of spillover from LAVs. A December 2022 study analyzed SARS-CoV-2 samples isolated from COVID-19 patients in India and identified two extremely similar sequences collected on 30 June 2020 that showed a high level of recombination relative to the dominant strains at the time (<xref rid="B36" ref-type="bibr">36</xref>). Comparing these samples to a database of SARS-CoV-2 sequences revealed that they were most similar to the sequence used for COVI-VAC (<xref rid="B36" ref-type="bibr">36</xref>). Based on phylogenetic reconstruction, the authors argued that these SARS-CoV-2 isolates were most likely to have spilled over from COVI-VAC trials (<xref rid="B36" ref-type="bibr">36</xref>). If this was a case of spillover, the effect seems to have been limited, as these sequences were just 2 among the more than 1,600 analyzed. However, these concerns may be one consideration in the development of LAV vaccines for COVID-19.</p><p><bold>(iii) Meissa Vaccines&#8217; MV-014-212.</bold> Another company, Meissa Vaccines in Kansas (USA), which also develops vaccines for respiratory syncytial virus (RSV), has developed an intranasal live attenuated chimeric vaccine, MV-014-212 (<xref rid="B37" ref-type="bibr">37</xref>). Chimeric vaccines integrate genomic content from multiple viruses to create a more stable LAV (<xref rid="B38" ref-type="bibr">38</xref>). To develop a SARS-CoV-2 vaccine candidate, Meissa Vaccines built on their prior work developing RSV vaccines (<xref rid="B37" ref-type="bibr">37</xref>). A live attenuated recombinant strain of RSV previously investigated as a vaccine candidate was modified to replace two surface glycoproteins with a chimeric protein containing components of the SARS-CoV-2 spike protein as well as the RSV fusion (F) protein (<xref rid="B37" ref-type="bibr">37</xref>). Preclinical results from the intranasal administration of MV-014-212 to African green monkeys and mice indicated that the vaccine candidate produced nAbs as well as a cellular immune response to SARS-CoV-2 challenge, including the Alpha, Beta, and Delta VOC (<xref rid="B37" ref-type="bibr">37</xref>). Enrollment for phase I human trials began in March 2021, and recruitment is ongoing (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B39" ref-type="bibr">39</xref>).</p><p><bold>(iv) Bacillus Calmette-Guerin vaccines.</bold> Finally, Bacillus Calmette-Guerin (BCG) vaccines that use LAVs are being investigated for the prophylaxis of COVID-19 (see online appendix [<xref rid="B40" ref-type="bibr">40</xref>]). The purpose of the BCG vaccine is to prevent tuberculosis, but nonspecific effects against other respiratory illnesses have suggested a possible benefit against COVID-19 (<xref rid="B41" ref-type="bibr">41</xref>). However, a multicenter trial that randomly assigned participants 60&#8201;years and older to vaccination with BCG (<italic toggle="yes">n&#8201;</italic>=&#8201;1,008) or a placebo (<italic toggle="yes">n&#8201;</italic>=&#8201;1,006) found that BCG vaccination had no effect on the incidence of SARS-CoV-2 or other respiratory infections over the course of 12&#8201;months (<xref rid="B42" ref-type="bibr">42</xref>). Despite these findings, BCG vaccination was associated with a stronger cytokine (specifically, interleukin 6 [IL-6]) response following <italic toggle="yes">ex vivo</italic> stimulation of peripheral blood mononuclear cells in patients with no known history of COVID-19 (<xref rid="B42" ref-type="bibr">42</xref>). Additionally, SARS-CoV-2-positive individuals who had received the BCG vaccine 1&#8201;year prior showed increased immunoglobulin (Ig) responses to the SARS-CoV-2 spike protein and receptor binding domain (RBD) relative to those in individuals who had received a placebo vaccine (<xref rid="B42" ref-type="bibr">42</xref>). Currently, investigations of BCG vaccines against COVID-19 are being sponsored by institutes in Australia in collaboration with the Bill and Melinda Gates Foundation (<xref rid="B43" ref-type="bibr">43</xref>) and by Texas A&amp;M University in collaboration with numerous other U.S. institutions (<xref rid="B44" ref-type="bibr">44</xref>).</p><p><bold>(v) Summary of LAV development.</bold> LAVs for COVID-19 have not advanced as far in development as vaccines developed using other technologies. As of December 2022, COVI-VAC was the only LAV candidate in phase III clinical trials (<xref rid="B45" ref-type="bibr">45</xref>). As a result, safety data are not yet available for human studies of these vaccines. In general, though, safety concerns previously associated with LAV have been largely mitigated in the modern manufacturing process. Manufacturers use safe and reliable methods to produce large quantities of vaccines once they have undergone rigorous preclinical studies and clinical trials to evaluate their safety and efficacy. However, one remaining safety concern may be contributing to the relatively slow emergence of LAV candidates against COVID-19: they still may present risk to individuals who are immunocompromised (<xref rid="B46" ref-type="bibr">46</xref>), which is an even greater concern when dealing with a novel virus and disease. Additional data are needed to ascertain how this technology performs in the case of SARS-CoV-2 and whether rare cases of spillover have indeed occurred. Additionally, modifications to the design of individual vaccine candidates may make this protection more robust as SARS-CoV-2 evolves, as the limited data about LAV performance against VOC suggest. Despite the long and trusted history of LAV development, this vaccine strategy has not been favored for COVID-19, as other technologies have shown greater expediency and safety compared to the time-consuming nature of developing LAVs for a novel virus.</p></sec></sec><sec id="s3"><title>INACTIVATED WHOLE-VIRUS VACCINES</title><p>Inactivated whole-virus (IWV) vaccines are another well-established vaccine platform. This platform uses full virus particles generally produced via cell culture that have been rendered noninfectious by chemical (i.e., formaldehyde or &#946;-propiolactone [<xref rid="B47" ref-type="bibr">47</xref>]) or physical (i.e., heat or UV radiation) means. In general, these vaccines mimic the key properties of the virus that stimulate a robust immune response, but the risk of adverse reactions is reduced because the virus is inactivated and thus unable to replicate. Though these viral particles are inactivated, they retain the capacity to prime the immune system. The size of the viral particle makes it ideal for uptake by antigen-presenting cells, which leads to the stimulation of helper T cells (<xref rid="B48" ref-type="bibr">48</xref>). Additionally, the array of epitopes on the surface of the virus increases antibody binding efficiency (<xref rid="B48" ref-type="bibr">48</xref>). The native conformation of the surface proteins, which is also important for eliciting an immune response, is preserved using these techniques (<xref rid="B49" ref-type="bibr">49</xref>). Membrane proteins, which support B cell responses to surface proteins, are also induced by this method (<xref rid="B50" ref-type="bibr">50</xref>).</p><p>IWV vaccines have been a valuable tool in efforts to control many viruses. Some targets of IWV vaccines have included influenza viruses, poliovirus, and hepatitis A virus. Inactivated vaccines can generally be generated relatively quickly once the pathogenic virus has been isolated and can be passaged in cell culture (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B51" ref-type="bibr">51</xref>). During COVID-19, though the World Health Organization (WHO) has been slower to approve IWV vaccine candidates than those developed with nucleic acid-based technologies, IWV vaccine development was also fast. In China, the first emergency use authorization (EUA) was granted to an IWV vaccine in July 2020, with full approval following that December (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>). The fact that these vaccines have not received as much public attention (at least in Western media) as nucleic acid vaccines for SARS-CoV-2 may be due at least in part to the novelty of nucleic acid vaccine technologies (<xref rid="B54" ref-type="bibr">54</xref>), which are more modular and immunogenic (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Past applications to human coronaviruses (HCoV) have focused predominantly on SARS-CoV-1. Preclinical studies have demonstrated that IWV SARS-CoV-1 vaccine candidates elicited immune responses <italic toggle="yes">in vivo</italic>. These vaccines generated nAb titers at concentrations similar to those evoked by recombinant protein vaccines (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Studies with ferrets and nonhuman primates demonstrated that IWV vaccines can offer protection against infection due to nAb and SARS-CoV-1-specific T cell responses (<xref rid="B56" ref-type="bibr">56</xref>). However, several attempts to develop IWV vaccines against both SARS-CoV-1 and MERS-CoV were hindered by incidences of vaccine-associated disease enhancement (VADE) in preclinical studies (<xref rid="B57" ref-type="bibr">57</xref>). In one example of a study with macaques, an inactivated SARS-CoV-1 vaccine induced even more severe lung damage than the virus due to an enhanced immune reaction (<xref rid="B58" ref-type="bibr">58</xref>). Independent studies with mice also demonstrated evidence of lung immunopathology due to VADE in response to MERS-CoV IWV vaccination (<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>). The exact mechanisms responsible for VADE remain elusive due to the specificity of the virus-host interactions involved, but VADE is the subject of investigation in preclinical SARS-CoV-2 vaccine studies to ensure the safety of any potential vaccines that may reach phase I trials and beyond (<xref rid="B57" ref-type="bibr">57</xref>).</p><sec id="s3-1"><title>Application to COVID-19.</title><p>Several whole-virus vaccines have been developed against COVID-19 and are available in countries around the world (<xref rid="tab1" ref-type="table">Table&#160;1</xref>). As of 10 January 2023, 10 vaccines developed with IWV technology are being distributed in 118 countries (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref>). Evidence of the value of these vaccines to combat SARS-CoV-2 is available not only from clinical trials but also from their rollout following approval. Here, a major consideration has been that vaccines often lose efficacy as mutations accumulate in the epitopes of the circulating virus; IWV vaccines may be particularly affected in such cases (<xref rid="B19" ref-type="bibr">19</xref>). This loss of specificity over time is likely to be influenced by the evolution of the virus and specifically by the rate of evolution in the region of the genome that codes for the antigenic spike protein. Here, we review three vaccine development programs and their successes in a real-world setting.</p><fig position="float" id="fig1" orientation="portrait"><label>FIG&#160;1</label><caption><p>Worldwide availability of vaccines developed using inactivated whole viruses. This figure reflects the number of vaccines based on whole inactivated virus technology that were available in each country as of 10 January 2023. These data are retrieved from Our World in Data (OWID) (<xref rid="B250" ref-type="bibr">250</xref>) and plotted using geopandas (<xref rid="B307" ref-type="bibr">307</xref>). The color scale is based on the number of vaccines of this type included in the OWID data set as a whole, not the maximum observed in a single country. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greenelab.github.io/covid19-review/" ext-link-type="uri">https://greenelab.github.io/covid19-review/</ext-link> for the most recent version of this figure, which is updated daily.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="msystems.00927-22-f001.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>TABLE&#160;1</label><caption><p>Inactivated whole-virus vaccines approved in at least one country (<xref rid="B311" ref-type="bibr">311</xref>) as of 2 December 2022 (<xref rid="B6" ref-type="bibr">6</xref>)</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Vaccine</th><th rowspan="1" colspan="1">Company</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Covaxin</td><td rowspan="1" colspan="1">Bharat Biotech</td></tr><tr><td rowspan="1" colspan="1">KoviVac</td><td rowspan="1" colspan="1">Chumakov Center</td></tr><tr><td rowspan="1" colspan="1">Turkovac</td><td rowspan="1" colspan="1">Health Institutes of Turkey</td></tr><tr><td rowspan="1" colspan="1">FAKHRAVAC (MIVAC)</td><td rowspan="1" colspan="1">Organization of Defensive Innovation and Research</td></tr><tr><td rowspan="1" colspan="1">QazVac</td><td rowspan="1" colspan="1">Research Institute for Biological Safety Problems</td></tr><tr><td rowspan="1" colspan="1">KCONVAC</td><td rowspan="1" colspan="1">Shenzhen Kangtai Biological Products Co.</td></tr><tr><td rowspan="1" colspan="1">COVIran Barekat</td><td rowspan="1" colspan="1">Shifa Pharmed Industrial Co.</td></tr><tr><td rowspan="1" colspan="1">Covilo</td><td rowspan="1" colspan="1">Sinopharm (Beijing, China)</td></tr><tr><td rowspan="1" colspan="1">Inactivated (Vero cells)</td><td rowspan="1" colspan="1">Sinopharm (Wuhan, China)</td></tr><tr><td rowspan="1" colspan="1">CoronaVac</td><td rowspan="1" colspan="1">Sinovac</td></tr><tr><td rowspan="1" colspan="1">VLA2001</td><td rowspan="1" colspan="1">Valneva</td></tr></tbody></table><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="msystems.00927-22-t001.jpg"/></alternatives></table-wrap><p><bold>(i) Sinovac&#8217;s CoronaVac.</bold> One IWV vaccine, CoronaVac, was developed by Sinovac, a biopharmaceutical company based in Beijing, China. The developers inactivated a SARS-CoV-2 strain collected in China with &#946;-propiolactone and propagated it using Vero cells (<xref rid="B25" ref-type="bibr">25</xref>). The vaccine is coupled with an aluminum adjuvant to increase immunogenicity (<xref rid="B25" ref-type="bibr">25</xref>). Administration follows a prime-boost regimen using a 0.5-mL dose containing 3&#8201;&#956;g of inactivated SARS-CoV-2 per dose (<xref rid="B61" ref-type="bibr">61</xref>). In phase I and II clinical trials, CoronaVac elicited a strong immunogenic response in animal models and the development of nAbs in human participants (<xref rid="B62" ref-type="bibr">62</xref><xref rid="B63" ref-type="bibr">&#8211;</xref><xref rid="B64" ref-type="bibr">64</xref>). The phase I/II clinical trials were conducted in adults 18 to 59&#8201;years old (<xref rid="B64" ref-type="bibr">64</xref>) and adults over 60&#8201;years old (<xref rid="B62" ref-type="bibr">62</xref>) in China. Safety analysis of the CoronaVac vaccine during the phase II trial revealed that most adverse reactions were either mild (grade 1) or moderate (grade 2) in severity (<xref rid="B64" ref-type="bibr">64</xref>). In adults aged 18 to 59&#8201;years receiving a variety of dosage schedules, site injection pain was consistently the most common symptom reported (<xref rid="B64" ref-type="bibr">64</xref>). In older adults, the most common local and systemic reactions were pain at the injection site (9%) and fever (3%) (<xref rid="B62" ref-type="bibr">62</xref>).</p><p>As of December 2022, a total of 17 CoronaVac trials had been registered in a variety of countries, including the Philippines and Hong Kong (<xref rid="B65" ref-type="bibr">65</xref>). Two of the earliest phase III trials to produce results examined a two-dose regimen of CoronaVac following a 14-day prime-boost regimen (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). These trials were conducted in Turkey (<xref rid="B67" ref-type="bibr">67</xref>) and Chile (<xref rid="B66" ref-type="bibr">66</xref>) and enrolled participants over an identical period from September 2020 and January 2021. The Chilean trial, which reported interim results regarding safety and immunogenicity, identified specific IgG nAbs against the S1 RBD, and a robust gamma interferon (IFN-&#947;)-secreting T cell response was induced via immunization with CoronaVac (<xref rid="B66" ref-type="bibr">66</xref>). In the Turkish trial, VE was estimated to be 83.5% against symptomatic COVID-19 (<xref rid="B67" ref-type="bibr">67</xref>). In the safety and immunogenicity study, minimal AEs were reported (<xref rid="B67" ref-type="bibr">67</xref>), and 18.9% of participants in the vaccine arm of the Turkish trial reported AEs, compared to 16.9% of participants in the placebo group (<xref rid="B67" ref-type="bibr">67</xref>). However, 2% (<italic toggle="yes">n&#8201;</italic>=&#8201;7) of Turkish participants aged 18 to 59 reported severe AEs (<xref rid="B62" ref-type="bibr">62</xref>), causing the trial to be halted for investigation (<xref rid="B68" ref-type="bibr">68</xref>). The investigation determined that these events were unrelated to the vaccine (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B68" ref-type="bibr">68</xref>).</p><p>An additional phase III trial was conducted in Brazil between July and December 2020 following a randomized, multicenter, endpoint-driven, double-blind, placebo-controlled design and enrolling nearly 10,000 health care workers (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>). The preprint reporting the results of this study (<xref rid="B70" ref-type="bibr">70</xref>) reports efficacies of 50.7% against symptomatic COVID-19 and 100% against moderate to severe cases. A large percentage of participants, 77.1% in the vaccine group and 66.4% in the placebo group, reported AEs, including two deaths, but all of the serious AEs were determined not to be related to the vaccine (<xref rid="B70" ref-type="bibr">70</xref>). CoronaVac also appears to be suitable for use in immunocompromised patients, such as those with autoimmune rheumatic diseases, according to phase IV trials (<xref rid="B71" ref-type="bibr">71</xref>), and the vaccine was also well tolerated and induced humoral responses in phase I trials in children aged 3 to 17&#8201;years, which will now be examined in phase II and III clinical trials (<xref rid="B72" ref-type="bibr">72</xref>).</p><p>Estimates of CoronaVac&#8217;s VE have varied across trials. The 50.7% VE reported from the Brazilian trial was contested by Turkish officials, as at the time the efficacy in the Turkish trial appeared to be 91.25% (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>). Ultimately, after multiple announcements, the efficacy debate was settled at over 50% (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>). Subsequently, the VE for the Turkish trial was finalized at 83.5% (<xref rid="B67" ref-type="bibr">67</xref>), and a prospective national cohort study in Chile reported an adjusted estimated effectiveness of 66% for the prevention of COVID-19, with an estimated 90% and 87% prevention of hospitalization and death, respectively (<xref rid="B75" ref-type="bibr">75</xref>).</p><p>Based on these results, CoronaVac was approved in China, and it has now been distributed in 66 countries across Africa, Asia, Europe, North America, and South America, including Brazil, Cambodia, Chile, Colombia, Laos, Malaysia, Mexico, Turkey, Ukraine, and Uruguay (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B76" ref-type="bibr">76</xref>). As of August 2021, Sinovac had reportedly produced over a billion doses of CoronaVac (<xref rid="B76" ref-type="bibr">76</xref>). Outside of trials, rare cases of VADE have been reported in association with the CoronaVac vaccine (<xref rid="B77" ref-type="bibr">77</xref>). In one case study, two male patients both presented with COVID-19 pneumonia following vaccination with CoronaVac (<xref rid="B77" ref-type="bibr">77</xref>). This study identified the timeline of disease presentation, vaccination, and known COVID-19 exposure in the two patients and suggested that the inflammatory response induced by the vaccine could have caused an asymptomatic case of COVID-19 to present with symptoms (<xref rid="B77" ref-type="bibr">77</xref>). However, no causal relationship between CoronaVac and COVID-19 symptom onset was evaluated, and the reports are extremely rare.</p><p>The effectiveness has also been questioned based on real-world data, such as when concerns were raised about the vaccine&#8217;s effectiveness following reports that over 350 doctors became ill with COVID-19 in Indonesia despite being immunized with CoronaVac (<xref rid="B78" ref-type="bibr">78</xref>). One possible explanation for such outbreaks was the evolution of the virus. Sera from individuals vaccinated with CoronaVac were found to show reduced neutralizing activity against the Alpha, Beta, and Delta VOC relative to the index strain (<xref rid="B79" ref-type="bibr">79</xref>). Similarly, a second study of 25 patients in Hong Kong in late 2021 evaluated serum neutralizing activity against the index strain, the Beta and Delta VOC, and two Omicron isolates (<xref rid="B80" ref-type="bibr">80</xref>). They reported that all individuals were seropositive for nAbs against the index strain, 68% against the Delta variant, and 0% against the Beta VOC and Omicron isolates (<xref rid="B80" ref-type="bibr">80</xref>). The Beta variant appears to be more resistant to nAbs in sera from individuals immunized with CoronaVac than the Alpha variant or wild-type virus, indicating that emerging variants may be of concern (<xref rid="B81" ref-type="bibr">81</xref>). Finally, a fourth study examined sera from 180 Thai health care workers vaccinated with CoronaVac and reported that neutralizing activity was significantly reduced against the Alpha, Delta, and Beta variants relative to the index strain (<xref rid="B82" ref-type="bibr">82</xref>). Together, these results suggest that viral evolution is likely to pose a significant challenge to immunity acquired from the CoronaVac vaccine.</p><p>Therefore, studies have also evaluated whether booster doses would provide additional protection to individuals vaccinated with CoronaVac. This strategy is supported by the fact that the antibody response elicited by CoronaVac has been found to wane following the second dose, though it was still detected 6&#8201;months out (<xref rid="B83" ref-type="bibr">83</xref>). A phase I/II clinical trial of CoronaVac in an elderly cohort (adults 60&#8201;years and older) in China determined that by 6 to 8&#8201;months following the second dose, nAb titers were detected below the seropositive cutoff (<xref rid="B84" ref-type="bibr">84</xref>). Data from two phase II trials indicated that the nAb response had declined 6&#8201;months after the second dose of the primary series, but a booster dose of CoronaVac administered 8&#8201;months after the second dose markedly increased geometric mean titers of SARS-CoV-2 nAbs (<xref rid="B85" ref-type="bibr">85</xref>). However, the reduction of nAbs was ameliorated by a booster dose administered 8&#8201;months after the second CoronaVac dose (<xref rid="B85" ref-type="bibr">85</xref>). Furthermore, Chinese (<xref rid="B86" ref-type="bibr">86</xref>) and Chilean (<xref rid="B87" ref-type="bibr">87</xref>) researchers have opted to investigate options to administer different vaccines (e.g., an mRNA vaccine dose) as a booster dose to individuals who have already received two doses of the IWV vaccine CoronaVac. Another study determined that using a virus-vectored vaccine (CanSino&#8217;s Convidecia) or an mRNA vaccine (Pfizer/BioNTech&#8217;s BNT162b2) instead of CoronaVac in a prime-boost vaccination regimen could induce a more robust immune response (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>). The WHO now suggests that a booster dose, either homologous or heterologous, can be considered 4 to 6&#8201;months after the primary series, especially for high-risk groups (<xref rid="B90" ref-type="bibr">90</xref>).</p><p><bold>(ii) Sinopharm&#8217;s Covilo.</bold> Two additional IWV vaccine candidates were developed following a similar approach by the state-owned China National Pharmaceutical Group Co., Ltd., more commonly known as Sinopharm CNBG. One, known as BBIBP-CorV or Covilo, was developed in Beijing using the HB02 variant of SARS-CoV-2. The other was developed at Sinopharm CNBG&#8217;s Wuhan Institute using the WIV04 variant of SARS-CoV-2 (<xref rid="B91" ref-type="bibr">91</xref>). The viruses were purified, propagated using Vero cells, isolated, and inactivated using &#946;-propiolactone (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>). Both vaccines are adjuvanted with aluminum hydroxide (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>). Here, we focus on Covilo.</p><p>Preclinical studies indicated that Covilo induced sufficient nAb titers in mice, and a prime-boost immunization scheme of 2&#8201;&#956;g/dose was sufficient to protect rhesus macaques from disease (<xref rid="B92" ref-type="bibr">92</xref>). In phase II trials, the Covilo vaccine appeared well tolerated, with 23% of participants in the vaccine condition (482 total participants; vaccine/placebo recipient ratio, 3:1) reporting at least one adverse reaction characterized as mild to moderate (<xref rid="B93" ref-type="bibr">93</xref>). No evidence of VADE was detected using this vaccine in phase II data (<xref rid="B94" ref-type="bibr">94</xref>). In phase III trials conducted between July and December 2020, Covilo achieved an efficacy of 72.8% and was well tolerated (<xref rid="B95" ref-type="bibr">95</xref>). However, questions were raised about efficacy when Sinopharm affiliates in the United Arab Emirates (UAE) in early December 2020 claimed the vaccine had 86% efficacy, which was at odds with a Sinopharm Beijing affiliate that stated later that same month that Covilo had a 79.34% efficacy (<xref rid="B96" ref-type="bibr">96</xref>).</p><p>Studies have also investigated expected differences in real-world effectiveness of Covilo given the continuing evolution of SARS-CoV-2. The antibody response elicited by Covilo was found to wane, but to still be detectable, by 6&#8201;months following the second dose (<xref rid="B83" ref-type="bibr">83</xref>). One study showed that the Alpha variant exhibited very little resistance to neutralization by sera of those immunized with Covilo, but the Beta variant was more resistant to neutralization by almost a factor of 3 (<xref rid="B81" ref-type="bibr">81</xref>). Another study examined sera from 282 participants and used a surrogate neutralizing assay, a test that generally correlates with nAbs, to determine that Covilo appears to induce nAbs against the binding of the RBD of wild-type SARS-CoV-2 and the Alpha, Beta, and Delta variants to ACE2 (<xref rid="B97" ref-type="bibr">97</xref>). Notably, a preprint reported that antisera (i.e., the antibody-containing component of the sera) from 12 people immunized with Covilo exhibited nAb capacity against the Beta variant (B.1.351), wild-type SARS-CoV-2 (NB02), and one of the original variants of SARS-CoV-2 (D614G) (<xref rid="B98" ref-type="bibr">98</xref>). As with many other vaccines, booster doses are being evaluated to mitigate some of the issues arising from viral evolution. A study of health care workers in China has since indicated that a booster shot of Covilo elevates B cell and T cell responses and increases nAb titers (<xref rid="B99" ref-type="bibr">99</xref>). In May 2021, the UAE announced that it would consider booster shots for all citizens who had been immunized with Covilo, which was shortly followed by a similar announcement in Bahrain, and by 29 August 2021, the UAE mandated booster shots for all residents who had received Covilo (<xref rid="B76" ref-type="bibr">76</xref>).</p><p><bold>(iii) Bharat Biotech&#8217;s Covaxin.</bold> Another IWV vaccine candidate was developed by Bharat Biotech International Ltd., which is the biggest producer of vaccines globally, in collaboration with the Indian Council of Medical Research (ICMR) National Institute of Virology (NIV). This candidate is known as Covaxin or BBV152. Preclinical studies of Covaxin in hamsters (<xref rid="B100" ref-type="bibr">100</xref>) and macaques (<xref rid="B101" ref-type="bibr">101</xref>) indicated that the vaccine induced protective responses deemed sufficient to move forward to human trials. Phase I (July 2020) and phase I/II (September to October 2020) studies indicated that Covaxin adjuvanted with alum and a Toll-like receptor 7/8 (TLR7/8) agonist was safe and immunogenic (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>). These two studies demonstrated that the vaccine induced significant humoral and cell-mediated responses, as assessed by measuring binding (<xref rid="B102" ref-type="bibr">102</xref>) and neutralizing (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>) antibodies, cytokines (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>), and CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells (<xref rid="B102" ref-type="bibr">102</xref>), with some formulations also eliciting Th1-skewed memory T cell responses (<xref rid="B103" ref-type="bibr">103</xref>). Only mild to moderate side effects were reported upon immunization (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>), and in phase II trials, the Covilo vaccine appeared to be well tolerated (<xref rid="B93" ref-type="bibr">93</xref>).</p><p>In India, the Covaxin vaccine received emergency authorization on 3 January 2021, but the phase III data were not released until 3 March 2021, and even then they were communicated via press release (<xref rid="B104" ref-type="bibr">104</xref>). This press release reported 80.6% efficacy in 25,800 participants (<xref rid="B104" ref-type="bibr">104</xref>, <xref rid="B105" ref-type="bibr">105</xref>), spurring Zimbabwe to follow suit and authorize the use of Covaxin (<xref rid="B106" ref-type="bibr">106</xref>). A detailed preprint describing the double-blind, randomized, controlled phase III trial that enrolled between November 2020 and January 2021 became available in July 2021, and the results collected as of 17 May 2021 were published in December 2021 (<xref rid="B107" ref-type="bibr">107</xref>). Based on a final enrollment of 25,798 people (vaccine/placebo recipient ratio, ~1:1), overall VE against symptomatic COVID-19 was estimated at 77.8% and VEs against severe disease and asymptomatic infection was reported as 93.4% and 63.6%, respectively (<xref rid="B107" ref-type="bibr">107</xref>). The vaccine was also reported to be well tolerated, with fewer severe events occurring in the Covaxin group (0.3%) than in the placebo group (0.5%) (<xref rid="B107" ref-type="bibr">107</xref>). One case of a serious AE potentially related to the vaccine, immune thrombocytopenic purpura, was reported, although this patient was seropositive for SARS-CoV-2 at the baseline observation point (<xref rid="B107" ref-type="bibr">107</xref>). As of 11 January 2023, Covaxin was approved for emergency use in 31 countries across Africa, Asia, Europe, and South America, including Guyana, India, Iran, Zimbabwe, Nepal, Mauritius, Mexico, Nepal, Paraguay, and Philippines (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>Like with all vaccines, the continued evolution of SARS-CoV-2 poses a challenge to the effectiveness of Covaxin. In this case, the phase III clinical trial did evaluate the efficacy of Covaxin in response to variants circulating in mid-2020 to late 2020 (<xref rid="B107" ref-type="bibr">107</xref>). In agreement with previous studies demonstrating that sera from individuals vaccinated with Covaxin efficiently neutralized the Alpha variant (B.1.1.7) and the Delta variant (B.1.617.2) (<xref rid="B109" ref-type="bibr">109</xref><xref rid="B110" ref-type="bibr">&#8211;</xref><xref rid="B111" ref-type="bibr">111</xref>), the phase III trial reported a 65.2% efficacy against the Delta variant (B.1.617.2) (<xref rid="B107" ref-type="bibr">107</xref>). Another study reported that sera from individuals immunized with Covaxin produced effective nAbs against the Delta variant and the so-called Delta plus variant (AY.1) (<xref rid="B109" ref-type="bibr">109</xref>). Indeed, sera obtained from Covaxin-boosted individuals (<italic toggle="yes">n&#8201;</italic>=&#8201;13) (<xref rid="B112" ref-type="bibr">112</xref>) and those who were vaccinated with Covaxin but recovered from a breakthrough infection (<italic toggle="yes">n&#8201;</italic>=&#8201;31) also neutralized the Omicron variant (<xref rid="B113" ref-type="bibr">113</xref>). Therefore, the data suggest that the vaccine does continue to confer protection against VOC.</p><p>The authorization of Covaxin has also offered opportunities to monitor how well the clinical trial results translate into a real-world setting. Additionally, an effort to monitor AEs and COVID-19 cases following vaccine rollout reported that most side effects were mild and that cases were rare, even though these data would seem to have been collected during the severe wave of COVID-19 brought on by the Delta VOC in India in early 2021; at the same time, the sample sizes were extremely small (<xref rid="B114" ref-type="bibr">114</xref>). Similarly, larger studies of adults (June to September 2021) (<xref rid="B115" ref-type="bibr">115</xref>) and adolescents (beginning in January 2022) (<xref rid="B116" ref-type="bibr">116</xref>) who received the vaccine outside a trial setting reported that safety was similar across age groups, with no severe AEs reported for adults and with no serious AEs reported for adolescents, although 0.9% (6 individuals) reported severe AEs. However, a much lower effectiveness (22 to 29%) was estimated in a real-world setting during an analysis of cases in health care workers from April to May 2021 (<xref rid="B117" ref-type="bibr">117</xref>). All the same, monitoring of hospitalized COVID-19 patients between April and June 2021 indicated that the vaccines were highly effective in preventing severe illness (<xref rid="B118" ref-type="bibr">118</xref>).</p><p>It is not yet clear what level of protection Covaxin offers beyond 6 to 8&#8201;months after the second vaccine; consequently, the potential requirement of a booster immunization is being explored (<xref rid="B119" ref-type="bibr">119</xref>). Furthermore, Bharat Biotech is considering other vaccine regimens, such as providing one initial immunization with Covaxin followed by two immunizations with its intranasal vaccine (BBV154) (<xref rid="B120" ref-type="bibr">120</xref>). U.S.-based Ocugen Inc., a codevelopment partner of Bharat Biotech, is leading the application for an EUA for Covaxin intended for the U.S. market. It has been reported that Bharat Biotech will soon release its phase II and III pediatric trial results (<xref rid="B121" ref-type="bibr">121</xref>).</p><p>However, the WHO approval of the Covaxin has been delayed (<xref rid="B122" ref-type="bibr">122</xref>), and in April 2022, the WHO suspended procurement of Covaxin due to concerns about deviation from good manufacturing practice in their production facilities (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>). All the same, no safety issues had been reported in association with this vaccine, and the suspension was unlikely to affect distribution given that Bharat Biotech had not been supplying doses through this mechanism (<xref rid="B125" ref-type="bibr">125</xref>). Clinical trials had recommenced in the United States as of May 2022 (<xref rid="B125" ref-type="bibr">125</xref>).</p></sec><sec id="s3-5"><title>Summary of IWV vaccine development.</title><p>In the past, problems that arose during the manufacturing of IWV vaccines could present safety issues, but oversight of the manufacturing process has helped to improve IWV vaccine safety (<xref rid="B126" ref-type="bibr">126</xref>). Nevertheless, the departure from norms necessitated by the COVID-19 crisis raised concerns about whether oversight would occur at prepandemic standards (<xref rid="B126" ref-type="bibr">126</xref>). In general, very few issues with safety have been reported for the IWV COVID-19 vaccines. Additionally, safety audits have proactively identified concerns, as demonstrated with the WHO&#8217;s suspension of Covaxin.</p><p>More concern has arisen around the issue of effectiveness due to the reduced neutralizing activity of IWV vaccines against VOC relative to the index strain. In several cases, estimates of VE have varied widely across different trials of a single vaccine. Such issues are likely to be exacerbated by spatiotemporal differences in viral evolution, though in the case of the very high estimate generated by the Turkish trial of CoronaVac (<xref rid="B67" ref-type="bibr">67</xref>), the design of the study may have inflated the VE estimate (<xref rid="B127" ref-type="bibr">127</xref>). Regardless, the authors of the original trial argued that all of the trials suggest a very high efficacy against severe disease (<xref rid="B128" ref-type="bibr">128</xref>), as is the case for all of the IWV vaccines discussed here. In addition to issues related to the evolution of SARS-CoV-2, it is important to consider the duration of immunity over time. With IWV vaccines, heterologous vaccine boosters are being considered in many cases. Today, the WHO has developed recommendations for booster immunization for several whole-virus vaccines. In some cases (Valneva-VLA2001 [<xref rid="B129" ref-type="bibr">129</xref>], Covaxin [<xref rid="B130" ref-type="bibr">130</xref>], Covilo [<xref rid="B131" ref-type="bibr">131</xref>], and Sinopharm-WIBP inactivated [Vero cell] [<xref rid="B132" ref-type="bibr">132</xref>]), boosters are recommended only for high-risk and high-priority groups (e.g., the immunocompromised and medical professionals, respectively), while for Sinovac&#8217;s CoronaVac (<xref rid="B90" ref-type="bibr">90</xref>), they are recommended more broadly. Studies are also investigating the effects of booster doses for other vaccines (<xref rid="B133" ref-type="bibr">133</xref><xref rid="B134" ref-type="bibr">&#8211;</xref><xref rid="B135" ref-type="bibr">135</xref>), though some are being investigated or deployed primarily as heterologous boosters in populations vaccinated with a different primary series (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B312" ref-type="bibr">312</xref>, <xref rid="B313" ref-type="bibr">313</xref>).</p><p>As new vaccines are approved by the WHO, more time elapses since many received the primary series, and new variants emerge, booster recommendations are likely to increase. Therefore, IWV vaccines have played an important role in vaccine access during the initial phase of vaccination against COVID-19, but many IWV vaccinees may receive booster doses developed with emergent vaccine technologies like DNA and mRNA. In head-to-head comparisons, these types of vaccines were typically found to outperform IWV vaccines (for examples, see references <xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B82" ref-type="bibr">82</xref>, and <xref rid="B136" ref-type="bibr">136</xref>). At the same time, IWV vaccines are among the easiest to store and transport due to requiring refrigeration only at 2 to 8&#176;C and remaining stable for years at a time (<xref rid="B95" ref-type="bibr">95</xref>). Therefore, these vaccines are likely to continue to play an important role in vaccine equity and accessibility.</p></sec></sec><sec id="s4"><title>SUBUNIT VACCINES</title><p>Efforts to overcome the limitations of live virus vaccines led to the development of approaches first to inactivate viruses (circa 1900), leading to IWV vaccines, and then to purify proteins from viruses cultured in eggs (circa 1920) (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B137" ref-type="bibr">137</xref>). The purification of proteins then set the stage for the development of subunit vaccines based on the principle that the immune system can be stimulated by introducing one or more proteins or peptides isolated from the virus. Today, such approaches often use antigens isolated from the surface of the viral particle that are key targets of the immune system (protein subunit vaccines). Advances in biological engineering have also facilitated the development of approaches like virus-like particle (VLP) vaccines using nanotechnology (<xref rid="B138" ref-type="bibr">138</xref>). VLPs share the conformation of a virus&#8217;s capsid, thereby acting as an antigen, but lack the replication machinery (<xref rid="B139" ref-type="bibr">139</xref>).</p><p>Unlike whole-virus vaccines, which introduce the whole virus, subunit vaccines stimulate the immune system by introducing one or more proteins or peptides of the virus that have been isolated. The main advantage of this platform is that subunit vaccines are considered very safe, as the antigen alone cannot cause an infection (<xref rid="B140" ref-type="bibr">140</xref>). Both protein subunit and VLP vaccines thus mimic the principle of whole-virus vaccines but lack the genetic material required for replication, removing the risk of infection (<xref rid="B141" ref-type="bibr">141</xref>). Protein subunit vaccines can stimulate antibodies and CD4<sup>+</sup> T cell responses (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B142" ref-type="bibr">142</xref>).</p><p>The subunit approach is also favored for its consistency in production. The components can be designed for a highly targeted immune response to a specific pathogen using synthetic immunogenic particles, allowing the vaccine to be engineered to avoid allergen and reactogenic sequences (<xref rid="B143" ref-type="bibr">143</xref>). One limitation is that, in the case of protein subunit vaccines, adjuvants are usually required to boost the immune response (<xref rid="B144" ref-type="bibr">144</xref>) (see online appendix [<xref rid="B40" ref-type="bibr">40</xref>]). Adjuvants, which are compounds that elicit an immunogenic effect, include alum (aluminum hydroxide), squalene- or saponin-based adjuvants, and Freund&#8217;s incomplete/complete adjuvants, although the last is avoided in human and veterinary medicine due to high toxicity (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B146" ref-type="bibr">146</xref>).</p><p>Protein subunit vaccine development efforts for both SARS-CoV-1 and MERS-CoV explored a variety of immunogens as potential targets. The search for a potential SARS-CoV-1 vaccine included the development of vaccines based on the full-length or trimeric S protein (<xref rid="B147" ref-type="bibr">147</xref><xref rid="B147" ref-type="bibr">&#8211;</xref><xref rid="B149" ref-type="bibr">149</xref>), those focused on the RBD protein only (<xref rid="B150" ref-type="bibr">150</xref><xref rid="B151" ref-type="bibr">&#8211;</xref><xref rid="B153" ref-type="bibr">153</xref>) or non-RBD S protein fragments (<xref rid="B148" ref-type="bibr">148</xref>, <xref rid="B154" ref-type="bibr">154</xref>), and those targeting the N and M proteins (<xref rid="B155" ref-type="bibr">155</xref><xref rid="B156" ref-type="bibr">&#8211;</xref><xref rid="B157" ref-type="bibr">157</xref>). These efforts have been thoroughly reviewed elsewhere (<xref rid="B158" ref-type="bibr">158</xref>). There have been examples of successful preclinical research including candidate RBD219N-1, a 218-amino-acid residue of the SARS-CoV-1 RBD that, when adjuvanted to aluminum hydroxide, was capable of eliciting a high antibody response of both nAbs and RBD-specific monoclonal antibodies in both pseudovirus and live virus infections of immunized mice (<xref rid="B159" ref-type="bibr">159</xref>).</p><p>Similarly to the SARS-CoV-1 vaccine candidates, the MERS-CoV protein subunit vaccine candidates generally target the RBD (<xref rid="B150" ref-type="bibr">150</xref>, <xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B160" ref-type="bibr">160</xref><xref rid="B161" ref-type="bibr">&#8211;</xref><xref rid="B163" ref-type="bibr">163</xref>), with some targeting the full-length S protein (<xref rid="B164" ref-type="bibr">164</xref>), non-RBD protein fragments such as the SP3 peptide (<xref rid="B165" ref-type="bibr">165</xref>), and the recombinant N-terminal domain (rNTD) (<xref rid="B166" ref-type="bibr">166</xref>). Other strategies for the potential use of the full-length S DNA have also been investigated with mice and rhesus macaques and elicited immune responses (<xref rid="B167" ref-type="bibr">167</xref>), but these responses were not as effective as the combination of S DNA and the S1 subunit protein together (<xref rid="B167" ref-type="bibr">167</xref>, <xref rid="B168" ref-type="bibr">168</xref>). No protein subunit vaccine for MERS-CoV has progressed beyond preclinical research to date. VLPs have been investigated for development of vaccines against MERS and SARS (<xref rid="B169" ref-type="bibr">169</xref>, <xref rid="B170" ref-type="bibr">170</xref>), including testing in animal models (<xref rid="B171" ref-type="bibr">171</xref>, <xref rid="B172" ref-type="bibr">172</xref>), but once again, only preclinical data for HCoV have been collected (<xref rid="B173" ref-type="bibr">173</xref>). However, protein subunit vaccines do play a role in public health and have contributed to vaccination against hepatitis B (<xref rid="B174" ref-type="bibr">174</xref>) and pertussis (<xref rid="B175" ref-type="bibr">175</xref>, <xref rid="B176" ref-type="bibr">176</xref>) since the 1980s and human papillomavirus since 2006 (<xref rid="B177" ref-type="bibr">177</xref>). They are likely to continue to contribute to public health for the foreseeable future due to ongoing research in vaccines against influenza, SARS-CoV-2, Epstein-Barr virus, dengue virus, and human papillomavirus, among others (<xref rid="B178" ref-type="bibr">178</xref><xref rid="B179" ref-type="bibr">&#8211;</xref><xref rid="B180" ref-type="bibr">180</xref>).</p><sec id="s4-1"><title>Application to COVID-19.</title><p>The development of subunit vaccines against SARS-CoV-2 is a remarkable achievement given the short period of time since the emergence of SARS-CoV-2 in late 2019, particularly considering that these types of vaccines have not played a major role in previous pandemics compared to LAV and IWV vaccines. More than 20 protein subunit vaccines from companies such as Sanofi/GlaxoSmithKline, Nanogen, and the Serum Institute of India have entered clinical trials for COVID-19 since the beginning of the pandemic (<xref rid="B179" ref-type="bibr">179</xref>), 20 have been approved, and at least 9 are being administered worldwide (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>) (<xref rid="tab2" ref-type="table">Table&#160;2</xref>). As of 10 January 2023, protein subunit vaccines are being distributed in at least 42 countries (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>).</p><fig position="float" id="fig2" orientation="portrait"><label>FIG&#160;2</label><caption><p>Worldwide availability of vaccines developed using protein subunit. This figure reflects the number of vaccines based on protein subunit technology that were available in each country as of 10 January 2023. These data are retrieved from Our World in Data (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B249" ref-type="bibr">249</xref>) and plotted using geopandas (<xref rid="B306" ref-type="bibr">306</xref>). The color scale is based on the number of vaccines of this type included in the OWID data set as a whole, not the maximum observed in a single country. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greenelab.github.io/covid19-review/" ext-link-type="uri">https://greenelab.github.io/covid19-review/</ext-link> for the most recent version of this figure, which is updated daily.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="msystems.00927-22-f002.jpg"/></fig><table-wrap position="float" id="tab2" orientation="portrait"><label>TABLE&#160;2</label><caption><p>Subunit vaccines approved for use in at least one country (<xref rid="B310" ref-type="bibr">310</xref>) as of 2 December 2022 (<xref rid="B6" ref-type="bibr">6</xref>)</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Vaccine</th><th rowspan="1" colspan="1">Company</th><th rowspan="1" colspan="1">Platform</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Zifivax</td><td rowspan="1" colspan="1">Anhui Zhifei Longcom</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Noora</td><td rowspan="1" colspan="1">Bagheiat-allah University of Medical Sciences</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Corbevax</td><td rowspan="1" colspan="1">Biological E. Limited</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Abdala</td><td rowspan="1" colspan="1">Center for Genetic Engineering and Biotechnology (CIGB)</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Soberana 02</td><td rowspan="1" colspan="1">Instituto Finlay de Vacunas Cuba</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Soberana Plus</td><td rowspan="1" colspan="1">Instituto Finlay de Vacunas Cuba</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">V-01</td><td rowspan="1" colspan="1">Livzon Mabpharm Inc.</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Covifenz</td><td rowspan="1" colspan="1">Medicago</td><td rowspan="1" colspan="1">VLP</td></tr><tr><td rowspan="1" colspan="1">MVC-COV1901</td><td rowspan="1" colspan="1">Medigen</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Recombinant SARS-CoV-2 (CHO cell)</td><td rowspan="1" colspan="1">National Vaccine and Serum Institute</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Nuvaxovid</td><td rowspan="1" colspan="1">Novavax</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">IndoVac</td><td rowspan="1" colspan="1">PT Bio Farma</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Razi Cov Pars</td><td rowspan="1" colspan="1">Razi Vaccine and Serum Research Institute</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">VidPrevtyn Beta</td><td rowspan="1" colspan="1">Sanofi/GSK</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">COVOVAX (Novavax formulation)</td><td rowspan="1" colspan="1">Serum Institute of India</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">SKYCovione</td><td rowspan="1" colspan="1">SK Bioscience Co. Ltd.</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">TAK-019 (Novavax formulation)</td><td rowspan="1" colspan="1">Takeda</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">SpikoGen</td><td rowspan="1" colspan="1">Vaxine/CinnaGen Co.</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">Aurora-CoV</td><td rowspan="1" colspan="1">Vector State Research Center of Virology and Biotechnology</td><td rowspan="1" colspan="1">Protein subunit</td></tr><tr><td rowspan="1" colspan="1">EpiVacCorona</td><td rowspan="1" colspan="1">Vector State Research Center of Virology and Biotechnology</td><td rowspan="1" colspan="1">Protein subunit</td></tr></tbody></table><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="msystems.00927-22-t002.jpg"/></alternatives></table-wrap><p>VLP vaccines have not progressed as rapidly. Programs seeking to develop VLP vaccines have used either the full-length S protein or the RBD of the S protein specifically as an antigen, although some use several different SARS-CoV-2 proteins (<xref rid="B140" ref-type="bibr">140</xref>). As of 10 January 2023, only one VLP vaccine was available in one country (Canada) (<xref rid="B7" ref-type="bibr">7</xref>).</p></sec><sec id="s4-2"><title>Novavax&#8217;s Nuvaxovid.</title><p>NVX-CoV2373, also known as Nuvaxovid or Covovax (<xref rid="B181" ref-type="bibr">181</xref>), is a protein subunit vaccine for SARS-CoV-2 produced by the U.S. company Novavax and partners. Nuvaxovid is a protein nanoparticle vaccine constructed from a mutated prefusion SARS-CoV-2 spike protein in combination with a specialized saponin-based adjuvant to elicit an immune response against SARS-CoV-2 (<xref rid="B182" ref-type="bibr">182</xref>). The spike protein is recombinantly expressed in Sf9 insect cells (<xref rid="B183" ref-type="bibr">183</xref>), which have previously been used for several other FDA-approved protein therapeutics (<xref rid="B184" ref-type="bibr">184</xref>), and contains mutations in the furin cleavage site (682-RRAR-685 to 682-QQAQ-685) along with two proline substitutions (K986P and V987P) that stabilize the protein (<xref rid="B185" ref-type="bibr">185</xref>), including improving thermostability (<xref rid="B183" ref-type="bibr">183</xref>).</p><p>In preclinical mouse models, Nuvaxovid elicited high anti-spike IgG titers 21 to 28&#8201;days postvaccination that could neutralize SARS-CoV-2 and protect the animals against viral challenge, with particularly strong effects when administered with the proprietary adjuvant Matrix-M (<xref rid="B183" ref-type="bibr">183</xref>). In a phase I/II trial, a two-dose regimen of Nuvaxovid was found to induce anti-spike IgG levels and nAb titers exceeding those observed in convalescent-phase plasma donated by symptomatic patients (<xref rid="B182" ref-type="bibr">182</xref>). In line with the preclinical studies, the use of Matrix-M adjuvant further increased anti-spike immunoglobulin levels and induced a Th1 response.</p><p>In a phase III randomized, observer-blinded, placebo-controlled clinical trial in the United Kingdom, 14,039 participants received two 5-&#956;g doses of Nuvaxovid or a placebo administered 21&#8201;days apart in a 1:1 ratio from late September to late November 2020 (<xref rid="B186" ref-type="bibr">186</xref>). The primary endpoint of the trial was the occurrence or absence of PCR-confirmed, symptomatic mild, moderate, or severe COVID-19 from 7&#8201;days after the second dose onward (<xref rid="B186" ref-type="bibr">186</xref>). The VE was reported to be 89.7%, with a total of 10 patients developing COVID-19 in the vaccine group versus 96 in the placebo group (<xref rid="B186" ref-type="bibr">186</xref>). No hospitalizations or deaths were reported for the vaccine group (<xref rid="B186" ref-type="bibr">186</xref>). An additional phase III randomized, observer-blinded, placebo-controlled trial was conducted in the United States and Mexico, enrolling 29,949 participants and administering at least 1 vaccine in a 2:1 ratio from late December 2020 to late February 2021 (<xref rid="B187" ref-type="bibr">187</xref>). This trial (<xref rid="B187" ref-type="bibr">187</xref>) used the same primary endpoints as the initial phase III trial conducted in the United Kingdom (<xref rid="B186" ref-type="bibr">186</xref>). A vaccine efficacy of 90.4% was reported based on 77 cases total, 63 of which occurred in the placebo group (<xref rid="B187" ref-type="bibr">187</xref>). All moderate to severe cases of COVID-19 occurred in the placebo group (<xref rid="B187" ref-type="bibr">187</xref>). Hospitalization and death were not evaluated as individual secondary endpoints but were instead included in the definition of severe COVID-19; all-cause mortalities were comparable between the placebo and treatment conditions (<xref rid="B187" ref-type="bibr">187</xref>).</p><p>In both trials, the vaccine was found to be well tolerated (<xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B187" ref-type="bibr">187</xref>). Analysis of 2,310 participants in the U.K. trial revealed that solicited AEs were much more common in the vaccine group than the placebo group across the two doses, but the rates of unsolicited events were much more similar, though the rate was higher in the vaccine group (<xref rid="B186" ref-type="bibr">186</xref>). A small number of severe AEs were reported by vaccine recipients, including one case of myocarditis; however, the myocarditis was determined to be viral myocarditis (<xref rid="B186" ref-type="bibr">186</xref>). Common AEs were generally considered mild, with low incidences of headache, muscle pain, and fatigue (<xref rid="B187" ref-type="bibr">187</xref>). In the trial conducted in the United States and Mexico, once again, the most common symptoms included headache, fatigue, and pain, as well as malaise (<xref rid="B187" ref-type="bibr">187</xref>). Here, severe AEs were balanced across the vaccine and placebo groups (<xref rid="B187" ref-type="bibr">187</xref>). Thus, both trials suggested that the Nuvaxovid vaccine is safe and effective against COVID-19.</p><p>However, Novavax experienced significant challenges in preparing Nuvaxovid for distribution. Prior to the pandemic&#8217;s onset, Novavax had sold their manufacturing facilities and reduced their staff dramatically (<xref rid="B188" ref-type="bibr">188</xref>). As a result, once they began producing Nuvaxovid, they struggled to establish a stable relationship with contractors who could produce the vaccine (<xref rid="B189" ref-type="bibr">189</xref>), especially given the challenge of producing vaccines at scale (<xref rid="B190" ref-type="bibr">190</xref>). Additionally, Novavax was not able to meet the purity standards laid out by the FDA (<xref rid="B191" ref-type="bibr">191</xref>). Eventually, the manufacturing issues were resolved (<xref rid="B192" ref-type="bibr">192</xref>), and Nuvaxovid has since been authorized by the WHO (<xref rid="B193" ref-type="bibr">193</xref>) and by political entities, including the United Kingdom (<xref rid="B194" ref-type="bibr">194</xref>), the European Union (<xref rid="B195" ref-type="bibr">195</xref>), and the United States (<xref rid="B196" ref-type="bibr">196</xref>). These delays obstructed some of the goals of the vaccine development program, which was undertaken with significant investment from the U.S. government through Operation Warp Speed (<xref rid="B191" ref-type="bibr">191</xref>). Novavax was supposed to provide over a billion doses of Nuvaxovid to countries around the world through the COVID-19 Vaccines Global Access (COVAX) Facility (<xref rid="B191" ref-type="bibr">191</xref>). However, following the delays, Gavi (which oversees COVAX) terminated the agreement, leading to ongoing legal disagreements between the nonprofit and Novavax as of late 2022 (<xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B197" ref-type="bibr">197</xref>).</p><p>As with other vaccines, the question of how well Nuvaxovid continues to provide protection as SARS-CoV-2 evolves has been raised. <italic toggle="yes">Post hoc</italic> analysis in the phase III trial indicated VE of 86.3% against the Alpha variant (identified based on the presence of the 69&#8211;70del polymorphism) and 96.4% against viral specimens lacking the 69&#8211;70del polymorphism (<xref rid="B186" ref-type="bibr">186</xref>). In the second phase III trial (<xref rid="B187" ref-type="bibr">187</xref>), whole-genome sequencing was obtained from 61 of the 77 observed cases, and 79% of infections were identified as being caused by a VOC or variant of interest (VOI) known at the time of the study. Vaccine efficacy against cases caused by VOCs, among which the Alpha variant was predominant (88.6%), was reported to be 92.6% (<xref rid="B187" ref-type="bibr">187</xref>). In late 2020, an analysis of efficacy in South African adults revealed an overall efficacy of 60.1% and a slightly lower efficacy (50.1%) against the Beta variant (B.1.351) in particular (<xref rid="B198" ref-type="bibr">198</xref>).</p><p>The company has also initiated the development of new constructs to select candidates that can be used as a booster against new strains and plans to initiate clinical trials for these new constructs in the second quarter of 2021. An analysis of a booster dose of Nuvaxovid administered 6&#8201;months after the primary series revealed a significant increase in neutralizing activity against VOC, including Delta and Omicron (<xref rid="B199" ref-type="bibr">199</xref>). This trial was conducted at 18 sites across the United States and Australia (<xref rid="B200" ref-type="bibr">200</xref>). Novavax has also initiated booster trials in the United Kingdom (<xref rid="B76" ref-type="bibr">76</xref>). Boosters may be especially important given that Omicron and related variants, in particular, may be associated with significantly reduced efficacy of Nuvaxovid (<xref rid="B201" ref-type="bibr">201</xref>).</p><p>Given the apparent need for boosters, interest has also emerged in whether booster doses of Nuvaxovid can be safely administered along with annual flu vaccines. In a subgroup of approximately 400 patients enrolled from the U.K. phase III trial who received either Nuvaxovid or a placebo at a ratio of 1:1, a concomitant dose of adjuvanted seasonal influenza vaccines (either a trivalent vaccine or a quadrivalent vaccine) was administered (<xref rid="B202" ref-type="bibr">202</xref>). This study demonstrated that the vaccines could be safely administered together (<xref rid="B202" ref-type="bibr">202</xref>). While no change to the immune response was noted for the influenza vaccine, a notable reduction of the antibody response elicited by Nuvaxovid was reported, but efficacy was still high, at 87.5% (<xref rid="B202" ref-type="bibr">202</xref>). Novavax has since started phase I/II trials to investigate the administration of its own influenza vaccine, NanoFlu, concomitantly with Nuvaxovid (<xref rid="B203" ref-type="bibr">203</xref>). The combination appeared to be safe and effective in preclinical studies (<xref rid="B204" ref-type="bibr">204</xref>).</p></sec><sec id="s4-3"><title>The Cuban Center for Genetic Engineering and Biotechnology&#8217;s Abdala vaccine.</title><p>Another notable protein subunit vaccine development program came out of Cuba. Concerned about their ability to access vaccines, especially given the United States&#8217; embargo (<xref rid="B205" ref-type="bibr">205</xref>), health officials in this developing country made the decision in March 2020 to undertake vaccine development on their own (<xref rid="B206" ref-type="bibr">206</xref>). Today, three Cuban protein subunit vaccines have been approved for use: Abdala, which was developed at the Cuban Genetic Engineering and Biotechnology Center, and SOBERANA 02 and SOBERANA Plus, which were developed at Cuba&#8217;s Finlay Vaccine Institute (Instituto Finlay de Vacunas Cuba) (<xref rid="B206" ref-type="bibr">206</xref>). Here, we focus on the development of the Abdala vaccine, but the SOBERANA 01/02/Plus vaccine development program has also achieved great success and reported VEs of over 90% for the three-dose regimen (<xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B208" ref-type="bibr">208</xref>).</p><p>Abdala, also known as CIGB-66, was developed using <named-content content-type="genus-species">Pichia pastoris</named-content> as a low-cost alternative to mammalian cell expression systems (e.g., human embryonic kidney cells) to cultivate the recombinant proteins that form the basis of this protein subunit vaccine (<xref rid="B209" ref-type="bibr">209</xref>). A sequence corresponding to the RBD of the spike protein in the index strain of SARS-CoV-2 was codon optimized for expression in yeast, and the RBD proteins were then purified and used to inoculate mice, rats, and African green monkeys (<xref rid="B209" ref-type="bibr">209</xref>). In addition to the proteins, the vaccine candidate included an adjuvant, aluminum hydroxide gel (<xref rid="B209" ref-type="bibr">209</xref>). Comparison of the immunogenicity of the yeast-cultivated proteins to those of proteins cultivated in human embryonic kidney cells revealed no significant difference in the immune response (<xref rid="B209" ref-type="bibr">209</xref>).</p><p>Based on promising results of laboratory animal testing, Abdala moved to phase I/II trials in human subjects ages 19 to 80, recruiting participants between December 2020 and February 2021 (<xref rid="B210" ref-type="bibr">210</xref>). The three-dose vaccine elicited no serious AEs across either phase I or II, and the vaccine was found to produce a strong immune response (<xref rid="B210" ref-type="bibr">210</xref>). In March 2021, phase III trials began (<xref rid="B211" ref-type="bibr">211</xref>), and by June, officials were reporting the VE to be 92.28% (<xref rid="B212" ref-type="bibr">212</xref>, <xref rid="B213" ref-type="bibr">213</xref>). This high efficacy estimate, along with the short timeline of data collection, initially elicited skepticism, especially given that the data were not made public (<xref rid="B214" ref-type="bibr">214</xref>). However, the trials were designed to enroll a large number of participants and were carried out during a wave of infections due to the arrival of variants carrying the D614G mutation in Cuba, which would be expected to allow an expedited timeline for interim analysis (<xref rid="B214" ref-type="bibr">214</xref>). Based on the reported results, Abdala gained emergency use authorization in Cuba in July 2021 (<xref rid="B215" ref-type="bibr">215</xref>), and by December 2021, cases in Cuba had dropped dramatically (<xref rid="B216" ref-type="bibr">216</xref>). The results of the phase III trial were posted to <italic toggle="yes">medRxiv</italic> in September 2022, describing the results of a randomized, placebo-controlled, multicenter, double-blind investigation of the Abdala vaccine candidate in 48,000 participants between 22 March and 3 April 2021 (<xref rid="B217" ref-type="bibr">217</xref>). The final results included 42 symptomatic cases of COVID-19 among participants in the placebo condition, compared to only 11 cases among participants who received the vaccine, yielding the reported VE of 92.28% (<xref rid="B217" ref-type="bibr">217</xref>). In terms of secondary endpoints, the VEs were 91.96% against mild/moderate COVID-19, 94.46% against severe COVID-19, and 100% against critical illness and death (<xref rid="B217" ref-type="bibr">217</xref>). The vaccine was also found to be very safe, with the overall incidence of AEs only 2.5% in vaccine recipients, compared to 1.9% in the placebo recipients (<xref rid="B217" ref-type="bibr">217</xref>). Therefore, the phase III trial suggests that this vaccine is highly effective and safe.</p><p>Evidence from the deployment of the vaccine also suggests that it is highly effective. A retrospective cohort study conducted between May and August 2021 evaluated public health data from over a million people in the city of Havana and found that the real-world effectiveness of the vaccine met or exceeded estimates of VE during the trial, with 98.2% effectiveness against severe disease and 98.7% effectiveness against death observed in fully vaccinated subjects (<xref rid="B218" ref-type="bibr">218</xref>). Notably, Cuba has vaccinated a high percentage of its population, with 87% of the population vaccinated by January 2022 and 90.3% by the end of December 2022 (<xref rid="B219" ref-type="bibr">219</xref>, <xref rid="B220" ref-type="bibr">220</xref>). Therefore, one consideration in interpreting retrospective cohort studies is that the vaccination rate in Cuba is so high that the two cohorts might not be directly comparable. All the same, the fact that the efficacy and effectiveness of the Abdala vaccine have both been estimated to be over 90% against severe illness suggests that this vaccine is highly effective for mitigating the risk of COVID-19. As of December 2022, the vaccine had been authorized for distribution in five additional countries, including Mexico and Vietnam, although its evaluation for WHO approval was ongoing (<xref rid="B221" ref-type="bibr">221</xref>, <xref rid="B222" ref-type="bibr">222</xref>).</p><p>However, limited data are available about the Abdala vaccine&#8217;s robustness to evolutionary changes in SARS-CoV-2. An <italic toggle="yes">in silico</italic> analysis identified several potential changes in the epitopes of the Omicron VOC relative to the sequence used in the development of Abdala (<xref rid="B223" ref-type="bibr">223</xref>). Instead, Cuban health officials have prioritized boosters. A representative of the Cuban state business group reportedly stated that immunity remains high at 6&#8201;months after the primary course but that some people may be prone to infection (<xref rid="B224" ref-type="bibr">224</xref>), suggesting waning immunity. The Cuban government authorized boosters in January 2022 in an effort to mitigate the effects of the Omicron variant (<xref rid="B224" ref-type="bibr">224</xref><xref rid="B225" ref-type="bibr">&#8211;</xref><xref rid="B226" ref-type="bibr">226</xref>). Additional support for the efficacy of Abdala and other Cuban vaccines comes from the fact that Cuba&#8217;s COVID-19 death rate has virtually flatlined since fall 2021, with fewer than 250 deaths reported during the entire year of 2022 in a population of 11.3 million (<xref rid="B227" ref-type="bibr">227</xref>). Therefore, in addition to developing a vaccine with an estimated VE paralleling that of vaccines developed using cutting-edge nucleic acid technologies (<xref rid="B5" ref-type="bibr">5</xref>), Cuba&#8217;s vaccine rollout has also been much more successful than in nearly all similar-size countries. This remarkable vaccine program underscores the continued importance of established, cost-effective vaccine development strategies (<xref rid="B225" ref-type="bibr">225</xref>) that make it possible for countries that have not traditionally been a leader in biotechnological innovation but have developed a solid vaccine production sector (<xref rid="B228" ref-type="bibr">228</xref>) to develop and produce vaccines that will serve their own population&#8217;s needs. Additionally, Cuba&#8217;s vaccines are uniquely accessible to many countries around the world (<xref rid="B225" ref-type="bibr">225</xref>).</p></sec><sec id="s4-4"><title>Medicago&#8217;s Covifenz.</title><p>The leading example of a VLP approach applied to COVID-19 comes from Covifenz, developed by the Canadian company Medicago (<xref rid="B229" ref-type="bibr">229</xref>). This vaccine was developed using plant-based VLP technology (<xref rid="B230" ref-type="bibr">230</xref>) that the company had been investigating in order to develop a high-throughput quadrivalent VLP platform to provide protection against influenza (<xref rid="B231" ref-type="bibr">231</xref>). The approach utilizes <named-content content-type="genus-species">Nicotiana benthamiana</named-content>, an Australian relative of the tobacco plant, as an upstream bioreactor (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B232" ref-type="bibr">232</xref>). Specifically, the <italic toggle="yes">S</italic> gene from SARS-CoV-2 in its prefusion conformation is inserted into a bacterial vector (<named-content content-type="genus-species">Agrobacterium tumefaciens</named-content>) that then infects the plant cells (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B232" ref-type="bibr">232</xref>). Expression of the S glycoprotein causes the production of VLPs composed of S trimers anchored in a lipid envelope that accumulate between the plasma membrane and the cell wall of the plant cell (<xref rid="B232" ref-type="bibr">232</xref>). Because these VLPs do not contain the SARS-CoV-2 genome, they offer advantages similar to those of whole-virus vaccines while mitigating the risks (<xref rid="B231" ref-type="bibr">231</xref>, <xref rid="B232" ref-type="bibr">232</xref>).</p><p>In the phase I study, 180 Canadian adults ages 18 to 55&#8201;years old were administered Covifenz as two doses, 21&#8201;days apart, with three different dosages evaluated (<xref rid="B232" ref-type="bibr">232</xref>). This study reported that when the VLPs were administered with AS03, an oil-in-water emulsion containing &#945;-tocopherol and squalene (<xref rid="B233" ref-type="bibr">233</xref>), as an adjuvant, the vaccine elicited an nAb response that was significantly (approximately 10 times) higher than that in convalescent-phase sera (<xref rid="B232" ref-type="bibr">232</xref>). The phase III trial examined 24,141 adults assigned to the treatment and control conditions at a 1:1 ratio between March and September of 2021 (<xref rid="B234" ref-type="bibr">234</xref>).</p><p>Covifenz was reported to be 71% effective in preventing COVID-19 in the per-protocol analysis (<xref rid="B234" ref-type="bibr">234</xref>). Efficacy was only slightly lower in the intention-to-treat group, at 69%, with the VE for the prevention of moderate to severe disease in this group estimated at 78.8% (<xref rid="B234" ref-type="bibr">234</xref>). Over 24,000 participants were included in the safety analysis, which showed that 92.3% of vaccine recipients reported local AEs, compared to 45.5% of placebo recipients, with rates for systemic AEs at 87.3% and 65.0%, respectively (<xref rid="B234" ref-type="bibr">234</xref>). The adverse effects reported were generally mild to moderate, with the most common adverse effects being injection site pain, headache, myalgia, fatigue, and general discomfort (<xref rid="B245" ref-type="bibr">234</xref>). Only three patients (two in the vaccine group) reported grade 4 events, all after the second dose (<xref rid="B234" ref-type="bibr">234</xref>). The vaccine was approved for use in adults ages 18 to 65 by Health Canada in February 2022 (<xref rid="B235" ref-type="bibr">235</xref>).</p><p>Plant-based expression systems such as the one used in Covifenz are relatively new (<xref rid="B232" ref-type="bibr">232</xref>) but are likely to offer unparalleled feasibility at scale given the speed and low cost associated with the platform (<xref rid="B236" ref-type="bibr">236</xref>). Additionally, the Covifenz vaccine offers the advantage of being stored at 2 to 8&#176;C. However, the worldwide footprint of Covifenz, and of VLP-based technologies against SARS-CoV-2 broadly, remains small, with only 1 VLP vaccine approved for distribution in 1 country (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref>). Approval and administration of Covifenz in countries outside Canada have been limited by concerns at the WHO about ties between Medicago and the tobacco industry (<xref rid="B229" ref-type="bibr">229</xref>, <xref rid="B237" ref-type="bibr">237</xref>). While other species of plants have been explored as the upstream bioreactors for plant-derived VLPs, the specific species of tobacco used increased yield dramatically (<xref rid="B238" ref-type="bibr">238</xref>). In December 2022, tobacco industry investors in Medicago divested, opening new possibilities for the distribution of the vaccine (<xref rid="B239" ref-type="bibr">239</xref>).</p><fig position="float" id="fig3" orientation="portrait"><label>FIG&#160;3</label><caption><p>Worldwide availability of vaccines developed with VLPs. This figure reflects the number of vaccines based on VLP technology that were available in each country as of 10 January 2023. These data are retrieved from Our World in Data (<xref rid="B249" ref-type="bibr">249</xref>) and plotted using geopandas (<xref rid="B306" ref-type="bibr">306</xref>). The color scale is based on the number of vaccines of this type included in the OWID data set as a whole, not the maximum observed in a single country. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greenelab.github.io/covid19-review/" ext-link-type="uri">https://greenelab.github.io/covid19-review/</ext-link> for the most recent version of this figure, which is updated daily.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="msystems.00927-22-f003.jpg"/></fig><p>As a result of this limited rollout and given that the phase III results were published only in May 2022, little is known about the real-world performance of Covifenz. However, it should be noted that the Covifenz trials were conducted in 2021, at a time during which the B.1.617.2 (Delta) and P.1 (Gamma) variants were predominant (<xref rid="B234" ref-type="bibr">234</xref>). Genomic analysis of 122 out of 176 cases (165 in the per-protocol population) revealed that none of the COVID-19 cases reported were caused by the original Wuhan strain (<xref rid="B234" ref-type="bibr">234</xref>). Instead, 45.9% of cases were identified as the Delta variant, 43.4% as Gamma, 4.9% as Alpha, and 5.8% as VOIs (<xref rid="B234" ref-type="bibr">234</xref>). Therefore, Covifenz and Nuvaxovid, despite both being designed based on the index strain, were tested under circumstances where different VOC were dominant, and differences in the spike proteins of different VOC relative to the index strain could affect vaccine efficacy. As of late 2022, Covifenz has not been authorized as a booster in Canada (<xref rid="B240" ref-type="bibr">240</xref>), and no studies on booster doses had been released by Medicago (<xref rid="B241" ref-type="bibr">241</xref>).</p></sec><sec id="s4-5"><title>Subunit vaccine summary.</title><p>Subunit vaccine technology is one of the best-represented platforms among COVID-19 vaccine candidates. Development programs are under way in many countries around the world, including low- and middle-income countries (<xref rid="B179" ref-type="bibr">179</xref>). To date, data about the effect of viral evolution on the effectiveness of subunit vaccines have been limited. Because these vaccines were developed using the spike protein from the index strain (<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B234" ref-type="bibr">234</xref>), a potential concern has been that these vaccines could lose effectiveness against SARS-CoV-2 containing mutations in the spike protein. Comparison of studies across vaccines suggests that some VOC, such as Alpha, may have minimal impact on vaccine efficacy/effectiveness (<xref rid="B242" ref-type="bibr">242</xref>). Additionally, to the extent that data are available, such as from the vaccine rollout in Cuba, they suggest that real-world effectiveness remains strong against severe illness and death.</p><p>Subunit platforms offer some unique advantages. Cuba&#8217;s successful vaccine development program highlights the fact that protein subunit vaccines can be developed using low-cost technologies. Additionally, they are more feasible to store and transport (<xref rid="B243" ref-type="bibr">243</xref>). Hoping to build on Cuba&#8217;s success and the continued lack of vaccine access in many countries, several Latin American nations have begun developing protein subunit vaccines (<xref rid="B244" ref-type="bibr">244</xref>).</p><p>The efficacy and effectiveness of these vaccines are also very high, especially for Nuvaxovid, Abdala, and SOBERANA 01/02/Plus, for which estimates exceeded 90%. Unfortunately, there seem to be limited studies directly comparing the immunogenicity of subunit vaccines to that of nucleic acid vaccines, and comparing efficacies across trials is subject to bias (<xref rid="B245" ref-type="bibr">245</xref>). All the same, the evidence suggests that some protein subunit vaccines are able to provide extremely strong protection. Coupled with the reduced barriers to development and transportation relative to most nucleic acid vaccines, it is clear that subunit technologies are important to vaccine access.</p></sec></sec><sec id="s5"><title>GLOBAL VACCINE STATUS AND DISTRIBUTION</title><p>The unprecedented deployment of COVID-19 vaccines in under a year from the identification of SARS-CoV-2 led to a new challenge: the formation of rapid global vaccine production and distribution plans. The development of vaccines is costly and complicated, but vaccine distribution can be just as challenging. Logistical considerations such as transport, storage, equipment (e.g., syringes), the workforce to administer the vaccines, and a continual supply from the manufacturers to meet global demands all must be accounted for and vary globally due to economic, geographic, and sociopolitical reasons (<xref rid="B246" ref-type="bibr">246</xref><xref rid="B247" ref-type="bibr">&#8211;</xref><xref rid="B248" ref-type="bibr">248</xref>). As of 4 January 2023, at least 13.0 billion vaccine doses had been administered in at least 223 countries worldwide using 28 different vaccines (<xref rid="B249" ref-type="bibr">249</xref>). The daily global vaccination rate at this time was 254.0 per million.</p><p>However, the distribution of these doses is not uniform around the globe. Latin America leads world vaccination rates, with at least 82% of individuals in this region receiving one vaccine dose, followed by the United States and Canada (81%), Asia-Pacific (81%), Europe (70%), the Middle East (58%), and Africa, with only 33% as of November 2022 (<xref rid="B250" ref-type="bibr">250</xref>). It is estimated that only ~25% of individuals in low- and middle-income countries have received one vaccine dose (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B249" ref-type="bibr">249</xref>). Vaccine production and distribution vary from region to region and seem to depend on the availability of the vaccines and potentially a country&#8217;s resources and wealth (<xref rid="B251" ref-type="bibr">251</xref>).</p><p>One effort to reduce these disparities is COVAX, a multilateral initiative as part of the Access to COVID-19 Tools (ACT) Accelerator coordinated by the WHO, Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI), the last two of which are supported by the Bill and Melinda Gates Foundation. Their intention is to accelerate the development of COVID-19 vaccines, diagnostics, and therapeutics and to ensure the equitable distribution of vaccines to low- and middle-income countries (<xref rid="B252" ref-type="bibr">252</xref>, <xref rid="B253" ref-type="bibr">253</xref>). COVAX invested in several vaccine programs to ensure they would have access to successful vaccine candidates (<xref rid="B254" ref-type="bibr">254</xref>). However, the initiative has been less successful than was initially hoped due to less participation from high-income countries than was required for COVAX to meet its goals (<xref rid="B255" ref-type="bibr">255</xref>).</p><p>Additionally, the vaccine technologies available differ widely around the globe. As we review elsewhere (<xref rid="B5" ref-type="bibr">5</xref>), wealthier nations have invested heavily in mRNA and DNA vaccines. In contrast, as we describe above, many countries outside Europe and North America have developed highly effective vaccines using more traditional approaches. There is a clear relationship between a country&#8217;s gross domestic product (GDP) and its access to these cutting-edge types of vaccines (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref>). Whole-virus and subunit vaccine development programs are responsible for a much higher percentage of the vaccinated populace in lower-income countries. Therefore, vaccine development programs that utilized established vaccine technologies have played a critical role in providing protection against SARS-CoV at the global level.</p><fig position="float" id="fig4" orientation="portrait"><label>FIG&#160;4</label><caption><p>Vaccine distribution across platform types as a function of GDP. The total number of doses of the original formulation of each vaccine that were distributed within each country as of 10 January 2023, by platform type, is shown as a function of GDP. These data are retrieved from Our World in Data (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B249" ref-type="bibr">249</xref>) and plotted using the Python package plotnine (<xref rid="B307" ref-type="bibr">307</xref>). Lines show a general trend in the data and are drawn using geom_smooth (<xref rid="B308" ref-type="bibr">308</xref>). The list of countries included in the data set is available from OWID (<xref rid="B309" ref-type="bibr">309</xref>). See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greenelab.github.io/covid19-review/" ext-link-type="uri">https://greenelab.github.io/covid19-review/</ext-link> for the most recent version of this figure, which is updated daily. Axes are not scaled per capita because both variables are modulated by population size.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="msystems.00927-22-f004.jpg"/></fig><p>When vaccines first became available, the wealthy nations of North America and Europe secured most of the limited COVID-19 vaccine stocks (<xref rid="B256" ref-type="bibr">256</xref>). Throughout 2021, low- and middle-income countries faced steep competition with high-income countries for vaccines, and the rates of vaccination reflected this unequal distribution (<xref rid="B257" ref-type="bibr">257</xref>). While the wealthiest countries in these regions could compete with each other for vaccines independent of programs such as COVAX (<xref rid="B257" ref-type="bibr">257</xref>), other countries in these regions have faced challenges in acquiring vaccines developed by the world&#8217;s wealthiest nations. Fortunately, while mRNA and DNA vaccine development programs are not widespread, vaccine development using whole-virus and subunit technologies has been undertaken worldwide. China and India, in particular, have developed several vaccines that are now widely available in these densely populated countries (see online appendix [<xref rid="B40" ref-type="bibr">40</xref>]).</p><p>Still, many nations, especially in Africa, are reliant on the COVAX Facility, which has promised 600 million doses to the continent (<xref rid="B258" ref-type="bibr">258</xref>). The COVAX plan seeks to ensure that all participating countries are allocated vaccines in proportion to their population sizes. Once each country has received vaccine doses to account for 20% of their population, the country&#8217;s risk profile will determine its place in subsequent phases of vaccine distribution. However, several limitations of this framework exist, including that the COVAX scheme seems to go against the WHO&#8217;s own ethical principles of human well-being, equal respect, and global equity and that other frameworks might have been more suitable (<xref rid="B259" ref-type="bibr">259</xref>). Furthermore, COVAX is supposed to allow poorer countries access to affordable vaccines, but the vaccines are driven by publicly traded companies that are required to make a profit (<xref rid="B251" ref-type="bibr">251</xref>).</p><p>In any case, COVAX provides access to COVID-19 vaccines that may otherwise have been difficult for some countries to obtain. COVAX aimed to distribute 2 billion vaccine doses globally by the end of 2021 (<xref rid="B260" ref-type="bibr">260</xref>). According to Gavi, as of January 2022, COVAX had distributed over 1 billion vaccines to 144 participants of the program (<xref rid="B261" ref-type="bibr">261</xref>), short of its target but still a major global achievement. It is envisaged that COVAX may also receive additional donations of doses from Western nations that purchased surplus vaccines in the race to vaccinate their populations, which will be a welcome boost to the vaccination programs of low- and middle-income countries (<xref rid="B262" ref-type="bibr">262</xref>).</p><p>In general, deciding on the prioritization and allocation of the COVID-19 vaccines is also a challenging task due to ethical and operational considerations. Various frameworks, models, and methods have been proposed to tackle these issues with many countries, regions, or U.S. states devising their own distribution and administration plans (<xref rid="B263" ref-type="bibr">263</xref><xref rid="B264" ref-type="bibr">&#8211;</xref><xref rid="B267" ref-type="bibr">267</xref>). The majority of the distribution plans prioritized offering vaccines to key workers such as health care workers and those who are clinically vulnerable, such as the elderly, the immunocompromised, and individuals with comorbidities, before targeting the rest of the population, who are less likely to experience severe outcomes from COVID-19 (<xref rid="B249" ref-type="bibr">249</xref>). The availability of vaccines developed in a variety of countries using a variety of platforms is likely to work in favor of worldwide vaccine access. The initiative by Texas Children&#8217;s Hospital and Baylor College of Medicine to develop Corbevax, a patent-free COVID-19 protein subunit vaccine, is an important step toward vaccine equity because the manufacturing specifications can be shared globally. Corbevax can be produced at low cost using existing technology and is now licensed to Biological E. Limited (BioE), an Indian company specializing in low-cost vaccine production (<xref rid="B268" ref-type="bibr">268</xref>). The vaccine has been approved for distribution in India and Botswana (<xref rid="B269" ref-type="bibr">269</xref>).</p><p>Logistical challenges and geographical barriers also dictate the availability of certain vaccines. Many countries have had poor availability of ultralow-temperature freezers, leading to challenges of distribution for vaccines, such as mRNA vaccines, that require storage at very low temperatures (<xref rid="B270" ref-type="bibr">270</xref><xref rid="B271" ref-type="bibr">&#8211;</xref><xref rid="B272" ref-type="bibr">272</xref>). Furthermore, ancillary supplies such as vaccine containers, diluents for frozen or lyophilized vaccines, disinfecting wipes, bandages, needles, syringes, sharps, and biological waste disposal containers are also required, which may not be readily available in geographically isolated locations and can be bulky and expensive to ship (<xref rid="B270" ref-type="bibr">270</xref>). While some of these challenges in vaccine rollout in low- and middle-income countries are being addressed through COVAX (<xref rid="B273" ref-type="bibr">273</xref>), many issues persist worldwide (<xref rid="B274" ref-type="bibr">274</xref><xref rid="B275" ref-type="bibr">&#8211;</xref><xref rid="B276" ref-type="bibr">276</xref>). COVAX also failed to distribute its promised two billion vaccine doses on time due to multiple complications (<xref rid="B277" ref-type="bibr">277</xref>).</p><p>Another major challenge to global vaccine distribution is vaccine hesitancy, which the WHO has designated a leading global health threat (<xref rid="B278" ref-type="bibr">278</xref>). Polling in the United States in January 2021 suggested that 20% of individuals were reluctant to receive a vaccine at that time, with a further 31% expressing some hesitancy to a lesser extent (<xref rid="B279" ref-type="bibr">279</xref>, <xref rid="B280" ref-type="bibr">280</xref>). A survey of 8,243 long-term health care workers in November 2020 (Indiana, USA) reported that only 69% of respondents would ever consider receiving an FDA-approved vaccine due to their perceived risk of side effects (70%), health concerns (34%), efficacy (20%), and religious beliefs (12%) (<xref rid="B281" ref-type="bibr">281</xref>). Notably, almost a third of parents surveyed in the United States in March 2021 expressed concerns about vaccinating their children against COVID-19 (<xref rid="B282" ref-type="bibr">282</xref>). Indeed, vaccine hesitancy has been reported as a significant barrier to vaccine distribution in countries in North and South America, Europe, Asia, and Africa (<xref rid="B283" ref-type="bibr">283</xref><xref rid="B284" ref-type="bibr">&#8211;</xref><xref rid="B287" ref-type="bibr">287</xref>). Various factors have been associated with increased vaccine hesitancy, including access to compelling misinformation via social media (<xref rid="B288" ref-type="bibr">288</xref>, <xref rid="B289" ref-type="bibr">289</xref>), religious and conservative political beliefs (<xref rid="B290" ref-type="bibr">290</xref><xref rid="B291" ref-type="bibr">&#8211;</xref><xref rid="B293" ref-type="bibr">293</xref>), and safety and efficacy concerns (<xref rid="B282" ref-type="bibr">282</xref>), to highlight a few. Many of the concerns regarding safety and efficacy have focused on the novel mRNA technologies due to the perceived speed of their development and expedited clinical trial process (<xref rid="B294" ref-type="bibr">294</xref>); however, general vaccine hesitancy relating to traditional vaccine platforms existed long before the pandemic and the distribution of the novel mRNA vaccines (<xref rid="B295" ref-type="bibr">295</xref>, <xref rid="B296" ref-type="bibr">296</xref>). While in the United States, it was hoped that Novavax&#8217;s Nuvaxovid would appeal to the vaccine hesitant (<xref rid="B297" ref-type="bibr">297</xref>, <xref rid="B298" ref-type="bibr">298</xref>), this protein subunit vaccine has not led to the uptake hoped for (<xref rid="B299" ref-type="bibr">299</xref>, <xref rid="B300" ref-type="bibr">300</xref>).</p><p>Overall, the vaccine landscape remains heterogeneous even as the pandemic nears its third year, with certain vaccines much more accessible in high-income countries than in low- and middle-income countries. The vaccines described in this review, which were developed using well-established technologies, have played a crucial role in improving the feasibility and accessibility of vaccination programs worldwide. While the novel technologies have received the bulk of public attention in countries like the United States, these more traditional vaccine platforms also provide safe and highly effective protection against SARS-CoV-2. Although companies developing cutting-edge technologies, namely, Moderna and Pfizer/BioNTech, reported very high efficacies (greater than 90%) in their clinical trials (<xref rid="B5" ref-type="bibr">5</xref>), the efficacies identified in whole-virus and subunit trials have also been very high. While the clinical trial efficacy estimates for IWV and subunit vaccines have been lower, some of these trials have also reported efficacies over 80% (e.g., Novavax&#8217;s Nuvaxovid, with 89.7% [<xref rid="B186" ref-type="bibr">186</xref>], or Sinovac&#8217;s CoronaVac, with 83.5% [<xref rid="B67" ref-type="bibr">67</xref>]). Variation among studies investigating the efficacy of these vaccines, especially CoronaVac, clearly indicate that clinical trials of the same vaccine might not identify the same efficacy, depending on conditions such as the specific variants circulating in a clinical trial population during the trial period. Additionally, there are many cohort- and population-level characteristics that can introduce bias within and between clinical trials (<xref rid="B245" ref-type="bibr">245</xref>, <xref rid="B301" ref-type="bibr">301</xref>), and the extent to which these different factors are present may influence trial outcomes. While head-to-head comparisons of VE across different studies may therefore not be appropriate, the results make it clear that effective vaccines have been developed with a wide variety of technologies. The vaccines discussed here, which took advantage of well-established approaches, have proven to be especially valuable in pursuing vaccine equity.</p></sec><sec sec-type="conclusions" id="s6"><title>CONCLUSIONS</title><p>Much attention has been focused on the most novel vaccine technologies that have been deployed against SARS-CoV-2, but the established vaccine platforms discussed here have all made a significant impact on human health during the 20th century and in some cases even earlier. The COVID-19 pandemic has demonstrated new potential in these established technologies. In the early 2000s, these technologies were explored for managing SARS-CoV-1 (<xref rid="B302" ref-type="bibr">302</xref>, <xref rid="B303" ref-type="bibr">303</xref>), but the epidemic was controlled before those efforts came to fruition (<xref rid="B304" ref-type="bibr">304</xref>). Similarly, these technologies were explored for MERS-CoV, but outbreaks were sporadic and difficult to predict, making vaccine testing and the development of a vaccination strategy difficult (<xref rid="B305" ref-type="bibr">305</xref>). However, in the COVID-19 pandemic, most of these technologies have been used to accelerate vaccine development programs worldwide. Therefore, they also offer the opportunity to respond quickly to an emergent pathogen.</p><p>While these tried-and-true technologies do not always produce vaccines with the highly desirable VE reported in mRNA clinical trials (which exceeded 90%), the efficacies are still very high, and these vaccines are extremely effective at preventing severe illness and death. Furthermore, some vaccine development programs using established technologies, especially protein subunit vaccines, have seen remarkably high VE and vaccine effectiveness. Some protein subunit vaccine phase III trials generated VE estimates of over 90%, comparable to those in the mRNA vaccine trials. Additionally, in some cases, such as Cuba&#8217;s highly successful vaccine development program, these vaccines have been developed by and for low- and middle-income nations. As a result, the greater accessibility and stability of these vaccines make them extremely valuable for the global effort to mitigate the loss of life from SARS-CoV-2. The outcomes of the response to COVID-19 suggest that these established vaccine technologies may continue to play an important role in tackling future viral threats.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank Yael Evelyn Marshall, who contributed writing (original draft) as well as reviewing and editing of pieces of the text but who did not formally approve the manuscript, as well as Ronnie Russell, who contributed text to and helped develop the structure of the manuscript early in the writing process. We are also very grateful to James Fraser for suggestions about successes and limitations in the area of computational screening for drug repurposing. We are grateful to the following contributors for reviewing pieces of the text: Nadia Danilova, James Eberwine, and Ipsita Krishnan.</p><p>Anthony Gitter is the inventor of patent US-11410440-B2, assigned to the Wisconsin Alumni Research Foundation related to classifying activated T cells. There are no conflicts of interest for any of the other authors.</p><p>Halie M. Rando, Project Administration, Software, Visualization, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing; Ronan Lordan, Project Administration, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing; Alexandra J. Lee, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing; Amruta Naik, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing; Nils Wellhausen, Project Administration, Writing &#8211; Review &amp; Editing; Elizabeth Sell, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing; Likhitha Kolla, Writing &#8211; Review &amp; Editing; COVID-19 Review Consortium, Project Administration; Anthony Gitter, Project Administration, Writing &#8211; Original Draft, Writing &#8211; Review &amp; Editing; Casey S. Greene, Conceptualization, Supervision.</p><p>The COVID-19 Review Consortium includes Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D&#8217;Agostino McGowan, Jesse G. Meyer, Ariel I. Mundo, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, and Nils Wellhausen.</p></ack><fn-group><fn fn-type="companion-article"><p>For a companion article on this topic, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1128/mSystems.00928-22" ext-link-type="uri">https://doi.org/10.1128/mSystems.00928-22</ext-link>.</p></fn><fn fn-type="other"><p>This represents one section of a larger evolving review on SARS-CoV-2 and COVID-19, which is regularly updated and available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greenelab.github.io/covid19-review/" ext-link-type="uri">https://greenelab.github.io/covid19-review/</ext-link>. This is a review paper that is authored by scientists for an audience of scientists to discuss research that is in progress. If you are interested in guidelines on testing, therapies, or other issues related to your health, you should not use this document. Instead, you should collect information from your local health department, the CDC&#8217;s guidance, or your own government.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Plotkin</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <article-title>History of vaccination</article-title>. <source>Proc Natl Acad Sci USA</source><volume>111</volume>:<fpage>12283</fpage>&#8211;<lpage>12287</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1400472111</pub-id>.<pub-id pub-id-type="pmid">25136134</pub-id><pub-id pub-id-type="pmcid">PMC4151719</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rando</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>MacLean</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lordan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bansal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Skelly</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Sell</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dziak</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Shinholster</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Agostino McGowan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ben Guebila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wellhausen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Knyazev</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Boca</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Capone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Boerckel</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Brueffer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Byrd</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Kamil</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Velazquez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Szeto</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Mangul</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lubiana</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bansal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Boca</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Boerckel</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Brueffer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Byrd</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Capone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dattoli</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Dziak</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Field</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gitter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Greene</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Ben Guebila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Himmelstein</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jadavji</surname><given-names>NM</given-names></string-name>, <collab>COVID-19 Review Consortium</collab></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Pathogenesis, symptomatology, and transmission of SARS-CoV-2 through analysis of viral genomics and structure</article-title>. <source>mSystems</source><volume>6</volume>:<elocation-id>e00095-21</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSystems.00095-21</pub-id>.<pub-id pub-id-type="pmid">34698547</pub-id><pub-id pub-id-type="pmcid">PMC8547481</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rando</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Wellhausen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Dattoli</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Byrd</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Rafizadeh</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Lordan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Brueffer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Field</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Ben Guebila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jadavji</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Skelly</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Ramsundar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bansal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Boca</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Boerckel</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Brueffer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Byrd</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Stephen Capone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Dattoli</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Dziak</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Field</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gitter</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Greene</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ben Guebila</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Himmelstein</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Jadavji</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Kamil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Knyazev</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kolla</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lordan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lubiana</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lukan</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>MacLean</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mangul</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Manheim</surname><given-names>LD</given-names></string-name>, <collab>COVID-19 Review Consortium</collab></person-group>, <etal>et al</etal>. <year>2021</year>. <article-title>Identification and development of therapeutics for COVID-19</article-title>. <source>mSystems</source><volume>6</volume>:<elocation-id>e00233-21</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSystems.00233-21</pub-id>.<pub-id pub-id-type="pmid">34726496</pub-id><pub-id pub-id-type="pmcid">PMC8562484</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krammer</surname><given-names>F</given-names></string-name></person-group>. <year>2020</year>. <article-title>SARS-CoV-2 vaccines in development</article-title>. <source>Nature</source><volume>586</volume>:<fpage>516</fpage>&#8211;<lpage>527</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2798-3</pub-id>.<pub-id pub-id-type="pmid">32967006</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rando</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Lordan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kolla</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sell</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Wellhausen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Naik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kamil</surname><given-names>JP</given-names></string-name>, <collab>Covid-Review Consortium</collab>, <string-name name-style="western"><surname>Gitter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Greene</surname><given-names>CS</given-names></string-name></person-group>. <year>2023</year>. <article-title>The coming of age of nucleic acid vaccines during COVID-19</article-title>. <source>mSystems</source><volume>8</volume>:<elocation-id>e00928-22</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSystems.00928-22</pub-id>.<pub-id pub-id-type="pmcid">PMC10134841</pub-id><pub-id pub-id-type="pmid">36861992</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/" ext-link-type="uri">https://covid19.trackvaccines.org/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathieu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ritchie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ortiz-Ospina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Roser</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hasell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Appel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Giattino</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rod&#233;s-Guirao</surname><given-names>L</given-names></string-name></person-group>. <year>2021</year>. <article-title>A global database of COVID-19 vaccinations</article-title>. <source>Nat Hum Behav</source><volume>5</volume>:<fpage>947</fpage>&#8211;<lpage>953</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41562-021-01122-8</pub-id>.<pub-id pub-id-type="pmid">33972767</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Corey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Fauci</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>FS</given-names></string-name></person-group>. <year>2020</year>. <article-title>A strategic approach to COVID-19 vaccine R&amp;D</article-title>. <source>Science</source><volume>368</volume>:<fpage>948</fpage>&#8211;<lpage>950</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abc5312</pub-id>.<pub-id pub-id-type="pmid">32393526</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>14</day><month>July</month> 2021. <article-title>Vaccine efficacy, effectiveness and protection</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection" ext-link-type="uri">https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Makhene</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Coler</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>McCullough</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Chappell</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Stevens</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Pruijssers</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Flach</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Doria-Rose</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Morabito</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Dell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Swanson</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Padilla</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Makowski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cross</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Buchanan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Pikaart-Tautges</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ledgerwood</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Beigel</surname><given-names>JH</given-names></string-name>, <collab>mRNA-1273 Study Group</collab></person-group>. <year>2020</year>. <article-title>An mRNA vaccine against SARS-CoV-2&#8212;preliminary report</article-title>. <source>N Engl J Med</source><volume>383</volume>:<fpage>1920</fpage>&#8211;<lpage>1931</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id>.<pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="book"><collab>COVID-19 Review Consortium</collab>. <year>2021</year>. <article-title>Evolutionary and genomic analysis of SARS-CoV-2</article-title>. <publisher-name>Manubot</publisher-name>.</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davidson</surname><given-names>MH</given-names></string-name></person-group>. <year>2006</year>. <article-title>Differences between clinical trial efficacy and real-world effectiveness</article-title>. <source>Am J Manag Care</source><volume>12</volume>:<fpage>S405</fpage>&#8211;<lpage>S411</lpage>.<pub-id pub-id-type="pmid">17112328</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Monti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grosso</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Todoerti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Caporali</surname><given-names>R</given-names></string-name></person-group>. <year>2018</year>. <article-title>Randomized controlled trials and real-world data: differences and similarities to untangle literature data</article-title>. <source>Rheumatology (Oxford)</source><volume>57</volume>:<fpage>vii54</fpage>&#8211;<lpage>vii58</lpage>. doi:<pub-id pub-id-type="doi">10.1093/rheumatology/key109</pub-id>.<pub-id pub-id-type="pmid">30289534</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stewart</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Devlin</surname><given-names>PM</given-names></string-name></person-group>. <year>2006</year>. <article-title>The history of the smallpox vaccine</article-title>. <source>J Infect</source><volume>52</volume>:<fpage>329</fpage>&#8211;<lpage>334</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinf.2005.07.021</pub-id>.<pub-id pub-id-type="pmid">16176833</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Leung</surname><given-names>AKC</given-names></string-name></person-group>. <year>2011</year>. <part-title>&#8220;Variolation&#8221; and vaccination in late imperial China, ca 1570&#8211;1911</part-title>, p <fpage>5</fpage>&#8211;<lpage>12</lpage>. <italic toggle="yes">In</italic><person-group person-group-type="editor"><string-name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></string-name></person-group> (ed), <source>History of vaccine development.</source><publisher-name>Springer</publisher-name>, <publisher-loc>New York, NY</publisher-loc>.</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stern</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Markel</surname><given-names>H</given-names></string-name></person-group>. <year>2005</year>. <article-title>The history of vaccines and immunization: familiar patterns, new challenges</article-title>. <source>Health Aff (Millwood)</source><volume>24</volume>:<fpage>611</fpage>&#8211;<lpage>621</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.24.3.611</pub-id>.<pub-id pub-id-type="pmid">15886151</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Esparza</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schrick</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Damaso</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Nitsche</surname><given-names>A</given-names></string-name></person-group>. <year>2017</year>. <article-title>Equination (inoculation of horsepox): an early alternative to vaccination (inoculation of cowpox) and the potential role of horsepox virus in the origin of the smallpox vaccine</article-title>. <source>Vaccine</source><volume>35</volume>:<fpage>7222</fpage>&#8211;<lpage>7230</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.11.003</pub-id>.<pub-id pub-id-type="pmid">29137821</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Minor</surname><given-names>PD</given-names></string-name></person-group>. <year>2015</year>. <article-title>Live attenuated vaccines: historical successes and current challenges</article-title>. <source>Virology</source><volume>479-480</volume>:<fpage>379</fpage>&#8211;<lpage>392</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virol.2015.03.032</pub-id>.<pub-id pub-id-type="pmid">25864107</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Maruggi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name></person-group>. <year>2019</year>. <article-title>Advances in mRNA vaccines for infectious diseases</article-title>. <source>Front Immunol</source><volume>10</volume>:<fpage>594</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id>.<pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>Z</given-names></string-name></person-group>. <year>2005</year>. <article-title>DNA vaccine</article-title>. <source>Adv Genet</source><volume>54</volume>:<fpage>257</fpage>&#8211;<lpage>289</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0065-2660(05)54011-2</pub-id>.<pub-id pub-id-type="pmid">16096015</pub-id><pub-id pub-id-type="pmcid">PMC7119308</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Barranco</surname><given-names>C</given-names></string-name></person-group>. <day>28</day><month>September</month><year>2020</year>. <article-title>The first live attenuated vaccines</article-title>. <source>Nat Res</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nature.com/articles/d42859-020-00008-5" ext-link-type="uri">https://www.nature.com/articles/d42859-020-00008-5</ext-link>.</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Flint</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Skalka</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Rall</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Racaniello</surname><given-names>VR</given-names></string-name></person-group>. <year>2015</year>. <article-title>Principles of virology</article-title>, vol <volume>I</volume>. <source>Molecular biology</source><publisher-name>American Society for Microbiology</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>.</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sanchez-Felipe</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vercruysse</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lemmens</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Van Looveren</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Arkalagud Javarappa</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Boudewijns</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Malengier-Devlies</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liesenborghs</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kaptein</surname><given-names>SJF</given-names></string-name>, <string-name name-style="western"><surname>De Keyzer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bervoets</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Debaveye</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rasulova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Seldeslachts</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L-H</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yakass</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Verstrepen</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>B&#246;sz&#246;rm&#233;nyi</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Kiemenyi-Kayere</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>van Driel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Quaye</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>ter Horst</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mishra</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Deboutte</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Matthijnssens</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Coelmont</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vandermeulen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Heylen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vergote</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schols</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bogers</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kuiken</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Verschoor</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cawthorne</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Van Laere</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Opdenakker</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Vande Velde</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Weynand</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Teuwen</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Matthys</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Neyts</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jan Thibaut</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dallmeier</surname><given-names>K</given-names></string-name></person-group>. <year>2021</year>. <article-title>A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate</article-title>. <source>Nature</source><volume>590</volume>:<fpage>320</fpage>&#8211;<lpage>325</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-3035-9</pub-id>.<pub-id pub-id-type="pmid">33260195</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Siegrist</surname><given-names>C-A</given-names></string-name></person-group>. <year>2018</year>. <part-title>Vaccine immunology</part-title>, p <fpage>16</fpage>&#8211;<lpage>34.e7</lpage>. <italic toggle="yes">In</italic><person-group person-group-type="editor"><string-name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Orenstein</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Offit</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>KM</given-names></string-name></person-group> (ed), <source>Plotkin&#8217;s vaccines</source>, <edition>7th ed</edition>. <publisher-name>Elsevier</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>.</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chodosh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name></person-group>. <year>2020</year>. <article-title>COVID-19: coronavirus vaccine development updates</article-title>. <source>Front Immunol</source><volume>11</volume>:<fpage>602256</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.602256</pub-id>.<pub-id pub-id-type="pmid">33424848</pub-id><pub-id pub-id-type="pmcid">PMC7785583</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="webpage"><collab>US Department of Health &amp; Human Services</collab>. <year>2021</year>. <article-title>Vaccine types</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/immunization/basics/types/index.html" ext-link-type="uri">https://www.hhs.gov/immunization/basics/types/index.html</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Khang</surname><given-names>D</given-names></string-name></person-group>. <day>21</day><month>November</month><year>2022</year>. <article-title>Mucosal delivery of nanovaccine strategy against COVID-19 and its variants</article-title>. <source>Acta Pharm Sin B</source> doi:<pub-id pub-id-type="doi">10.1016/j.apsb.2022.11.022</pub-id>.<pub-id pub-id-type="pmcid">PMC9676163</pub-id><pub-id pub-id-type="pmid">36438851</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>X</given-names></string-name></person-group>. <year>2022</year>. <article-title>Intranasal COVID-19 vaccines: from bench to bed</article-title>. <source>eBioMedicine</source><volume>76</volume>:<fpage>103841</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2022.103841</pub-id>.<pub-id pub-id-type="pmid">35085851</pub-id><pub-id pub-id-type="pmcid">PMC8785603</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="working-paper"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Vercruysse</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Felipe</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kerstens</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rasulova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abdelnabi</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Foo</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Lemmens</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Van Looveren</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Maes</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Baele</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Weynand</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lemey</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Neyts</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Thibaut</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Dallmeier</surname><given-names>K</given-names></string-name></person-group>. <day>16</day><month>February</month><year>2022</year>. <article-title>Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters</article-title>. <source>bioRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.11.12.468374</pub-id>.<pub-id pub-id-type="pmcid">PMC9636174</pub-id><pub-id pub-id-type="pmid">36333374</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Marshall</surname><given-names>D</given-names></string-name></person-group>. <day>23</day><month>April</month><year>2020</year>. <article-title>Griffith University researchers on the road to COVID-19 vaccine</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/" ext-link-type="uri">https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="webpage"><collab>Milken Institute</collab>. <article-title>COVID-19 Treatment and Vaccine Tracker</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker_WEB.pdf" ext-link-type="uri">https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker_WEB.pdf</ext-link>. <date-in-citation content-type="access-date">Accessed 5 August 2022</date-in-citation>.</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Coleman</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Stawowczyk</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tafrova</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tasker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Boltz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Seale</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Kushnir</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wimmer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mueller</surname><given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy</article-title>. <source>Proc Natl Acad Sci USA</source><volume>118</volume>:<elocation-id>e2102775118</elocation-id>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2102775118</pub-id>.<pub-id pub-id-type="pmid">34193524</pub-id><pub-id pub-id-type="pmcid">PMC8307828</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coleman</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Papamichail</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Skiena</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Futcher</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wimmer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mueller</surname><given-names>S</given-names></string-name></person-group>. <year>2008</year>. <article-title>Virus attenuation by genome-scale changes in codon pair bias</article-title>. <source>Science</source><volume>320</volume>:<fpage>1784</fpage>&#8211;<lpage>1787</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1155761</pub-id>.<pub-id pub-id-type="pmid">18583614</pub-id><pub-id pub-id-type="pmcid">PMC2754401</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="webpage"><collab>Codagenix, Inc</collab>. <year>2022</year>. <article-title>First-in-human, randomised, double-blind, placebo-controlled, dose-escalation study in healthy young adults evaluating the safety and immunogenicity of COVI-VAC, a live attenuated vaccine candidate for prevention of COVID-19</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04619628">NCT04619628</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04619628" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04619628</ext-link>.</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kushnir</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mueller</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tasker</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Robert Coleman</surname><given-names>J</given-names></string-name></person-group>. <year>2021</year>. <article-title>COVI-VAC&#8482;, a live attenuated COVID-19 vaccine, provides single dose protection against heterologous challenge with SARS-CoV-2 Beta (B.1.351) in the Syrian golden hamster model</article-title>. <source>Open Forum Infect Dis</source><volume>8</volume>:<fpage>S390</fpage>. doi:<pub-id pub-id-type="doi">10.1093/ofid/ofab466.775</pub-id>.</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>C-Q</given-names></string-name></person-group>. <year>2022</year>. <article-title>Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human</article-title>. <source>Virol J</source><volume>19</volume>:<fpage>209</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12985-022-01945-5</pub-id>.<pub-id pub-id-type="pmid">36482293</pub-id><pub-id pub-id-type="pmcid">PMC9733243</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tioni</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Jordan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pena</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Phan</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Greenhouse</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Orekov</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Valentin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pessaint</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Stobart</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Bloodworth</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Stokes Peebles</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>P-Y</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>RS</given-names></string-name></person-group>. <year>2022</year>. <article-title>Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2</article-title>. <source>NPJ Vaccines</source><volume>7</volume>:<fpage>85</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-022-00509-6</pub-id>.<pub-id pub-id-type="pmid">35906244</pub-id><pub-id pub-id-type="pmcid">PMC9334537</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name></person-group>. <year>2019</year>. <article-title>Recent progress in vaccine development against chikungunya virus</article-title>. <source>Front Microbiol</source><volume>10</volume>:<fpage>2881</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2019.02881</pub-id>.<pub-id pub-id-type="pmid">31921059</pub-id><pub-id pub-id-type="pmcid">PMC6930866</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="webpage"><collab>Meissa Vaccines, Inc</collab>. <year>2022</year>. <article-title>Phase 1, open-label, dose-escalation study to evaluate tolerability, safety, and immunogenicity of an intranasal live attenuated respiratory syncytial virus vaccine expressing spike protein of SARS-CoV-2 in healthy adults ages 18&#8211;69 years</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04798001">NCT04798001</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04798001" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04798001</ext-link>.</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Rando</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Greene</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Robson</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Boca</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Wellhausen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lordan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Brueffer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Agostino McGowan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gitter</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dattoli</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Velazquez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Barton</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Field</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Ramsundar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>MacLean</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AJ</given-names></string-name>, <collab>Immunology Institute of the Icahn School ofMedicine</collab>, <string-name name-style="western"><surname>Hu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jadavji</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Sell</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rafizadeh</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Skelly</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Ben Guebila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kolla</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Manheim</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Byrd</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Bansal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Capone</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dziak</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shinholster</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lukan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Knyazev</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Perrin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mangul</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Szeto</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Lubiana</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mai</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Goel</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Boerckel</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Naik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Himmelstein</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Kamil</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Mundo</surname><given-names>AI</given-names></string-name>, <collab>COVID-19 Review Consortium</collab></person-group>. <year>2023</year>. <article-title>SARS-CoV-2 and COVID-19: an evolving review of diagnostics and therapeutics</article-title>. <source>Manubot</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://greenelab.github.io/covid19-review/" ext-link-type="uri">https://greenelab.github.io/covid19-review/</ext-link>.</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O&#8217;Neill</surname><given-names>LAJ</given-names></string-name>, <string-name name-style="western"><surname>Netea</surname><given-names>MG</given-names></string-name></person-group>. <year>2020</year>. <article-title>BCG-induced trained immunity: can it offer protection against COVID-19?</article-title><source>Nat Rev Immunol</source><volume>20</volume>:<fpage>335</fpage>&#8211;<lpage>337</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41577-020-0337-y</pub-id>.<pub-id pub-id-type="pmid">32393823</pub-id><pub-id pub-id-type="pmcid">PMC7212510</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moorlag</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Taks</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ten Doesschate</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>van der Vaart</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Janssen</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ostermann</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dijkstra</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lemmers</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Simonetti</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mazur</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schaal</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ter Heine</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>van de Veerdonk</surname><given-names>FL</given-names></string-name>, <string-name name-style="western"><surname>Bleeker-Rovers</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>van Crevel</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ten Oever</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>de Jonge</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Bonten</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>van Werkhoven</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Netea</surname><given-names>MG</given-names></string-name></person-group>. <year>2022</year>. <article-title>Efficacy of BCG vaccination against respiratory tract infections in older adults during the coronavirus disease 2019 pandemic</article-title>. <source>Clin Infect Dis</source><volume>75</volume>:<fpage>e938</fpage>&#8211;<lpage>e946</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac182</pub-id>.<pub-id pub-id-type="pmid">35247264</pub-id><pub-id pub-id-type="pmcid">PMC8903481</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="webpage">Murdoch Childrens Research Institute. <article-title>BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04327206">NCT04327206</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04327206" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04327206</ext-link>. <date-in-citation content-type="access-date">Accessed 8 February 2021</date-in-citation>.</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="webpage"><collab>Texas A&amp;M University</collab>. <article-title>Bacillus Calmette-Guerin vaccination as defense against SARS-CoV-2: a randomized controlled trial to protect health care workers by enhanced trained immune responses</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348370">NCT04348370</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04348370" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04348370</ext-link>. <date-in-citation content-type="access-date">Accessed 8 February 2021</date-in-citation>.</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker. Codagenix Inc: COVI-VAC</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/59/" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/59/</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robert-Guroff</surname><given-names>M</given-names></string-name></person-group>. <year>2007</year>. <article-title>Replicating and non-replicating viral vectors for vaccine development</article-title>. <source>Curr Opin Biotechnol</source><volume>18</volume>:<fpage>546</fpage>&#8211;<lpage>556</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.010</pub-id>.<pub-id pub-id-type="pmid">18063357</pub-id><pub-id pub-id-type="pmcid">PMC2245896</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barrett</surname><given-names>PN</given-names></string-name>, <string-name name-style="western"><surname>Terpening</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Snow</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cobb</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Kistner</surname><given-names>O</given-names></string-name></person-group>. <year>2017</year>. <article-title>Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases</article-title>. <source>Expert Rev Vaccines</source><volume>16</volume>:<fpage>883</fpage>&#8211;<lpage>894</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14760584.2017.1357471</pub-id>.<pub-id pub-id-type="pmid">28724343</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Jennings</surname><given-names>GT</given-names></string-name></person-group>. <year>2010</year>. <article-title>Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns</article-title>. <source>Nat Rev Immunol</source><volume>10</volume>:<fpage>787</fpage>&#8211;<lpage>796</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri2868</pub-id>.<pub-id pub-id-type="pmid">20948547</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roberts</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Paddock</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Guarner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zaki</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Sheahan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Baric</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></string-name></person-group>. <year>2008</year>. <article-title>Animal models and vaccines for SARS-CoV infection</article-title>. <source>Virus Res</source><volume>133</volume>:<fpage>20</fpage>&#8211;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.025</pub-id>.<pub-id pub-id-type="pmid">17499378</pub-id><pub-id pub-id-type="pmcid">PMC2323511</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scherle</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Gerhard</surname><given-names>W</given-names></string-name></person-group>. <year>1986</year>. <article-title>Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin</article-title>. <source>J Exp Med</source><volume>164</volume>:<fpage>1114</fpage>&#8211;<lpage>1128</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.164.4.1114</pub-id>.<pub-id pub-id-type="pmid">2944982</pub-id><pub-id pub-id-type="pmcid">PMC2188433</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Br&#252;ssow</surname><given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>COVID-19: vaccine&#8217;s progress</article-title>. <source>Microb Biotechnol</source><volume>14</volume>:<fpage>1246</fpage>&#8211;<lpage>1257</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1751-7915.13818</pub-id>.<pub-id pub-id-type="pmid">33960659</pub-id><pub-id pub-id-type="pmcid">PMC8209887</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="book"><collab>Reuters</collab>. <day>30</day><month>December</month><year>2020</year>. <article-title>China gives its first COVID-19 vaccine approval to Sinopharm</article-title>. <publisher-name>Reuters</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/business/healthcare-pharmaceuticals/china-gives-its-first-covid-19-vaccine-approval-sinopharm-2020-12-31/" ext-link-type="uri">https://www.reuters.com/business/healthcare-pharmaceuticals/china-gives-its-first-covid-19-vaccine-approval-sinopharm-2020-12-31/</ext-link>.</mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Wee</surname><given-names>S-L</given-names></string-name>, <string-name name-style="western"><surname>Sim&#245;es</surname><given-names>M</given-names></string-name></person-group>. <day>16</day><month>July</month><year>2020</year>. <article-title>In coronavirus vaccine race, China strays from the official paths</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/2020/07/16/business/china-vaccine-coronavirus.html" ext-link-type="uri">https://www.nytimes.com/2020/07/16/business/china-vaccine-coronavirus.html</ext-link>.</mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ball</surname><given-names>P</given-names></string-name></person-group>. <year>2021</year>. <article-title>The lightning-fast quest for COVID vaccines&#8212;and what it means for other diseases</article-title>. <source>Nature</source><volume>589</volume>:<fpage>16</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1038/d41586-020-03626-1</pub-id>.<pub-id pub-id-type="pmid">33340018</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ohnishi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Takemori</surname><given-names>T</given-names></string-name></person-group>. <year>2006</year>. <article-title>Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine</article-title>. <source>Rev Med Virol</source><volume>16</volume>:<fpage>117</fpage>&#8211;<lpage>131</lpage>. doi:<pub-id pub-id-type="doi">10.1002/rmv.492</pub-id>.<pub-id pub-id-type="pmid">16518829</pub-id><pub-id pub-id-type="pmcid">PMC7169118</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Takasuka</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fujii</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kasai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Morikawa</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Itamura</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ishii</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sakaguchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ohnishi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ohshima</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hashimoto</surname><given-names>S-i</given-names></string-name>, <string-name name-style="western"><surname>Odagiri</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tashiro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yoshikura</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Takemori</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></string-name></person-group>. <year>2004</year>. <article-title>A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice</article-title>. <source>Int Immunol</source><volume>16</volume>:<fpage>1423</fpage>&#8211;<lpage>1430</lpage>. doi:<pub-id pub-id-type="doi">10.1093/intimm/dxh143</pub-id>.<pub-id pub-id-type="pmid">15314040</pub-id><pub-id pub-id-type="pmcid">PMC7108621</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>Learning from the past: development of safe and effective COVID-19 vaccines</article-title>. <source>Nat Rev Microbiol</source><volume>19</volume>:<fpage>211</fpage>&#8211;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-020-00462-y</pub-id>.<pub-id pub-id-type="pmid">33067570</pub-id><pub-id pub-id-type="pmcid">PMC7566580</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kuwahara</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Morioka</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sakaguchi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name></person-group>. <year>2016</year>. <article-title>Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates</article-title>. <source>ACS Infect Dis</source><volume>2</volume>:<fpage>361</fpage>&#8211;<lpage>376</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00006</pub-id>.<pub-id pub-id-type="pmid">27627203</pub-id><pub-id pub-id-type="pmcid">PMC7075522</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garron</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Narayanan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>B-H</given-names></string-name>, <string-name name-style="western"><surname>Couch</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></string-name></person-group>. <year>2016</year>. <article-title>Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title>. <source>Hum Vaccin Immunother</source><volume>12</volume>:<fpage>2351</fpage>&#8211;<lpage>2356</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id>.<pub-id pub-id-type="pmid">27269431</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McCray</surname><given-names>PB</given-names>, <suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>He</surname><given-names>B</given-names></string-name></person-group>. <year>2020</year>. <article-title>Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection</article-title>. <source>mBio</source><volume>11</volume>:<elocation-id>e00554-20</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mBio.00554-20</pub-id>.<pub-id pub-id-type="pmid">32265331</pub-id><pub-id pub-id-type="pmcid">PMC7157776</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>1</day><month>June</month><year>2021</year>. <article-title>Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1" ext-link-type="uri">https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name></person-group>. <year>2021</year>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>803</fpage>&#8211;<lpage>812</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30987-7</pub-id>.<pub-id pub-id-type="pmid">33548194</pub-id><pub-id pub-id-type="pmcid">PMC7906628</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>C</given-names></string-name></person-group>. <year>2020</year>. <article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title>. <source>Science</source><volume>369</volume>:<fpage>77</fpage>&#8211;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id>.<pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>181</fpage>&#8211;<lpage>192</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id>.<pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker. Sinovac: CoronaVac</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/7/" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/7/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bueno</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Abarca</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>G&#225;lvez</surname><given-names>NMS</given-names></string-name>, <string-name name-style="western"><surname>Soto</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Duarte</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Pacheco</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>V&#225;zquez</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>R&#237;os</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Melo-Gonz&#225;lez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rivera-P&#233;rez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Iturriaga</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Urz&#250;a</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dom&#237;nguez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Andrade</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Berr&#237;os-Rojas</surname><given-names>RV</given-names></string-name>, <string-name name-style="western"><surname>Canedo-Marroqu&#237;n</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Covi&#225;n</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Moreno-Tapia</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Saavedra</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Vallejos</surname><given-names>OP</given-names></string-name>, <string-name name-style="western"><surname>Donato</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Espinoza</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fuentes</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guzm&#225;n</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz Venturelli</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Potin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>&#193;</given-names></string-name>, <string-name name-style="western"><surname>Fasce</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mora</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ram&#237;rez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gaete-Argel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Oyarz&#250;n-Arrau</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Valiente-Echeverr&#237;a</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Soto-Rifo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sette</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez-Aramundiz</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Kalergis</surname><given-names>AM</given-names></string-name></person-group>. <year>2022</year>. <article-title>Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile</article-title>. <source>Clin Infect Dis</source><volume>75</volume>:<fpage>e792</fpage>&#8211;<lpage>e804</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciab823</pub-id>.<pub-id pub-id-type="pmid">34537835</pub-id><pub-id pub-id-type="pmcid">PMC9402626</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanriover</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Do&#287;anay</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Akova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>G&#252;ner</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Azap</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Akhan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>K&#246;se</surname><given-names>&#350;</given-names></string-name>, <string-name name-style="western"><surname>Erdin&#231;</surname><given-names>F&#350;</given-names></string-name>, <string-name name-style="western"><surname>Akal&#305;n</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Tabak</surname><given-names>&#214;F</given-names></string-name>, <string-name name-style="western"><surname>Pulluk&#231;u</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Batum</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>&#350;im&#351;ek Yavuz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Turhan</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>Y&#305;ld&#305;rmak</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>K&#246;ksal</surname><given-names>&#304;</given-names></string-name>, <string-name name-style="western"><surname>Ta&#351;ova</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Korten</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Y&#305;lmaz</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>&#199;elen</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Alt&#305;n</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>&#199;elik</surname><given-names>&#304;</given-names></string-name>, <string-name name-style="western"><surname>Bay&#305;nd&#305;r</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Karao&#287;lan</surname><given-names>&#304;</given-names></string-name>, <string-name name-style="western"><surname>Y&#305;lmaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>&#214;zkul</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>G&#252;r</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Unal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kayaaslan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hasano&#287;lu</surname><given-names>&#304;</given-names></string-name>, <string-name name-style="western"><surname>Dalk&#305;ran</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Aydos</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>&#199;&#305;nar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Akdemir-Kalkan</surname><given-names>&#304;</given-names></string-name>, <string-name name-style="western"><surname>&#304;nkaya</surname><given-names>A&#199;</given-names></string-name>, <string-name name-style="western"><surname>Aydin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>&#199;akir</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Y&#305;ld&#305;z</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kocab&#305;y&#305;k</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>Arslan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nall&#305;</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Demir</surname><given-names>&#214;</given-names></string-name>, <string-name name-style="western"><surname>Singil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ataman-Hatipo&#287;lu</surname><given-names>&#199;</given-names></string-name>, <string-name name-style="western"><surname>Tuncer-Ertem</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>K&#305;n&#305;kl&#305;</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>&#214;nal</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Mete</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dalgan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ta&#351;bakan</surname><given-names>M</given-names></string-name>, <collab>CoronaVac Study Group</collab></person-group>. <year>2021</year>. <article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey</article-title>. <source>Lancet</source><volume>398</volume>:<fpage>213</fpage>&#8211;<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)01429-X</pub-id>.<pub-id pub-id-type="pmid">34246358</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Corum</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>C</given-names></string-name></person-group>. <day>7</day><month>May</month><year>2021</year>. <article-title>How the Sinovac vaccine works</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html" ext-link-type="uri">https://www.nytimes.com/interactive/2020/health/sinovac-covid-19-vaccine.html</ext-link>.</mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palacios</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pati&#241;o</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira Piorelli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Conde</surname><given-names>MTRP</given-names></string-name>, <string-name name-style="western"><surname>Batista</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xin</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Kallas</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Flores</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ockenhouse</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Gast</surname><given-names>C</given-names></string-name></person-group>. <year>2020</year>. <article-title>Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac&#8212;PROFISCOV: a structured summary of a study protocol for a randomised controlled trial</article-title>. <source>Trials</source><volume>21</volume>:<fpage>853</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13063-020-04775-4</pub-id>.<pub-id pub-id-type="pmid">33059771</pub-id><pub-id pub-id-type="pmcid">PMC7558252</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palacios</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Batista</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Albuquerque</surname><given-names>CSN</given-names></string-name>, <string-name name-style="western"><surname>Pati&#241;o</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Santos J do</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tilli Reis Pessoa Conde</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Piorelli R de</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Pereira J&#250;nior</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Raboni</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Ramos</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sierra Romero</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Leal</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>Camargo</surname><given-names>LFA</given-names></string-name>, <string-name name-style="western"><surname>Aoki</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Coelho</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Oliveira</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Fontes</surname><given-names>CJF</given-names></string-name>, <string-name name-style="western"><surname>Pileggi</surname><given-names>GCS</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>ALL</given-names></string-name>, <string-name name-style="western"><surname>de Siqueira</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>DBL</given-names></string-name>, <string-name name-style="western"><surname>Botosso</surname><given-names>VF</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xin</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Teixeira</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Nogueira</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Kallas</surname><given-names>EG</given-names></string-name></person-group>. <day>14</day><month>April</month><year>2021</year>. <article-title>Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study</article-title>. <source>SSRN J</source> doi:<pub-id pub-id-type="doi">10.2139/ssrn.3822780</pub-id>.</mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Medeiros-Ribeiro</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Aikawa</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Saad</surname><given-names>CGS</given-names></string-name>, <string-name name-style="western"><surname>Yuki</surname><given-names>EFN</given-names></string-name>, <string-name name-style="western"><surname>Pedrosa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fusco</surname><given-names>SRG</given-names></string-name>, <string-name name-style="western"><surname>Rojo</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>RMR</given-names></string-name>, <string-name name-style="western"><surname>Shinjo</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Andrade</surname><given-names>DCO</given-names></string-name>, <string-name name-style="western"><surname>Sampaio-Barros</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Ribeiro</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Deveza</surname><given-names>GBH</given-names></string-name>, <string-name name-style="western"><surname>Martins</surname><given-names>VAO</given-names></string-name>, <string-name name-style="western"><surname>Silva</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Duarte</surname><given-names>AJS</given-names></string-name>, <string-name name-style="western"><surname>Antonangelo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sabino</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Kallas</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Pasoto</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Bonfa</surname><given-names>E</given-names></string-name></person-group>. <year>2021</year>. <article-title>Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial</article-title>. <source>Nat Med</source><volume>27</volume>:<fpage>1744</fpage>&#8211;<lpage>1751</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01469-5</pub-id>.<pub-id pub-id-type="pmid">34331051</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jiao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Q</given-names></string-name></person-group>. <year>2021</year>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>1645</fpage>&#8211;<lpage>1653</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00319-4</pub-id>.<pub-id pub-id-type="pmid">34197764</pub-id><pub-id pub-id-type="pmcid">PMC8238449</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="book"><collab>Reuters</collab>. <day>23</day><month>December</month><year>2020</year>. <article-title>Brazil institute says CoronaVac efficacy above 50%, delays full results</article-title>. <publisher-name>Reuters</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/article/us-health-coronavirus-sinovac-butantan/brazil-institute-says-coronavac-efficacy-above-50-delays-full-results-idUKKBN28X2FC" ext-link-type="uri">https://www.reuters.com/article/us-health-coronavirus-sinovac-butantan/brazil-institute-says-coronavac-efficacy-above-50-delays-full-results-idUKKBN28X2FC</ext-link>.</mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Londo&#241;o</surname><given-names>E</given-names></string-name></person-group>. <day>25</day><month>December</month><year>2020</year>. <article-title>Turkey and Brazil say Chinese vaccine effective, with sparse supporting data</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/2020/12/25/health/turkey-brazil-sinovac-coronavirus-vaccine.html" ext-link-type="uri">https://www.nytimes.com/2020/12/25/health/turkey-brazil-sinovac-coronavirus-vaccine.html</ext-link>.</mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Undurraga</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paredes</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fontecilla</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jara</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pizarro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Acevedo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Leo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sans</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Leighton</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Su&#225;rez</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Escorza</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Araos</surname><given-names>R</given-names></string-name></person-group>. <year>2021</year>. <article-title>Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile</article-title>. <source>N Engl J Med</source><volume>385</volume>:<fpage>875</fpage>&#8211;<lpage>884</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2107715</pub-id>.<pub-id pub-id-type="pmid">34233097</pub-id><pub-id pub-id-type="pmcid">PMC8279092</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Corum</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wee</surname><given-names>S-L</given-names></string-name>, <string-name name-style="western"><surname>Kristoffersen</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Coronavirus vaccine tracker</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html" ext-link-type="uri">https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html</ext-link>.</mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tunjungputri</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Tetrasiwi</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Veronica</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pandelaki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ibrahim</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Nelwan</surname><given-names>EJ</given-names></string-name></person-group>. <year>2021</year>. <article-title>Vaccine-associated disease enhancement (VADE): considerations in postvaccination COVID-19</article-title>. <source>Case Rep in Medicine</source><volume>2021</volume>:<fpage>9673453</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2021/9673453</pub-id>.<pub-id pub-id-type="pmcid">PMC8570879</pub-id><pub-id pub-id-type="pmid">34745267</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Wee</surname><given-names>S-L</given-names></string-name></person-group>. <day>16</day><month>September</month><year>2021</year>. <article-title>They relied on Chinese vaccines. Now they&#8217;re battling outbreaks</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html" ext-link-type="uri">https://www.nytimes.com/2021/06/22/business/economy/china-vaccines-covid-outbreak.html</ext-link>.</mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vacharathit</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Aiewsakun</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Manopwisedjaroen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Srisaowakarn</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Laopanupong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ludowyke</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Phuphuakrat</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Setthaudom</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ekronarongchai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Srichatrapimuk</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wongsirisin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sangrajrang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Imsuwansri</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kirdlarp</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nualkaew</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sensorn</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sawaengdee</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wichukchinda</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sungkanuparph</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chantratita</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kunakorn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rojanamatin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hongeng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thitithanyanont</surname><given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>CoronaVac induces lower neutralising activity against variants of concern than natural infection</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>1352</fpage>&#8211;<lpage>1354</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00568-5</pub-id>.<pub-id pub-id-type="pmid">34454652</pub-id><pub-id pub-id-type="pmcid">PMC8389976</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mok</surname><given-names>BWY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>JMC</given-names></string-name>, <string-name name-style="western"><surname>Tsang</surname><given-names>OTY</given-names></string-name>, <string-name name-style="western"><surname>Lam</surname><given-names>BHS</given-names></string-name>, <string-name name-style="western"><surname>Chuang</surname><given-names>VWM</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>AWH</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Ip</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>BPC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yip</surname><given-names>CCY</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>VCC</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>IFN</given-names></string-name>, <string-name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>To</surname><given-names>KKW</given-names></string-name></person-group>. <year>2022</year>. <article-title>Neutralization of severe acute respiratory syndrome coronavirus 2 Omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients</article-title>. <source>Clin Infect Dis</source><volume>75</volume>:<fpage>e822</fpage>&#8211;<lpage>e826</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciab1041</pub-id>.<pub-id pub-id-type="pmid">34915551</pub-id><pub-id pub-id-type="pmcid">PMC8754807</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>G-L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z-Y</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>L-J</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>Q-C</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>M-D</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>K-L</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>W-C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>M-J</given-names></string-name></person-group>. <year>2021</year>. <article-title>Susceptibility of circulating SARS-CoV-2 variants to neutralization</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>2354</fpage>&#8211;<lpage>2356</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMc2103022</pub-id>.<pub-id pub-id-type="pmid">33822491</pub-id><pub-id pub-id-type="pmcid">PMC8063885</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Angkasekwinai</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sewatanon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Niyomnaitham</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Phumiamorn</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sukapirom</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sapsutthipas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sirijatuphat</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wittawatmongkol</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Senawong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mahasirimongkol</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Trisiriwanich</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chokephaibulkit</surname><given-names>K</given-names></string-name></person-group>. <year>2022</year>. <article-title>Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers</article-title>. <source>Vaccine X</source><volume>10</volume>:<fpage>100153</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jvacx.2022.100153</pub-id>.<pub-id pub-id-type="pmid">35282410</pub-id><pub-id pub-id-type="pmcid">PMC8896862</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hua</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name></person-group>. <year>2022</year>. <article-title>Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 vaccine: a 6-month population-based cohort study</article-title>. <source>Front Immunol</source><volume>13</volume>:<fpage>939311</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2022.939311</pub-id>.<pub-id pub-id-type="pmid">36032136</pub-id><pub-id pub-id-type="pmcid">PMC9411798</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name></person-group>. <day>8</day><month>August</month><year>2021</year>. <article-title>A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.08.03.21261544</pub-id>.</mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name></person-group>. <year>2022</year>. <article-title>Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials</article-title>. <source>Lancet Infect Dis</source><volume>22</volume>:<fpage>483</fpage>&#8211;<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00681-2</pub-id>.<pub-id pub-id-type="pmid">34890537</pub-id><pub-id pub-id-type="pmcid">PMC8651254</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="webpage"><collab>Medical Xpress</collab>. <day>11</day><month>August</month><year>2021</year>. <article-title>China approves first mixed-vaccine trial as Delta spreads</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medicalxpress.com/news/2021-08-china-mixed-vaccine-trial-delta.html" ext-link-type="uri">https://medicalxpress.com/news/2021-08-china-mixed-vaccine-trial-delta.html</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Araos</surname><given-names>R</given-names></string-name></person-group>. <year>2021</year>. <article-title>Reactogenicidad, seguridad e inmunogenicidad de dosis de refuerzo de vacunas contra SARS-CoV-2 en Chile (Estudio REFUERZO)</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04992182">NCT04992182</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04992182" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04992182</ext-link>.</mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>F</given-names></string-name></person-group>. <year>2022</year>. <article-title>Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial</article-title>. <source>Nat Med</source><volume>28</volume>:<fpage>401</fpage>&#8211;<lpage>409</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01677-z</pub-id>.<pub-id pub-id-type="pmid">35087233</pub-id><pub-id pub-id-type="pmcid">PMC8863573</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>P&#233;rez-Then</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lucas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Monteiro</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Miric</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brache</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Cochon</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vogels</surname><given-names>CBF</given-names></string-name>, <string-name name-style="western"><surname>Malik</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>De la Cruz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jorge</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>De los Santos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Breban</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Billig</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yildirim</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Downing</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gagnon</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Muyombwe</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Razeq</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ko</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Omer</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Grubaugh</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Vermund</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></string-name></person-group>. <year>2022</year>. <article-title>Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination</article-title>. <source>Nat Med</source><volume>28</volume>:<fpage>481</fpage>&#8211;<lpage>485</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-01705-6</pub-id>.<pub-id pub-id-type="pmid">35051990</pub-id><pub-id pub-id-type="pmcid">PMC8938264</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>10</day><month>June</month><year>2022</year>. <article-title>The Sinovac-CoronaVac COVID-19 vaccine: what you need to know</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know" ext-link-type="uri">https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kyriakidis</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez</surname><given-names>EV</given-names></string-name>, <string-name name-style="western"><surname>Grimaldos</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Prado</surname><given-names>EO</given-names></string-name></person-group>. <year>2021</year>. <article-title>SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates</article-title>. <source>NPJ Vaccines</source><volume>6</volume>:<fpage>28</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-021-00292-w</pub-id>.<pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Quan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name></person-group>. <year>2020</year>. <article-title>Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2</article-title>. <source>Cell</source><volume>182</volume>:<fpage>713</fpage>&#8211;<lpage>721.e9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.06.008</pub-id>.<pub-id pub-id-type="pmid">32778225</pub-id><pub-id pub-id-type="pmcid">PMC7275151</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name></person-group>. <year>2021</year>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>39</fpage>&#8211;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30831-8</pub-id>.<pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name></person-group>. <year>2020</year>. <article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes</article-title>. <source>JAMA</source><volume>324</volume>:<fpage>951</fpage>&#8211;<lpage>960</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.15543</pub-id>.<pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al Kaabi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Al Qahtani</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Abdulrazzaq</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Al Nusair</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hassany</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jawad</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Abdalla</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hussein</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Al Mazrouei</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Al Karam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hussain</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Saifuddin Fasihuddin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>You</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mahmoud</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>ElTantawy</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Koshy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zaher</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name></person-group>. <year>2021</year>. <article-title>Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults</article-title>. <source>JAMA</source><volume>326</volume>:<fpage>35</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.8565</pub-id>.<pub-id pub-id-type="pmid">34037666</pub-id><pub-id pub-id-type="pmcid">PMC8156175</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="book"><collab>Reuters</collab>. <day>29</day><month>December</month><year>2020</year>. <article-title>Sinopharm&#8217;s COVID-19 vaccine 79% effective, seeks approval in China</article-title>. <publisher-name>Reuters</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/article/health-coronavirus-china-vaccine-int/sinopharms-covid-19-vaccine-79-effective-seeks-approval-in-china-idUSKBN2940CA" ext-link-type="uri">https://www.reuters.com/article/health-coronavirus-china-vaccine-int/sinopharms-covid-19-vaccine-79-effective-seeks-approval-in-china-idUSKBN2940CA</ext-link>.</mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jeewandara</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Aberathna</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Pushpakumara</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Kamaladasa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guruge</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jayathilaka</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gunasekara</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tanussiya</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kuruppu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ranasinghe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Dayarathne</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dissanayake</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Gamalath</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ekanayake</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jayamali</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wijesinghe</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dissanayake</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Madusanka</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jayadas</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Mudunkotuwa</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Somathilake</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Harvie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nimasha</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Danasekara</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wijayamuni</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schimanski</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Townsend</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ogg</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Malavige</surname><given-names>GN</given-names></string-name></person-group>. <day>19</day><month>July</month><year>2021</year>. <article-title>Antibody and T cell responses to Sinopharm/BBIBP-CorV in na&#239;ve and previously infected individuals in Sri Lanka</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.07.15.21260621</pub-id>.</mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="working-paper"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dai</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name></person-group>. <day>2</day><month>February</month><year>2021</year>. <article-title>Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines</article-title>. <source>bioRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.02.01.429069</pub-id>.</mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ruan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>H</given-names></string-name></person-group>. <year>2022</year>. <article-title>Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine</article-title>. <source>Cell Discov</source><volume>8</volume>:<fpage>10</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41421-022-00373-7</pub-id>.<pub-id pub-id-type="pmid">35102140</pub-id><pub-id pub-id-type="pmcid">PMC8803973</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mohandas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Shete-Aich</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mote</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nyayanit</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Srinivas</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Kadam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Majumdar</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deshpande</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sarkale</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <article-title>Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model</article-title>. <source>iScience</source><volume>24</volume>:<fpage>102054</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.isci.2021.102054</pub-id>.<pub-id pub-id-type="pmid">33521604</pub-id><pub-id pub-id-type="pmcid">PMC7829205</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Mohandas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shete</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Bhati</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kaushal</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deshpande</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gokhale</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mathapati</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Metkari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mote</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Nyayanit</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Sai Prasad</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Suryawanshi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kadam</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Daigude</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gopale</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Majumdar</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Mali</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sarkale</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Baradkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gawande</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fulari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dighe</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gunjikar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kalele</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Srinivas</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Gangakhedkar</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <article-title>Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques</article-title>. <source>Nat Commun</source><volume>12</volume>:<fpage>1386</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-21639-w</pub-id>.<pub-id pub-id-type="pmid">33654090</pub-id><pub-id pub-id-type="pmcid">PMC7925524</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ganneru</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kumar Rai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Redkar</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Gillurkar</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Kushwaha</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Mohapatra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Guleria</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>637</fpage>&#8211;<lpage>646</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30942-7</pub-id>.<pub-id pub-id-type="pmid">33485468</pub-id><pub-id pub-id-type="pmcid">PMC7825810</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ganneru</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Raju</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Praturi</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Redkar</surname><given-names>SV</given-names></string-name>, <string-name name-style="western"><surname>Gillurkar</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Kushwaha</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Mohapatra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhate</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></string-name></person-group>. <year>2021</year>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial</article-title>. <source>Lancet Infect Dis</source><volume>21</volume>:<fpage>950</fpage>&#8211;<lpage>961</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(21)00070-0</pub-id>.<pub-id pub-id-type="pmid">33705727</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="book"><collab>Bharat Biotech</collab>. <year>2021</year>. <article-title>Bharat Biotech announces phase 3 results of COVAXIN</article-title>. <publisher-name>Bharat Biotech</publisher-name>, <publisher-loc>Hyderabad, India</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf" ext-link-type="uri">https://www.bharatbiotech.com/images/press/covaxin-phase3-efficacy-results.pdf</ext-link>.</mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="book"><collab>Biogenetech</collab>. <year>2021</year>. <article-title>Ocugen&#8217;s COVID-19 vaccine co-development partner, Bharat Biotech shares phase 3 interim results of COVAXIN, demonstrates efficacy of 81%</article-title>. <publisher-name>Biogenetech</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biogenetech.co.th/wp-content/uploads/2021/03/5-Ocugen.pdf" ext-link-type="uri">https://www.biogenetech.co.th/wp-content/uploads/2021/03/5-Ocugen.pdf</ext-link>.</mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="webpage"><collab>Xinhuanet</collab>. <day>4</day><month>March</month><year>2021</year>. <article-title>Zimbabwe authorizes use of India&#8217;s first indigenous COVID-19 vaccine</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.xinhuanet.com/english/2021-03/04/c_139783893.htm" ext-link-type="uri">http://www.xinhuanet.com/english/2021-03/04/c_139783893.htm</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Blackwelder</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Potdar</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Aileni</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Kanungo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Redkar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mohapatra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pandey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ranganadin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gumashta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Multani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mohammad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kumari</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></string-name>, <collab>COVAXIN Study Group</collab></person-group>. <year>2021</year>. <article-title>Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial</article-title>. <source>Lancet</source><volume>398</volume>:<fpage>2173</fpage>&#8211;<lpage>2184</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02000-6</pub-id>.<pub-id pub-id-type="pmid">34774196</pub-id><pub-id pub-id-type="pmcid">PMC8584828</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker. Bharat Biotech: Covaxin</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/9/" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/9/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Nyayanit</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shete</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Deshpande</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <article-title>Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta in individuals sera vaccinated with BBV152</article-title>. <source>J Travel Med</source><volume>28</volume>:<fpage>taab154</fpage>. doi:<pub-id pub-id-type="doi">10.1093/jtm/taab154</pub-id>.<pub-id pub-id-type="pmid">34581415</pub-id><pub-id pub-id-type="pmcid">PMC8500129</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Nyayanit</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Deshpande</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shete</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mohan</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <article-title>Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin</article-title>. <source>J Travel Med</source><volume>28</volume>:<fpage>taab104</fpage>. doi:<pub-id pub-id-type="doi">10.1093/jtm/taab104</pub-id>.<pub-id pub-id-type="pmid">34230972</pub-id><pub-id pub-id-type="pmcid">PMC8344909</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sapkal</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Ella</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Deshpande</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vadrevu</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Panda</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bhargava</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <article-title>Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2</article-title>. <source>J Travel Med</source><volume>28</volume>:<fpage>taab051</fpage>. doi:<pub-id pub-id-type="doi">10.1093/jtm/taab051</pub-id>.<pub-id pub-id-type="pmid">33772577</pub-id><pub-id pub-id-type="pmcid">PMC8083765</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Edara</surname><given-names>V-V</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Suthar</surname><given-names>MS</given-names></string-name></person-group>. <day>28</day><month>January</month><year>2022</year>. <article-title>Covaxin (BBV152) vaccine neutralizes SARS-CoV-2 Delta and Omicron variants</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2022.01.24.22269189</pub-id>.</mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Sapkal</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Patil</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Deshpande</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Nyayanit</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Shete</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Suryawanshi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nandapurkar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gurav</surname><given-names>YK</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>P</given-names></string-name></person-group>. <year>2022</year>. <article-title>Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose na&#239;ve vaccinees</article-title>. <source>J Infect</source><volume>84</volume>:<fpage>834</fpage>&#8211;<lpage>872</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jinf.2022.03.016</pub-id>.<pub-id pub-id-type="pmcid">PMC8934181</pub-id><pub-id pub-id-type="pmid">35318093</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rajpurohit</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Suva</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rajpurohit</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Boda</surname><given-names>P</given-names></string-name></person-group>. <year>2021</year>. <article-title>A retrospective observational survey of adverse events following immunization comparing tolerability of covishield and covaxin vaccines in the real world</article-title>. <source>J Pharmacovigil Drug Res</source><volume>2</volume>:<fpage>21</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.53411/jpadr.2021.2.3.5</pub-id>.</mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parida</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Sahu</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Alekhya</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Subba</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Mishra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Padhy</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Patro</surname><given-names>BK</given-names></string-name></person-group>. <year>2022</year>. <article-title>Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India</article-title>. <source>J Med Virol</source><volume>94</volume>:<fpage>2453</fpage>&#8211;<lpage>2459</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmv.27655</pub-id>.<pub-id pub-id-type="pmid">35149993</pub-id><pub-id pub-id-type="pmcid">PMC9088522</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaur</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Kl</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chauhan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kansal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jaisawal</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Patwardhan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chakrabarti</surname><given-names>SS</given-names></string-name></person-group>. <year>2022</year>. <article-title>A prospective observational study on BBV152 coronavirus vaccine use in adolescents and comparison with adults: interim results of the first real-world safety analysis</article-title>. <source>Drug Saf</source><volume>45</volume>:<fpage>1099</fpage>&#8211;<lpage>1109</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40264-022-01226-8</pub-id>.<pub-id pub-id-type="pmid">36030299</pub-id><pub-id pub-id-type="pmcid">PMC9419918</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Behera</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Subba</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Mc</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sahu</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Chandanshive</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Pradhan</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Parida</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Mishra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Patro</surname><given-names>BK</given-names></string-name>, <string-name name-style="western"><surname>Batmanabane</surname><given-names>G</given-names></string-name></person-group>. <year>2022</year>. <article-title>Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India</article-title>. <source>Human Vaccine Immunother</source><volume>18</volume>:<fpage>2034456</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2022.2034456</pub-id>.<pub-id pub-id-type="pmcid">PMC9009960</pub-id><pub-id pub-id-type="pmid">35321625</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sagiraju</surname><given-names>HKR</given-names></string-name>, <string-name name-style="western"><surname>Elavarasi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Paul</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Vig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sirohiya</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ratre</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pandit</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nalwa</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Meena</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Wig</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mittal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pahuja</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Madan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Dwivedi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wundawalli</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mishra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pandey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Matharoo</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mohan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guleria</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bhatnagar</surname><given-names>S</given-names></string-name></person-group>. <day>29</day><month>August</month><year>2021</year>. <article-title>The effectiveness of SARS-CoV-2 vaccination in preventing severe illness and death&#8212;real-world data from a cohort of patients hospitalized with COVID-19</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.08.26.21262705</pub-id>.<pub-id pub-id-type="pmcid">PMC9891054</pub-id><pub-id pub-id-type="pmid">36742977</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="book"><collab>Hindustan Times</collab>. <day>7</day><month>July</month><year>2021</year>. <article-title>Covaxin booster dose: what is it? What does govt say about this?</article-title><publisher-name>Hindustan Times</publisher-name>, <publisher-loc>New Delhi, India</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hindustantimes.com/india-news/covaxin-booster-dose-what-is-it-what-does-govt-say-about-this-101625644184446.html" ext-link-type="uri">https://www.hindustantimes.com/india-news/covaxin-booster-dose-what-is-it-what-does-govt-say-about-this-101625644184446.html</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Das</surname><given-names>S</given-names></string-name></person-group>. <day>25</day><month>September</month><year>2021</year>. <article-title>Booster dose: Bharat Biotech&#8217;s nasal vaccine may be used with Covaxin</article-title>. <publisher-name>Business Standard</publisher-name>, <publisher-loc>New Delhi, India</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.business-standard.com/article/current-affairs/booster-dose-bharat-biotech-s-nasal-vaccine-may-be-used-with-covaxin-121092500034_1.html" ext-link-type="uri">https://www.business-standard.com/article/current-affairs/booster-dose-bharat-biotech-s-nasal-vaccine-may-be-used-with-covaxin-121092500034_1.html</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Bharadwaj</surname><given-names>S</given-names></string-name></person-group>. <day>21</day><month>September</month><year>2021</year>. <article-title>Covaxin kids trial over, Bharat Biotech to submit data to DCGI next week</article-title>. <publisher-name>The Times of India</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://timesofindia.indiatimes.com/india/bharat-biotech-to-submit-covaxin-kids-trials-data-to-dcgi-in-weeks-time/articleshow/86392325.cms" ext-link-type="uri">https://timesofindia.indiatimes.com/india/bharat-biotech-to-submit-covaxin-kids-trials-data-to-dcgi-in-weeks-time/articleshow/86392325.cms</ext-link>.</mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="book"><collab>India Today</collab>. <day>24</day><month>September</month><year>2021</year>. <article-title>WHO emergency approval for Covaxin delayed till October 5</article-title>. <publisher-name>India Today</publisher-name>, <publisher-loc>New Delhi, India</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.indiatoday.in/coronavirus-covid-19-outbreak/video/who-emergency-approval-for-covaxin-delayed-till-october-1856178-2021-09-23" ext-link-type="uri">https://www.indiatoday.in/coronavirus-covid-19-outbreak/video/who-emergency-approval-for-covaxin-delayed-till-october-1856178-2021-09-23</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>2</day><month>April</month><year>2022</year>. <article-title>Suspension of supply of COVID-19 vaccine (COVAXIN&#174;)</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int/pqweb/vaccines/suspension-supply-covid-19-vaccine-covaxin" ext-link-type="uri">https://extranet.who.int/pqweb/vaccines/suspension-supply-covid-19-vaccine-covaxin</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thiagarajan</surname><given-names>K</given-names></string-name></person-group>. <year>2022</year>. <article-title>Covid-19: WHO suspends supplies of India&#8217;s Covaxin through UN agencies</article-title>. <source>BMJ</source><volume>377</volume>:<fpage>o902</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.o902</pub-id>.<pub-id pub-id-type="pmid">35387784</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="book"><collab>PTI</collab>. <day>24</day><month>May</month><year>2022</year>. <article-title>FDA lifts hold on Bharat Biotech&#8217;s Covaxin clinical trials in US</article-title>. <publisher-name>Business Today</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.businesstoday.in/coronavirus/story/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24" ext-link-type="uri">https://www.businesstoday.in/coronavirus/story/fda-lifts-hold-on-bharat-biotechs-covaxin-clinical-trials-in-us-334915-2022-05-24</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moir</surname><given-names>NL</given-names></string-name></person-group>. <year>2020</year>. <article-title>To boldly remember where we have already been</article-title>. <source>J Appl Hist</source><volume>2</volume>:<fpage>17</fpage>&#8211;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1163/25895893-bja10009</pub-id>.</mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McMenamin</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></string-name></person-group>. <year>2021</year>. <article-title>CoronaVac efficacy data from Turkey</article-title>. <source>Lancet</source><volume>398</volume>:<fpage>1873</fpage>&#8211;<lpage>1874</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02288-1</pub-id>.<pub-id pub-id-type="pmid">34801104</pub-id><pub-id pub-id-type="pmcid">PMC8601678</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanriover</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Do&#287;anay</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Unal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Akova</surname><given-names>M</given-names></string-name></person-group>. <year>2021</year>. <article-title>CoronaVac efficacy data from Turkey&#8212;authors&#8217; reply</article-title>. <source>Lancet</source><volume>398</volume>:<fpage>1874</fpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02286-8</pub-id>.<pub-id pub-id-type="pmcid">PMC8601718</pub-id><pub-id pub-id-type="pmid">34801106</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <year>2022</year>. <article-title>The Valneva VLA2001 COVID-19 vaccine: what you need to know</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/the-valneva-vla2001-covid-19-vaccine--what-you-need-to-know" ext-link-type="uri">https://www.who.int/news-room/feature-stories/detail/the-valneva-vla2001-covid-19-vaccine--what-you-need-to-know</ext-link>. <date-in-citation content-type="access-date">Accessed 1 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>10</day><month>June</month><year>2022</year>. <article-title>The Bharat Biotech BBV152 COVAXIN vaccine against COVID-19: what you need to know</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/the-bharat-biotech-bbv152-covaxin-vaccine-against-covid-19-what-you-need-to-know" ext-link-type="uri">https://www.who.int/news-room/feature-stories/detail/the-bharat-biotech-bbv152-covaxin-vaccine-against-covid-19-what-you-need-to-know</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="webpage"><collab>WHO Collaborating Centre for Vaccine Safety</collab>. <day>20</day><month>September</month><year>2022</year>. <article-title>Is the Sinopharm BIBP (Covilo) COVID-19 vaccine safe and effective?</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.covid19infovaccines.com/en-posts/is-the-sinopharm-bibp-covilo-covid-19-vaccine-safe-and-effective" ext-link-type="uri">https://www.covid19infovaccines.com/en-posts/is-the-sinopharm-bibp-covilo-covid-19-vaccine-safe-and-effective</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>3</day><month>June</month><year>2022</year>. <article-title>COVID-19 vaccine (Vero cell), inactivated (Sinopharm)</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf" ext-link-type="uri">https://cdn.who.int/media/docs/default-source/immunization/covid-19/16-june-22080-sinopharm-vaccine-explainer-update.pdf</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>C</given-names></string-name></person-group>. <year>2022</year>. <article-title>Effectiveness of booster doses of the SARS-CoV-2 inactivated vaccine KCONVAC against the mutant strains</article-title>. <source>Viruses</source><volume>14</volume>:<fpage>2016</fpage>. doi:<pub-id pub-id-type="doi">10.3390/v14092016</pub-id>.<pub-id pub-id-type="pmid">36146822</pub-id><pub-id pub-id-type="pmcid">PMC9503905</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Sattwika</surname><given-names>PD</given-names></string-name></person-group>. <year>2022</year>. <article-title>A phase II non-randomized open labelled clinical trial to evaluate the safety &amp; immunogenicity of SARS-COV-2 vaccine (Vero cell) inactivated as a booster dose</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05172193">NCT05172193</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05172193" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT05172193</ext-link>.</mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="webpage"><collab>China National Biotec Group Company Limited</collab>. <year>2022</year>. <article-title>Multicenter, randomized, double blind, parallel placebo controlled, phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy population aged 18 years old and above</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04510207">NCT04510207</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04510207" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04510207</ext-link>.</mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Silva</surname><given-names>VO</given-names></string-name>, <string-name name-style="western"><surname>Yamashiro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ahagon</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>de Campos</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>IP</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez-Lopes</surname><given-names>GIS</given-names></string-name>, <string-name name-style="western"><surname>Matsuda</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Castejon</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>de Macedo Br&#237;gido</surname><given-names>LF</given-names></string-name></person-group>. <year>2022</year>. <article-title>Inhibition of receptor-binding domain&#8212;ACE2 interaction after two doses of Sinovac&#8217;s CoronaVac or AstraZeneca/Oxford&#8217;s AZD1222 SARS-CoV-2 vaccines</article-title>. <source>J Med Virol</source><volume>94</volume>:<fpage>1217</fpage>&#8211;<lpage>1223</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmv.27396</pub-id>.<pub-id pub-id-type="pmid">34647623</pub-id><pub-id pub-id-type="pmcid">PMC8662120</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pizza</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Del Giudice</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></string-name></person-group>. <year>2014</year>. <article-title>Vaccines, new opportunities for a new society</article-title>. <source>Proc Natl Acad Sci USA</source><volume>111</volume>:<fpage>12288</fpage>&#8211;<lpage>12293</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1402981111</pub-id>.<pub-id pub-id-type="pmid">25136130</pub-id><pub-id pub-id-type="pmcid">PMC4151714</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Donaldson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Al-Barwani</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Scullion</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <part-title>Virus-like particles, a versatile subunit vaccine platform</part-title>, p <fpage>159</fpage>&#8211;<lpage>180</lpage>. <italic toggle="yes">In</italic><person-group person-group-type="editor"><string-name name-style="western"><surname>Foged</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rades</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Perrie</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hook</surname><given-names>S</given-names></string-name></person-group> (ed), <source>Subunit vaccine delivery. Advances in delivery science and technology.</source><publisher-name>Springer</publisher-name>, <publisher-loc>New York, NY</publisher-loc>.</mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Noad</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>P</given-names></string-name></person-group>. <year>2003</year>. <article-title>Virus-like particles as immunogens</article-title>. <source>Trends Microbiol</source><volume>11</volume>:<fpage>438</fpage>&#8211;<lpage>444</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0966-842x(03)00208-7</pub-id>.<pub-id pub-id-type="pmid">13678860</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pollet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W-H</given-names></string-name>, <string-name name-style="western"><surname>Strych</surname><given-names>U</given-names></string-name></person-group>. <year>2021</year>. <article-title>Recombinant protein vaccines, a proven approach against coronavirus pandemics</article-title>. <source>Adv Drug Deliv Rev</source><volume>170</volume>:<fpage>71</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addr.2021.01.001</pub-id>.<pub-id pub-id-type="pmid">33421475</pub-id><pub-id pub-id-type="pmcid">PMC7788321</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nooraei</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bahrulolum</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hoseini</surname><given-names>ZS</given-names></string-name>, <string-name name-style="western"><surname>Katalani</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hajizade</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Ahmadian</surname><given-names>G</given-names></string-name></person-group>. <year>2021</year>. <article-title>Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title>. <source>J Nanobiotechnol</source><volume>19</volume>:<fpage>59</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id>.<pub-id pub-id-type="pmcid">PMC7905985</pub-id><pub-id pub-id-type="pmid">33632278</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Powell</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Newman</surname><given-names>MJ</given-names></string-name></person-group> (ed). <year>1995</year>. <source>Vaccine design. The subunit and adjuvant approach.</source><publisher-name>Springer</publisher-name>, <publisher-loc>New York, NY</publisher-loc>.</mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Singhania</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ramsey</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Murthy</surname><given-names>A</given-names></string-name></person-group>. <year>2014</year>. <article-title>Peptide vaccine: progress and challenges</article-title>. <source>Vaccines (Basel)</source><volume>2</volume>:<fpage>515</fpage>&#8211;<lpage>536</lpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines2030515</pub-id>.<pub-id pub-id-type="pmid">26344743</pub-id><pub-id pub-id-type="pmcid">PMC4494216</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wettendorff</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></string-name></person-group>. <year>2011</year>. <article-title>Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile</article-title>. <source>Expert Opin Biol Ther</source><volume>11</volume>:<fpage>667</fpage>&#8211;<lpage>677</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14712598.2011.573624</pub-id>.<pub-id pub-id-type="pmid">21457083</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>B</given-names></string-name></person-group>. <year>2019</year>. <article-title>Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity</article-title>. <source>Vaccine</source><volume>37</volume>:<fpage>3167</fpage>&#8211;<lpage>3178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id>.<pub-id pub-id-type="pmid">31047671</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stils</surname><given-names>HF</given-names></string-name></person-group>. <year>2005</year>. <article-title>Adjuvants and antibody production: dispelling the myths associated with Freund&#8217;s complete and other adjuvants</article-title>. <source>ILAR J</source><volume>46</volume>:<fpage>280</fpage>&#8211;<lpage>293</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ilar.46.3.280</pub-id>.<pub-id pub-id-type="pmid">15953835</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heck</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lustigman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <year>2006</year>. <article-title>Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design</article-title>. <source>J Virol</source><volume>80</volume>:<fpage>5757</fpage>&#8211;<lpage>5767</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.00083-06</pub-id>.<pub-id pub-id-type="pmid">16731915</pub-id><pub-id pub-id-type="pmcid">PMC1472569</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ulitzky</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Silberstein</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Viscidi</surname><given-names>R</given-names></string-name></person-group>. <year>2013</year>. <article-title>Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates</article-title>. <source>Viral Immunol</source><volume>26</volume>:<fpage>126</fpage>&#8211;<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.1089/vim.2012.0076</pub-id>.<pub-id pub-id-type="pmid">23573979</pub-id><pub-id pub-id-type="pmcid">PMC3624630</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Post</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chubet</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Holtz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mcpherson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Petric</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cox</surname><given-names>M</given-names></string-name></person-group>. <year>2006</year>. <article-title>A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice</article-title>. <source>Vaccine</source><volume>24</volume>:<fpage>3624</fpage>&#8211;<lpage>3631</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.059</pub-id>.<pub-id pub-id-type="pmid">16497416</pub-id><pub-id pub-id-type="pmcid">PMC7115485</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>B-J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name></person-group>. <year>2007</year>. <article-title>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</article-title>. <source>Vaccine</source><volume>25</volume>:<fpage>2832</fpage>&#8211;<lpage>2838</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.10.031</pub-id>.<pub-id pub-id-type="pmid">17092615</pub-id><pub-id pub-id-type="pmcid">PMC7115660</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>B-J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <year>2009</year>. <article-title>Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells</article-title>. <source>Biochem Biophys Res Commun</source><volume>384</volume>:<fpage>486</fpage>&#8211;<lpage>490</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2009.05.003</pub-id>.<pub-id pub-id-type="pmid">19422787</pub-id><pub-id pub-id-type="pmcid">PMC2750803</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>B-J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <year>2010</year>. <article-title>A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity</article-title>. <source>Viral Immunol</source><volume>23</volume>:<fpage>211</fpage>&#8211;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1089/vim.2009.0090</pub-id>.<pub-id pub-id-type="pmid">20374001</pub-id><pub-id pub-id-type="pmcid">PMC2883479</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zakhartchouk</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Sharon</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Satkunarajah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Auperin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Viswanathan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Petric</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>See</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Brunham</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Finlay</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Cameron</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kelvin</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Cochrane</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rini</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Babiuk</surname><given-names>LA</given-names></string-name></person-group>. <year>2007</year>. <article-title>Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine</article-title>. <source>Vaccine</source><volume>25</volume>:<fpage>136</fpage>&#8211;<lpage>143</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.084</pub-id>.<pub-id pub-id-type="pmid">16919855</pub-id><pub-id pub-id-type="pmcid">PMC7115608</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name></person-group>. <year>2005</year>. <article-title>Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus</article-title>. <source>DNA Cell Biol</source><volume>24</volume>:<fpage>510</fpage>&#8211;<lpage>515</lpage>. doi:<pub-id pub-id-type="doi">10.1089/dna.2005.24.510</pub-id>.<pub-id pub-id-type="pmid">16101349</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <year>2005</year>. <article-title>Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus</article-title>. <source>J Clin Microbiol</source><volume>43</volume>:<fpage>3718</fpage>&#8211;<lpage>3726</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JCM.43.8.3718-3726.2005</pub-id>.<pub-id pub-id-type="pmid">16081901</pub-id><pub-id pub-id-type="pmcid">PMC1234014</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Q</given-names></string-name></person-group>. <year>2009</year>. <article-title>Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice</article-title>. <source>Vaccine</source><volume>27</volume>:<fpage>5001</fpage>&#8211;<lpage>5007</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.073</pub-id>.<pub-id pub-id-type="pmid">19523911</pub-id><pub-id pub-id-type="pmcid">PMC7115566</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Leng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lien</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hsieh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chong</surname><given-names>P</given-names></string-name></person-group>. <year>2006</year>. <article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title>. <source>Vaccine</source><volume>24</volume>:<fpage>3100</fpage>&#8211;<lpage>3108</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.058</pub-id>.<pub-id pub-id-type="pmid">16494977</pub-id><pub-id pub-id-type="pmcid">PMC7115648</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name></person-group>. <year>2020</year>. <article-title>Subunit vaccines against emerging pathogenic human coronaviruses</article-title>. <source>Front Microbiol</source><volume>11</volume>:<fpage>298</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2020.00298</pub-id>.<pub-id pub-id-type="pmid">32265848</pub-id><pub-id pub-id-type="pmcid">PMC7105881</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>W-H</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chag</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tricoche</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Seid</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Hudspeth</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Lustigman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></string-name>, <string-name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Zhan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <year>2014</year>. <article-title>Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate</article-title>. <source>Hum Vaccin Immunother</source><volume>10</volume>:<fpage>648</fpage>&#8211;<lpage>658</lpage>. doi:<pub-id pub-id-type="doi">10.4161/hv.27464</pub-id>.<pub-id pub-id-type="pmid">24355931</pub-id><pub-id pub-id-type="pmcid">PMC4130269</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name></person-group>. <year>2015</year>. <article-title>Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge</article-title>. <source>EBioMedicine</source><volume>2</volume>:<fpage>1438</fpage>&#8211;<lpage>1446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.031</pub-id>.<pub-id pub-id-type="pmid">26629538</pub-id><pub-id pub-id-type="pmcid">PMC4634622</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name></person-group>. <year>2014</year>. <article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title>. <source>PLoS One</source><volume>9</volume>:<elocation-id>e112602</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0112602</pub-id>.<pub-id pub-id-type="pmid">25405618</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nyon</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></string-name>, <string-name name-style="western"><surname>Seid</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Pollet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Naceanceno</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>B-H</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Strych</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></string-name></person-group>. <year>2018</year>. <article-title>Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen</article-title>. <source>Vaccine</source><volume>36</volume>:<fpage>1853</fpage>&#8211;<lpage>1862</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.065</pub-id>.<pub-id pub-id-type="pmid">29496347</pub-id><pub-id pub-id-type="pmcid">PMC5860679</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>C-TK</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name></person-group>. <year>2016</year>. <article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title>. <source>Virology</source><volume>499</volume>:<fpage>375</fpage>&#8211;<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id>.<pub-id pub-id-type="pmid">27750111</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pallesen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kirchdoerfer</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Cottrell</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>W-P</given-names></string-name>, <string-name name-style="western"><surname>Andres</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Kettenbach</surname><given-names>AN</given-names></string-name>, <string-name name-style="western"><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Chappell</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>McLellan</surname><given-names>JS</given-names></string-name></person-group>. <year>2017</year>. <article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen</article-title>. <source>Proc Natl Acad Sci USA</source><volume>114</volume>:<fpage>E7348</fpage>&#8211;<lpage>E7357</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id>.<pub-id pub-id-type="pmid">28807998</pub-id><pub-id pub-id-type="pmcid">PMC5584442</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name></person-group>. <year>2014</year>. <article-title>The amino acids 736&#8211;761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents</article-title>. <source>Viral Immunol</source><volume>27</volume>:<fpage>543</fpage>&#8211;<lpage>550</lpage>. doi:<pub-id pub-id-type="doi">10.1089/vim.2014.0080</pub-id>.<pub-id pub-id-type="pmid">25387086</pub-id><pub-id pub-id-type="pmcid">PMC4259179</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiaming</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yanfeng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yawei</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Linlin</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baoying</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jinghua</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Chuan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wenjie</surname><given-names>T</given-names></string-name></person-group>. <year>2017</year>. <article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title>. <source>Vaccine</source><volume>35</volume>:<fpage>10</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.064</pub-id>.<pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Olinger</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Todd</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Bagci</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mollura</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Hensley</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jahrling</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Denison</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Rao</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kwong</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Kong</surname><given-names>W-P</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>BS</given-names></string-name></person-group>. <year>2015</year>. <article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title>. <source>Nat Commun</source><volume>6</volume>:<fpage>7712</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id>.<pub-id pub-id-type="pmid">26218507</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>GF</given-names></string-name></person-group>. <year>2016</year>. <article-title>MERS-CoV spike protein: targets for vaccines and therapeutics</article-title>. <source>Antiviral Res</source><volume>133</volume>:<fpage>165</fpage>&#8211;<lpage>177</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.antiviral.2016.07.015</pub-id>.<pub-id pub-id-type="pmid">27468951</pub-id><pub-id pub-id-type="pmcid">PMC7113765</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hashemzadeh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Avan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ferns</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Khazaei</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Vaccines based on virus-like nano-particles for use against Middle East respiratory syndrome (MERS) coronavirus</article-title>. <source>Vaccine</source><volume>38</volume>:<fpage>5742</fpage>&#8211;<lpage>5746</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.07.003</pub-id>.<pub-id pub-id-type="pmid">32684497</pub-id><pub-id pub-id-type="pmcid">PMC7837099</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>YV</given-names></string-name>, <string-name name-style="western"><surname>Mu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Massare</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Flyer</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></string-name></person-group>. <year>2014</year>. <article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title>. <source>Vaccine</source><volume>32</volume>:<fpage>3169</fpage>&#8211;<lpage>3174</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.016</pub-id>.<pub-id pub-id-type="pmid">24736006</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xia</surname><given-names>X</given-names></string-name></person-group>. <year>2017</year>. <article-title>MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity [<italic toggle="yes">sic</italic>] in rhesus macaques</article-title>. <source>Oncotarget</source><volume>8</volume>:<fpage>12686</fpage>&#8211;<lpage>12694</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.8475</pub-id>.<pub-id pub-id-type="pmid">27050368</pub-id><pub-id pub-id-type="pmcid">PMC5355045</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>W</given-names></string-name></person-group>. <year>2018</year>. <article-title>Significant spike-specific IgG and neutralizing antibodies in mice induced by a novel chimeric virus-like particle vaccine candidate for Middle East respiratory syndrome coronavirus</article-title>. <source>Virol Sin</source><volume>33</volume>:<fpage>453</fpage>&#8211;<lpage>455</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12250-018-0064-8</pub-id>.<pub-id pub-id-type="pmid">30374826</pub-id><pub-id pub-id-type="pmcid">PMC6235757</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y-D</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>W-Y</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>J-H</given-names></string-name>, <string-name name-style="western"><surname>Ferrall</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hung</surname><given-names>C-F</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>T-C</given-names></string-name></person-group>. <year>2020</year>. <article-title>Coronavirus vaccine development: from SARS and MERS to COVID-19</article-title>. <source>J Biomed Sci</source><volume>27</volume>:<fpage>104</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12929-020-00695-2</pub-id>.<pub-id pub-id-type="pmid">33341119</pub-id><pub-id pub-id-type="pmcid">PMC7749790</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liljeqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>St&#229;hl</surname><given-names>S</given-names></string-name></person-group>. <year>1999</year>. <article-title>Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines</article-title>. <source>J Biotechnol</source><volume>73</volume>:<fpage>1</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0168-1656(99)00107-8</pub-id>.<pub-id pub-id-type="pmid">10483112</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ausiello</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Cassone</surname><given-names>A</given-names></string-name></person-group>. <year>2014</year>. <article-title>Acellular pertussis vaccines and pertussis resurgence: revise or replace?</article-title><source>mBio</source><volume>5</volume>:<elocation-id>e01339-14</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mBio.01339-14</pub-id>.<pub-id pub-id-type="pmid">24917600</pub-id><pub-id pub-id-type="pmcid">PMC4056554</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cherry</surname><given-names>JD</given-names></string-name></person-group>. <year>2013</year>. <article-title>Pertussis: challenges today and for the future</article-title>. <source>PLoS Pathog</source><volume>9</volume>:<elocation-id>e1003418</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1003418</pub-id>.<pub-id pub-id-type="pmid">23935481</pub-id><pub-id pub-id-type="pmcid">PMC3723573</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McLemore</surname><given-names>MR</given-names></string-name></person-group>. <year>2006</year>. <article-title>Gardasil: introducing the new human papillomavirus vaccine</article-title>. <source>Clin J Oncol Nurs</source><volume>10</volume>:<fpage>559</fpage>&#8211;<lpage>560</lpage>. doi:<pub-id pub-id-type="doi">10.1188/06.CJON.559-560</pub-id>.<pub-id pub-id-type="pmid">17063609</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>B-J</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name></person-group>. <year>2015</year>. <article-title>Advancements in the development of subunit influenza vaccines</article-title>. <source>Microbes Infect</source><volume>17</volume>:<fpage>123</fpage>&#8211;<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micinf.2014.12.006</pub-id>.<pub-id pub-id-type="pmid">25529753</pub-id><pub-id pub-id-type="pmcid">PMC4336774</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker. Vaccines candidates in clinical trials</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name></person-group>. <year>2016</year>. <article-title>Recent advances in the production of recombinant subunit vaccines in Pichia pastoris</article-title>. <source>Bioengineered</source><volume>7</volume>:<fpage>155</fpage>&#8211;<lpage>165</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21655979.2016.1191707</pub-id>.<pub-id pub-id-type="pmid">27246656</pub-id><pub-id pub-id-type="pmcid">PMC4927204</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <article-title>The Novavax vaccine against COVID-19: what you need to know</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know" ext-link-type="uri">https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keech</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Reed</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Neal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Plested</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cloney-Clark</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Logue</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McGrath</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Weston</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Piedra</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Desai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Callahan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Price-Abbott</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Formica</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shinde</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Fries</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lickliter</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Griffin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></string-name></person-group>. <year>2020</year>. <article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title>. <source>N Engl J Med</source><volume>383</volume>:<fpage>2320</fpage>&#8211;<lpage>2332</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id>.<pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tian</surname><given-names>J-H</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Weston</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hammond</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Logue</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Portnoff</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Guebre-Xabier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jacobson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Maciejewski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khatoon</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wisniewska</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Moffitt</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kluepfel-Stahl</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ekechukwu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Papin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boddapati</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jason Wong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Piedra</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Massare</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Fries</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bengtsson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Stertman</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ellingsworth</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>G</given-names></string-name></person-group>. <year>2021</year>. <article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title>. <source>Nat Commun</source><volume>12</volume>:<fpage>372</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-20653-8</pub-id>.<pub-id pub-id-type="pmid">33446655</pub-id><pub-id pub-id-type="pmcid">PMC7809486</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yee</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Zak</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>F</given-names></string-name></person-group>. <year>2018</year>. <article-title>The coming age of insect cells for manufacturing and development of protein therapeutics</article-title>. <source>Ind Eng Chem Res</source><volume>57</volume>:<fpage>10061</fpage>&#8211;<lpage>10070</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.iecr.8b00985</pub-id>.<pub-id pub-id-type="pmid">30886455</pub-id><pub-id pub-id-type="pmcid">PMC6420222</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Riley</surname><given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Chou</surname><given-names>H-T</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bzymek</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Correia</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Partin</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Manzanillo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Garces</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>Enhancing the prefusion conformational stability of SARS-CoV-2 spike protein through structure-guided design</article-title>. <source>Front Immunol</source><volume>12</volume>:<fpage>660198</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2021.660198</pub-id>.<pub-id pub-id-type="pmid">33968063</pub-id><pub-id pub-id-type="pmcid">PMC8100506</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Heath</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Galiza</surname><given-names>EP</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Boffito</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Browne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chadwick</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cosgrove</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Galloway</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Heer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Higham</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Iyengar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jamal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Jeanes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kalra</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Kyriakidou</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McAuley</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Meyrick</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Minton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Munsoor</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nicholls</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Osanlou</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Packham</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pretswell</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>San Francisco Ramos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Saralaya</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sheridan</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Soiza</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Swift</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Thomson</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Viljoen</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dubovsky</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rivers</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Toback</surname><given-names>S</given-names></string-name>, <collab>2019nCoV-302 Study Group</collab></person-group>. <year>2021</year>. <article-title>Safety and efficacy of NVX-CoV2373 Covid-19 vaccine</article-title>. <source>N Engl J Med</source><volume>385</volume>:<fpage>1172</fpage>&#8211;<lpage>1183</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2107659</pub-id>.<pub-id pub-id-type="pmid">34192426</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dunkle</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Kotloff</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Gay</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>&#193;&#241;ez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Adelglass</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Barrat Hern&#225;ndez</surname><given-names>AQ</given-names></string-name>, <string-name name-style="western"><surname>Harper</surname><given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Duncanson</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>McArthur</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Florescu</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>McClelland</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Garcia-Fragoso</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Riesenberg</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Musante</surname><given-names>DB</given-names></string-name>, <string-name name-style="western"><surname>Fried</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Safirstein</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jeanfreau</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Kingsley</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Lane</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Ru&#237;z-Palacios</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Corey</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Coombs</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Greninger</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Hutter</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ake</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Dubovsky</surname><given-names>F</given-names></string-name>, <collab>2019nCoV-301 Study Group</collab></person-group>. <year>2022</year>. <article-title>Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico</article-title>. <source>N Engl J Med</source><volume>386</volume>:<fpage>531</fpage>&#8211;<lpage>543</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2116185</pub-id>.<pub-id pub-id-type="pmid">34910859</pub-id><pub-id pub-id-type="pmcid">PMC8693692</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Allen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tribble</surname><given-names>SJ</given-names></string-name></person-group>. <day>4</day><month>June</month><year>2022</year>. <article-title>Novavax missed its global moonshot but is angling to win over mRNA defectors</article-title>. <publisher-name>ASBMB Today</publisher-name>, <publisher-loc>Rockville, MD</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.asbmb.org/asbmb-today/industry/060422/novavax-missed-its-global-moonshot-but-is-angling" ext-link-type="uri">https://www.asbmb.org/asbmb-today/industry/060422/novavax-missed-its-global-moonshot-but-is-angling</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tinari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Riva</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Covid-19: whatever happened to the Novavax vaccine?</article-title><source>BMJ</source><volume>375</volume>:<fpage>n2965</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n2965</pub-id>.<pub-id pub-id-type="pmid">34880071</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Price</surname><given-names>WN</given-names>, <suffix>II</suffix></string-name>, <string-name name-style="western"><surname>Rai</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Minssen</surname><given-names>T</given-names></string-name></person-group>. <year>2020</year>. <article-title>Knowledge transfer for large-scale vaccine manufacturing</article-title>. <source>Science</source><volume>369</volume>:<fpage>912</fpage>&#8211;<lpage>914</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abc9588</pub-id>.<pub-id pub-id-type="pmid">32792464</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Owermohle</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Banco</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cancryn</surname><given-names>A</given-names></string-name></person-group>. <day>19</day><month>October</month><year>2021</year>. <article-title>&#8216;They rushed the process&#8217;: vaccine maker&#8217;s woes hamper global inoculation campaign</article-title>. <publisher-name>POLITICO</publisher-name>, <publisher-loc>Arlington, VA</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298" ext-link-type="uri">https://www.politico.com/news/2021/10/19/novavax-vaccine-rush-process-global-campaign-516298</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Kimball</surname><given-names>S</given-names></string-name></person-group>. <day>13</day><month>May</month><year>2022</year>. <article-title>Novavax confident Covid vaccine will receive FDA authorization in June after delays</article-title>. <publisher-name>CNBC</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cnbc.com/2022/05/13/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html" ext-link-type="uri">https://www.cnbc.com/2022/05/13/novavax-confident-covid-vaccine-will-receive-fda-authorization-in-june-after-delays.html</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>17</day><month>December</month><year>2021</year>. <article-title>WHO lists 9th COVID-19 vaccine for emergency use with aim to increase access to vaccination in lower-income countries</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries" ext-link-type="uri">https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.<pub-id pub-id-type="pmcid">PMC9280553</pub-id><pub-id pub-id-type="pmid">35022296</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="book"><collab>Medicines and Healthcare Products Regulatory Agency</collab>. <day>3</day><month>February</month><year>2022</year>. <article-title>Novavax COVID-19 vaccine Nuvaxovid approved by MHRA</article-title>. <publisher-name>Medicines and Healthcare Products Regulatory Agency</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra" ext-link-type="uri">https://www.gov.uk/government/news/novavax-covid-19-vaccine-nuvaxovid-approved-by-mhra</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="webpage"><collab>European Medicines Agency</collab>. <day>20</day><month>December</month><year>2021</year>. <article-title>EMA recommends Nuvaxovid for authorisation in the EU</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu" ext-link-type="uri">https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu</ext-link>.</mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="book"><collab>FDA</collab>. <day>13</day><month>July</month><year>2022</year>. <article-title>Coronavirus (COVID-19) update: FDA authorizes emergency use of Novavax COVID-19 vaccine, adjuvanted</article-title>. <publisher-name>FDA</publisher-name>, <publisher-loc>Silver Spring, MD</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="book"><collab>Reuters</collab>. <day>22</day><month>November</month><year>2022</year>. <article-title>Gavi rejects Novavax&#8217;s claim on COVID vaccine deal breach</article-title>. <publisher-name>Reuters</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/business/healthcare-pharmaceuticals/gavi-says-it-is-not-breach-novavax-vaccine-deal-2022-11-22/" ext-link-type="uri">https://www.reuters.com/business/healthcare-pharmaceuticals/gavi-says-it-is-not-breach-novavax-vaccine-deal-2022-11-22/</ext-link>.</mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shinde</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bhikha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hoosain</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Archary</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bhorat</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lalloo</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Masilela</surname><given-names>MSL</given-names></string-name>, <string-name name-style="western"><surname>Moodley</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hanley</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fouche</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Louw</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tameris</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Goga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dheda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Grobbelaar</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kruger</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Carrim-Ganey</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Baillie</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lombard Koen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lombaard</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Mngqibisa</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bhorat</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Benad&#233;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lalloo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pitsi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vollgraaff</surname><given-names>P-L</given-names></string-name>, <string-name name-style="western"><surname>Luabeya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Esmail</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Petrick</surname><given-names>FG</given-names></string-name>, <string-name name-style="western"><surname>Oommen-Jose</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Foulkes</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Thombrayil</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fries</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cloney-Clark</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Faust</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Plested</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Neal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Dubovsky</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></string-name>, <collab>2019nCoV-501 Study Group</collab></person-group>. <year>2021</year>. <article-title>Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>1899</fpage>&#8211;<lpage>1909</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2103055</pub-id>.<pub-id pub-id-type="pmid">33951374</pub-id><pub-id pub-id-type="pmcid">PMC8091623</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mallory</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Formica</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pfeiffer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Marcheschi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>McFall</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Plested</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cloney-Clark</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chau</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Maciejewski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Dubovsky</surname><given-names>F</given-names></string-name>, <collab>Novavax Inc 2019nCoV-101 Study Group</collab></person-group>. <year>2021</year>. <article-title>Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.12.23.21267374</pub-id>.</mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="webpage"><collab>Novavax</collab>. <year>2022</year>. <article-title>A 2-part, phase 1/2, randomized, observer-blinded study to evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with or without MATRIX-M&#8482; adjuvant in healthy subjects</article-title>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link></comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04368988" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04368988</ext-link>.</mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="working-paper"><person-group person-group-type="author"><string-name name-style="western"><surname>Bhiman</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Lambson</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Kgagudi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mzindle</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kaldine</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Crowther</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bekker</surname><given-names>L-G</given-names></string-name>, <string-name name-style="western"><surname>Shinde</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Madhi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>PL</given-names></string-name></person-group>. <day>17</day><month>July</month><year>2022</year>. <article-title>Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages</article-title>. <source>bioRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2022.07.14.500148</pub-id>.<pub-id pub-id-type="pmcid">PMC9867547</pub-id><pub-id pub-id-type="pmid">36681693</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Toback</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Galiza</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cosgrove</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Galloway</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Swift</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Rajaram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Graves-Jones</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Plested</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Rivers</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Robertson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dubovsky</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>PT</given-names></string-name></person-group>. <day>13</day><month>June</month><year>2021</year>. <article-title>Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.06.09.21258556</pub-id>.<pub-id pub-id-type="pmcid">PMC8598212</pub-id><pub-id pub-id-type="pmid">34800364</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="book"><collab>Novavax</collab>. <day>8</day><month>September</month><year>2021</year>. <article-title>Novavax initiates phase 1/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza</article-title>. <publisher-name>Novavax</publisher-name>, <publisher-loc>Gaithersburg, MD</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ir.novavax.com/2021-09-08-Novavax-Initiates-Phase-1-2-Clinical-Trial-of-Combination-Vaccine-for-COVID-19-and-Seasonal-Influenza" ext-link-type="uri">https://ir.novavax.com/2021-09-08-Novavax-Initiates-Phase-1-2-Clinical-Trial-of-Combination-Vaccine-for-COVID-19-and-Seasonal-Influenza</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="working-paper"><person-group person-group-type="author"><string-name name-style="western"><surname>Massare</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Maciejewski</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Flores</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Guebre-Xabier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>J-H</given-names></string-name>, <string-name name-style="western"><surname>Portnoff</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Fries</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shinde</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ellingsworth</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Glenn</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>G</given-names></string-name></person-group>. <day>5</day><month>May</month><year>2021</year>. <article-title>Combination respiratory vaccine containing recombinant SARS-CoV-2 spike and quadrivalent seasonal influenza hemagglutinin nanoparticles with Matrix-M adjuvant</article-title>. <source>bioRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.05.05.442782</pub-id>.</mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reardon</surname><given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>Cuba&#8217;s bet on home-grown COVID vaccines is paying off</article-title>. <source>Nature</source><volume>600</volume>:<fpage>15</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1038/d41586-021-03470-x</pub-id>.<pub-id pub-id-type="pmid">34811530</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Osterholm</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rabad&#225;n-Diehl</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Anzinger</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bottazzi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Christie-Samuels</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Erondu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Marrazzo</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Milan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Quashie</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Schwaab</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>D</given-names></string-name></person-group>. <year>2022</year>. <article-title>Executive summary. Insights from Cuba&#8217;s COVID-19 vaccine enterprise: report from a high level fact-finding delegation to Cuba</article-title>. <source>MEDICC Rev</source><volume>24</volume>:<fpage>109</fpage>&#8211;<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.37757/mr2022.v24.n3-4.13</pub-id>.<pub-id pub-id-type="pmid">36417339</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Toledo-Roman&#237;</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Carmenate</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valenzuela-Silva</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Baldoqu&#237;n-Rodr&#237;guez</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez-P&#233;rez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Paredes-Moreno</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mendoza-Hern&#225;ndez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez-Mujica Romero</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sam&#243;n-Tabio</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Velazco-Villares</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bacallao-Castillo</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Licea-Mart&#237;n</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Ortega</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Herrera-Marrero</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Caballero-Gonz&#225;lez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Eg&#252;es-Torres</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Duartes-Gonz&#225;lez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Blanco</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Cabrera</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huete-Ferreira</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Idalmis-Cisnero</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Fonte-Galindo</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Meli&#225;-P&#233;rez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rojas-Remedios</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Doroud</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gouya</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Biglari</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez-Castillo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Climent-Ruiz</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Valdes-Balb&#237;n</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Rivera</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Van der Stuyft</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Verez-Bencomo</surname><given-names>V</given-names></string-name>, <collab>SOBERANA Phase 3 team</collab></person-group>. <year>2023</year>. <article-title>Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial</article-title>. <source>Lancet Reg Health Am</source><volume>18</volume>:<fpage>100423</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.lana.2022.100423</pub-id>.<pub-id pub-id-type="pmid">36618081</pub-id><pub-id pub-id-type="pmcid">PMC9803910</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Toledo-Romani</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Carmenate</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Verdecia-S&#225;nchez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Rodr&#237;guez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez-Gonz&#225;lez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valenzuela-Silva</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Paredes-Moreno</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Ramirez</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez-Mugica</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez-Garcia</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Orosa-V&#225;zquez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>D&#237;az-Hern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Guevara</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Enriquez-Puertas</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Noa-Romero</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Palenzuela-Diaz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baro-Roman</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mendoza-Hern&#225;ndez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>G&#243;mez-Maceo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Santos-Vega</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Fernandez-Castillo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Climent-Ruiz</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Noda</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Santana-Mederos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Vega</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>G-W</given-names></string-name>, <string-name name-style="western"><surname>Doroud</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Biglari</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Boggiano-Ayo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Vald&#233;s-Balb&#237;n</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rivera</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a-Rivera</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>V&#233;rez-Bencomo</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Cubas-Curbelo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Castillo</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Acevedo-Mart&#237;nez</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Estoque-Cabrera</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>&#193;vila-Cabreja</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Alfaro-Guzm&#225;n</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Zulueta-P&#233;rez</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Espino-Rojas</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Medinas-Santos</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Sarda-Rodriguez</surname><given-names>IL</given-names></string-name>, <string-name name-style="western"><surname>Acosta-Martinez</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Reyes-Matienzo</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Coviella-Artime</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Morffi-Cinta</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez-P&#233;rez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Valera-Fern&#225;ndez</surname><given-names>R</given-names></string-name>, <collab>SOBERANA Research Group</collab></person-group>. <year>2022</year>. <article-title>Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: phase IIb clinical trial in adults</article-title>. <source>Med (N Y)</source><volume>3</volume>:<fpage>760</fpage>&#8211;<lpage>773.e5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.medj.2022.08.001</pub-id>.<pub-id pub-id-type="pmcid">PMC9359498</pub-id><pub-id pub-id-type="pmid">35998623</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Limonta-Fern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chinea-Santiago</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;n-Dunn</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez-Roche</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bequet-Romero</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marquez-Perera</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez-Moya</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Canaan-Haden-Ayala</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cabrales-Rico</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Espinosa-Rodr&#237;guez</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Ramos-G&#243;mez</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Andujar-Mart&#237;nez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>de la Iglesia</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Zamora-Sanchez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cruz-Sui</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lemos-P&#233;rez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cabrera-Herrera</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Valdes-Hern&#225;ndez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Martinez-Diaz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pimentel-Vazquez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ayala-Avila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guill&#233;n-Nieto</surname><given-names>G</given-names></string-name></person-group>. <year>2022</year>. <article-title>An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen</article-title>. <source>N Biotechnol</source><volume>72</volume>:<fpage>11</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nbt.2022.08.002</pub-id>.<pub-id pub-id-type="pmid">35953030</pub-id><pub-id pub-id-type="pmcid">PMC9359770</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hern&#225;ndez-Bernal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ricardo-Cobas</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;n-Bauta</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Navarro-Rodr&#237;guez</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Pi&#241;era-Mart&#237;nez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Quintana-Guerra</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Urrutia-P&#233;rez</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Urrutia-P&#233;rez</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ch&#225;vez-Chong</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Azor-Hern&#225;ndez</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Reinoso</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Lobaina-Lambert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Colina-&#193;vila</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bizet-Almeida</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Nuviola</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>del Valle-Pi&#241;era</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ram&#237;rez-Dom&#237;nguez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tablada-Ferreiro</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Alonso-Vald&#233;s</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lemos-P&#233;rez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guill&#233;n-Nieto</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Palenzuela-D&#237;az</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Noa-Romero</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Limonta-Fern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez-&#193;vila</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Ali-Mros</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>del Toro-Lahera</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Remedios-Reyes</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ayala-&#193;vila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Muzio-Gonz&#225;lez</surname><given-names>VL</given-names></string-name></person-group>. <year>2022</year>. <article-title>Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)</article-title>. <source>EClinicalMedicine</source><volume>46</volume>:<fpage>101383</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101383</pub-id>.<pub-id pub-id-type="pmid">35434578</pub-id><pub-id pub-id-type="pmcid">PMC8994669</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="webpage"><collab>Xinhuanet</collab>. <day>20</day><month>March</month><year>2021</year>. <article-title>Cuba&#8217;s Abdala COVID-19 vaccine enters phase 3 clinical trial</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm" ext-link-type="uri">http://www.xinhuanet.com/english/northamerica/2021-03/20/c_139823225.htm</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="book"><collab>Reuters</collab>. <day>22</day><month>June</month><year>2021</year>. <article-title>Cuba says Abdala vaccine 92.28% effective against coronavirus</article-title>. <publisher-name>Reuters</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-abdala-vaccine-9228-effective-against-coronavirus-2021-06-21/" ext-link-type="uri">https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-abdala-vaccine-9228-effective-against-coronavirus-2021-06-21/</ext-link>.</mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Hern&#225;ndez</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Le&#243;n</surname><given-names>RT</given-names></string-name></person-group>. <day>21</day><month>June</month><year>2021</year>. <article-title>Abdala, con tres dosis, tiene una eficacia de 92,28%</article-title>. <publisher-name>Granma</publisher-name>, <publisher-loc>Havana, Cuba</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.granma.cu/cuba/2021-06-21/abdala-con-tres-dosis-tiene-una-eficacia-de-9228-porciento-21-06-2021-21-06-01" ext-link-type="uri">https://www.granma.cu/cuba/2021-06-21/abdala-con-tres-dosis-tiene-una-eficacia-de-9228-porciento-21-06-2021-21-06-01</ext-link>. <date-in-citation content-type="access-date">Accessed 22 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="book"><collab>OnCuba Staff</collab>. <day>27</day><month>June</month><year>2021</year>. <article-title>How was the efficacy of the Cuban COVID-19 vaccine candidates calculated?</article-title><publisher-name>OnCubaNews English</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://oncubanews.com/en/cuba/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated/" ext-link-type="uri">https://oncubanews.com/en/cuba/how-was-the-efficacy-of-the-cuban-covid-19-vaccine-candidates-calculated/</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="webpage"><collab>CECMED</collab>. <day>9</day><month>July</month><year>2021</year>. <article-title>Aprueba el CECMED el Autorizo de Uso de Emergencia del candidato vacunal cubano ABDALA</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-candidato-vacunal-cubano-abdala" ext-link-type="uri">https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergencia-candidato-vacunal-cubano-abdala</ext-link>. <date-in-citation content-type="access-date">Accessed 22 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>L</given-names></string-name></person-group>. <day>23</day><month>December</month><year>2021</year>. <article-title>Cuba&#8217;s home-grown vaccines have massively cut covid-19 cases</article-title>. <publisher-name>New Scientist</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.newscientist.com/article/2303121-cubas-home-grown-vaccines-have-massively-cut-covid-19-cases" ext-link-type="uri">https://www.newscientist.com/article/2303121-cubas-home-grown-vaccines-have-massively-cut-covid-19-cases</ext-link>. <date-in-citation content-type="access-date">Accessed 13 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hern&#225;ndez-Bernal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ricardo-Cobas</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;n-Bauta</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Mart&#237;nez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Urrutia-P&#233;rez</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Urrutia-P&#233;rez</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Quintana-Guerra</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Navarro-Rodr&#237;guez</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Pi&#241;era-Mart&#237;nez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Reinoso</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Ch&#225;vez-Chong</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Baladr&#243;n-Castrillo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Melo-Su&#225;rez</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Batista-Izquierdo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pupo-Mic&#243;</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mora-Betancourt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Soler-Cano</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bizet-Almeida</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez-Rodr&#237;guez</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Lobaina-Lambert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vel&#225;zquez-P&#233;rez</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Soler-D&#237;az</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Blanco-Garrido</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Laurencio-Vallina</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Meri&#241;o-Hechavarr&#237;a</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Carmenaty-Campos</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rodr&#237;guez-Montero</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Limonta-Fern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Alonso-Vald&#233;s</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez-Rodr&#237;guez</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pimentel-V&#225;zquez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Catas&#250;s-&#193;lvarez</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Cabrera-N&#250;&#241;ez</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Ayala-&#193;vila</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Muzio-Gonz&#225;lez</surname><given-names>VL</given-names></string-name>, <collab>ABDALA Group of Investigators</collab></person-group>. <day>10</day><month>September</month><year>2022</year>. <article-title>A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 study)</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2022.09.08.22279690</pub-id>.</mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#225;s-Bermejo</surname><given-names>PI</given-names></string-name>, <string-name name-style="western"><surname>Dickinson-Meneses</surname><given-names>FO</given-names></string-name>, <string-name name-style="western"><surname>Almenares-Rodr&#237;guez</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>S&#225;nchez-Vald&#233;s</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Guinovart-D&#237;az</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Vidal-Ledo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Galb&#225;n-Garc&#237;a</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Olivera-Nodarse</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Morgado-Vega</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Due&#241;as-Carrera</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pujol</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hern&#225;ndez-Bernal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Limonta-Fern&#225;ndez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guill&#233;n-Nieto</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Muzio-Gonz&#225;lez</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Ayala-&#193;vila</surname><given-names>M</given-names></string-name></person-group>. <year>2022</year>. <article-title>Cuban Abdala vaccine: effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; a cohort study</article-title>. <source>Lancet Reg Health Am</source><volume>16</volume>:<fpage>100366</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.lana.2022.100366</pub-id>.<pub-id pub-id-type="pmid">36185968</pub-id><pub-id pub-id-type="pmcid">PMC9507841</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="book"><collab>Ministerio de Salud P&#250;blica de Cuba</collab>. <year>2023</year>. <article-title>Actualizaci&#243;n de la estrategia para el desarrollo de las vacunas cubanas</article-title>. <publisher-name>Ministerio de Salud P&#250;blica de Cuba</publisher-name>, <publisher-loc>Havana, Cuba</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/" ext-link-type="uri">https://salud.msp.gob.cu/actualizacion-de-la-vacunacion-en-el-marco-de-los-estudios-de-los-candidatos-vacunales-cubanos-y-la-intervencion-sanitaria/</ext-link>.</mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gorry</surname><given-names>C</given-names></string-name></person-group>. <year>2022</year>. <article-title>Vaccines and public trust: containing COVID-19 in Cuba. Verena Muzio-Gonz&#225;lez PhD DSc. Director of Clinical Research, Genetic Engineering and Biotechnology Center</article-title>. <source>MEDICC Rev</source><volume>24</volume>:<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.37757/MR2022.V24.N1.11</pub-id>.<pub-id pub-id-type="pmid">35157633</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <year>2021</year>. <article-title>Status of COVID-19 vaccines within WHO EUL/PQ evaluation process</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_12January2023.pdf" ext-link-type="uri">https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_12January2023.pdf</ext-link>.</mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>L</given-names></string-name></person-group>. <year>2022</year>. <article-title>Covid-19: Cuba will request WHO approval for homegrown vaccine</article-title>. <source>BMJ</source><volume>376</volume>:<fpage>o230</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.o230</pub-id>.<pub-id pub-id-type="pmid">35082133</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Serrano-Barrera</surname><given-names>OR</given-names></string-name>, <string-name name-style="western"><surname>Bello-Rodr&#237;guez</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Pupo-Rodr&#237;guez</surname><given-names>OL</given-names></string-name>, <string-name name-style="western"><surname>Robinson-Agramonte</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de los</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez</surname><given-names>O</given-names></string-name></person-group>. <year>2022</year>. <article-title>Variantes &#243;micron y delta de SARS-CoV-2 conservan ep&#237;topes presentes en vacunas cubanas anti-covid-19 Abdala y Soberana</article-title>. <source>Revista Electr&#243;nica Dr Zoilo E Marinello Vidaurreta</source><volume>47</volume>:<elocation-id>e299</elocation-id>.</mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="book"><collab>EFE</collab>. <day>13</day><month>October</month><year>2021</year>. <article-title>Cuba to apply booster doses of its COVID-19 vaccines</article-title>. <publisher-name>OnCubaNews English</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://oncubanews.com/en/coronavirus/cuba-to-apply-booster-doses-of-its-covid-19-vaccines/" ext-link-type="uri">https://oncubanews.com/en/coronavirus/cuba-to-apply-booster-doses-of-its-covid-19-vaccines/</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Meredith</surname><given-names>S</given-names></string-name></person-group>. <day>13</day><month>January</month><year>2022</year>. <article-title>Why Cuba&#8217;s extraordinary Covid vaccine success could provide the best hope for low-income countries</article-title>. <publisher-name>CNBC</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cnbc.com/2022/01/13/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html" ext-link-type="uri">https://www.cnbc.com/2022/01/13/why-cubas-extraordinary-covid-vaccine-success-could-provide-the-best-hope-for-the-global-south.html</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Frank</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sherwood</surname><given-names>D</given-names></string-name></person-group>. <day>29</day><month>December</month><year>2021</year>. <article-title>Cuba to fast-track boosters as Omicron looms</article-title>. <publisher-name>Reuters</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.reuters.com/world/americas/cuba-fast-track-boosters-omicron-looms-2021-12-29/" ext-link-type="uri">https://www.reuters.com/world/americas/cuba-fast-track-boosters-omicron-looms-2021-12-29/</ext-link>.</mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="webpage"><collab>Worldometer</collab>. <article-title>Cuba COVID. Coronavirus statistics</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.worldometers.info/coronavirus/country/cuba" ext-link-type="uri">https://www.worldometers.info/coronavirus/country/cuba</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>L</given-names></string-name></person-group>. <year>2021</year>. <article-title>Why Cuba developed its own covid vaccine&#8212;and what happened next</article-title>. <source>BMJ</source><volume>374</volume>:<fpage>n1912</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n1912</pub-id>.<pub-id pub-id-type="pmid">34353811</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duong</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>L</given-names></string-name></person-group>. <year>2022</year>. <article-title>Why is WHO pushing back on a Health Canada&#8211;approved Medicago SARS-CoV-2 vaccine?</article-title><source>CMAJ</source><volume>194</volume>:<fpage>E504</fpage>&#8211;<lpage>E505</lpage>. doi:<pub-id pub-id-type="doi">10.1503/cmaj.1095992</pub-id>.<pub-id pub-id-type="pmid">35379666</pub-id><pub-id pub-id-type="pmcid">PMC8985905</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="book"><collab>Medicago</collab>. <article-title>Covifenz&#174;</article-title>. <publisher-name>Medicago</publisher-name>, <publisher-loc>Quebec, Canada</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medicago.com/en/our-products/our-vaccines/covifenz-covid-19-vlp-vaccine/" ext-link-type="uri">https://medicago.com/en/our-products/our-vaccines/covifenz-covid-19-vlp-vaccine/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Makarkov</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>S&#233;guin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pillet</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tr&#233;panier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dhaliwall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Libman</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Vesikari</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>N</given-names></string-name></person-group>. <year>2020</year>. <article-title>Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18&#8211;64 years) and older adults (&#8805;65 years): two multicentre, randomised phase 3 trials</article-title>. <source>Lancet</source><volume>396</volume>:<fpage>1491</fpage>&#8211;<lpage>1503</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32014-6</pub-id>.<pub-id pub-id-type="pmid">33065035</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Gobeil</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>S&#233;guin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Atkins</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boulay</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Charbonneau</surname><given-names>P-Y</given-names></string-name>, <string-name name-style="western"><surname>Couture</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D&#8217;Aoust</surname><given-names>M-A</given-names></string-name>, <string-name name-style="western"><surname>Dhaliwall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Finkle</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hager</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mahmood</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Makarkov</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Pillet</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schimke</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>St-Martin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tr&#233;panier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>N</given-names></string-name></person-group>. <year>2021</year>. <article-title>Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19</article-title>. <source>Nat Med</source><volume>27</volume>:<fpage>1071</fpage>&#8211;<lpage>1078</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01370-1</pub-id>.<pub-id pub-id-type="pmid">34007070</pub-id><pub-id pub-id-type="pmcid">PMC8205852</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vaughn</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></string-name></person-group>. <year>2012</year>. <article-title>Development and evaluation of AS03, an adjuvant system containing &#945;-tocopherol and squalene in an oil-in-water emulsion</article-title>. <source>Expert Rev Vaccines</source><volume>11</volume>:<fpage>349</fpage>&#8211;<lpage>366</lpage>. doi:<pub-id pub-id-type="doi">10.1586/erv.11.192</pub-id>.<pub-id pub-id-type="pmid">22380826</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hager</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gobeil</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Heizer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Llapur</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Makarkov</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Vasconcellos</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pillet</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Riera</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Saxena</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Geller Wolff</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bhutada</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Aazami</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Polack</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Ferrara</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Atkins</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boulay</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dhaliwall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Charland</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Couture</surname><given-names>MMJ</given-names></string-name>, <string-name name-style="western"><surname>Jiang-Wright</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lapointe</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lorin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mahmood</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Moulton</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Pahmer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Parent</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>S&#233;guin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Breuer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ceregido</surname><given-names>M-A</given-names></string-name>, <string-name name-style="western"><surname>Koutsoukos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roman</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Namba</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>D'Aoust</surname><given-names>M-A</given-names></string-name>, <string-name name-style="western"><surname>Trepanier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kimura</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></string-name>, <collab>CoVLP Study Team</collab></person-group>. <year>2022</year>. <article-title>Efficacy and safety of a recombinant plant-based adjuvanted Covid-19 vaccine</article-title>. <source>N Engl J Med</source><volume>386</volume>:<fpage>2084</fpage>&#8211;<lpage>2096</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2201300</pub-id>.<pub-id pub-id-type="pmid">35507508</pub-id><pub-id pub-id-type="pmcid">PMC9127773</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="webpage"><collab>GSK</collab>. <day>24</day><month>February</month><year>2022</year>. <article-title>Medicago and GSK announce the approval by Health Canada of COVIFENZ, an adjuvanted plant-based COVID-19 vaccine</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz/" ext-link-type="uri">https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>D&#8217;Aoust</surname><given-names>M-A</given-names></string-name>, <string-name name-style="western"><surname>Lavoie</surname><given-names>P-O</given-names></string-name>, <string-name name-style="western"><surname>Couture</surname><given-names>MM-J</given-names></string-name>, <string-name name-style="western"><surname>Tr&#233;panier</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Guay</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Dargis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mongrand</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Landry</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>V&#233;zina</surname><given-names>L-P</given-names></string-name></person-group>. <year>2008</year>. <article-title>Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice</article-title>. <source>Plant Biotechnol J</source><volume>6</volume>:<fpage>930</fpage>&#8211;<lpage>940</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1467-7652.2008.00384.x</pub-id>.<pub-id pub-id-type="pmid">19076615</pub-id></mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dyer</surname><given-names>O</given-names></string-name></person-group>. <year>2022</year>. <article-title>Covid-19: WHO set to reject Canadian plant based vaccine because of links with tobacco industry</article-title>. <source>BMJ</source><volume>376</volume>:<fpage>o811</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.o811</pub-id>.<pub-id pub-id-type="pmid">35346968</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>H</given-names></string-name></person-group>. <year>2013</year>. <article-title>Plant-derived virus-like particles as vaccines</article-title>. <source>Hum Vaccin Immunother</source><volume>9</volume>:<fpage>26</fpage>&#8211;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.4161/hv.22218</pub-id>.<pub-id pub-id-type="pmid">22995837</pub-id><pub-id pub-id-type="pmcid">PMC3667944</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Lam</surname><given-names>P</given-names></string-name></person-group>. <day>29</day><month>December</month><year>2022</year>. <article-title>Big Tobacco&#8217;s divestment from Quebec&#8217;s Medicago &#8216;a step in the right direction&#8217; for its COVID vaccine</article-title>. <publisher-name>CBC News</publisher-name>, <publisher-loc>Toronto, Canada</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cbc.ca/news/health/philips-morris-divestment-medicago-1.6700103" ext-link-type="uri">https://www.cbc.ca/news/health/philips-morris-divestment-medicago-1.6700103</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="webpage"><collab>Government of Canada</collab>. <year>2022</year>. <article-title>COVID-19 vaccine: Canadian immunization guide</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html" ext-link-type="uri">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html</ext-link>. <date-in-citation content-type="access-date">Accessed 22 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="webpage"><collab>Medicago</collab>. <article-title>News releases</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medicago.com/en/news-releases/" ext-link-type="uri">https://medicago.com/en/news-releases/</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mohammadi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shayestehpour</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mirzaei</surname><given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines</article-title>. <source>Braz J Infect Dis</source><volume>25</volume>:<fpage>101606</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bjid.2021.101606</pub-id>.<pub-id pub-id-type="pmid">34428473</pub-id><pub-id pub-id-type="pmcid">PMC8367756</pub-id></mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Triccas</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kint</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wurm</surname><given-names>FM</given-names></string-name></person-group>. <year>2022</year>. <article-title>Affordable SARS-CoV-2 protein vaccines for the pandemic endgame</article-title>. <source>NPJ Vaccines</source><volume>7</volume>:<fpage>89</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41541-022-00507-8</pub-id>.<pub-id pub-id-type="pmid">35918346</pub-id><pub-id pub-id-type="pmcid">PMC9344252</pub-id></mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodr&#237;guez Mega</surname><given-names>E</given-names></string-name></person-group>. <year>2020</year>. <article-title>Latin American scientists join the coronavirus vaccine race: &#8216;No one&#8217;s coming to rescue us.&#8217;</article-title><source>Nature</source><volume>582</volume>:<fpage>470</fpage>&#8211;<lpage>471</lpage>. doi:<pub-id pub-id-type="doi">10.1038/d41586-020-01756-0</pub-id>.<pub-id pub-id-type="pmid">32576992</pub-id></mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rapaka</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Hammershaimb</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Neuzil</surname><given-names>KM</given-names></string-name></person-group>. <year>2022</year>. <article-title>Are some COVID-19 vaccines better than others? Interpreting and comparing estimates of efficacy in vaccine trials</article-title>. <source>Clin Infect Dis</source><volume>74</volume>:<fpage>352</fpage>&#8211;<lpage>358</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciab213</pub-id>.<pub-id pub-id-type="pmid">33693552</pub-id><pub-id pub-id-type="pmcid">PMC7989512</pub-id></mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mills</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Salisbury</surname><given-names>D</given-names></string-name></person-group>. <year>2021</year>. <article-title>The challenges of distributing COVID-19 vaccinations</article-title>. <source>EClinicalMedicine</source><volume>31</volume>:<fpage>100674</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100674</pub-id>.<pub-id pub-id-type="pmid">33319186</pub-id><pub-id pub-id-type="pmcid">PMC7725651</pub-id></mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Emanuel</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Persad</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kern</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Buchanan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fabre</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Halliday</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Herzog</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leland</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Lemango</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Luna</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>McCoy</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Norheim</surname><given-names>OF</given-names></string-name>, <string-name name-style="western"><surname>Ottersen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schaefer</surname><given-names>GO</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>K-C</given-names></string-name>, <string-name name-style="western"><surname>Wellman</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Wolff</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname><given-names>HS</given-names></string-name></person-group>. <year>2020</year>. <article-title>An ethical framework for global vaccine allocation</article-title>. <source>Science</source><volume>369</volume>:<fpage>1309</fpage>&#8211;<lpage>1312</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abe2803</pub-id>.<pub-id pub-id-type="pmid">32883884</pub-id><pub-id pub-id-type="pmcid">PMC8691258</pub-id></mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matrajt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Eaton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Leung</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>ER</given-names></string-name></person-group>. <year>2021</year>. <article-title>Vaccine optimization for COVID-19: who to vaccinate first?</article-title><source>Sci Adv</source><volume>7</volume>:<elocation-id>eabf1374</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/sciadv.abf1374</pub-id>.<pub-id pub-id-type="pmid">33536223</pub-id><pub-id pub-id-type="pmcid">PMC8128110</pub-id></mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathieu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ritchie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rod&#233;s-Guirao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Appel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Giattino</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hasell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Macdonald</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dattani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Beltekian</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ortiz-Ospina</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Roser</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>Coronavirus pandemic (COVID-19)</article-title>. <publisher-name>Our World in Data</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ourworldindata.org/coronavirus" ext-link-type="uri">https://ourworldindata.org/coronavirus</ext-link>.</mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Holder</surname><given-names>J</given-names></string-name></person-group>. <year>2021</year>. <article-title>Tracking coronavirus vaccinations around the world</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html" ext-link-type="uri">https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html</ext-link>.</mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Goodman</surname><given-names>PS</given-names></string-name></person-group>. <day>25</day><month>December</month><year>2020</year>. <article-title>One vaccine side effect: global economic inequality</article-title>. <publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/2020/12/25/business/coronavirus-vaccines-global-economy.html" ext-link-type="uri">https://www.nytimes.com/2020/12/25/business/coronavirus-vaccines-global-economy.html</ext-link>.</mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eccleston-Turner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Upton</surname><given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>International collaboration to ensure equitable access to vaccines for COVID-19: the ACT-Accelerator and the COVAX Facility</article-title>. <source>Milbank Q</source><volume>99</volume>:<fpage>426</fpage>&#8211;<lpage>449</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1468-0009.12503</pub-id>.<pub-id pub-id-type="pmid">33650737</pub-id><pub-id pub-id-type="pmcid">PMC8014072</pub-id></mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <day>9</day><month>September</month><year>2020</year>. <article-title>Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility" ext-link-type="uri">https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kupferschmidt</surname><given-names>K</given-names></string-name></person-group>. <year>2020</year>. <article-title>Global plan seeks to promote vaccine equity, spread risks</article-title>. <source>Science</source><volume>369</volume>:<fpage>489</fpage>&#8211;<lpage>490</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.369.6503.489</pub-id>.<pub-id pub-id-type="pmid">32732400</pub-id></mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Usher</surname><given-names>AD</given-names></string-name></person-group>. <year>2021</year>. <article-title>A beautiful idea: how COVAX has fallen short</article-title>. <source>Lancet</source><volume>397</volume>:<fpage>2322</fpage>&#8211;<lpage>2325</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)01367-2</pub-id>.<pub-id pub-id-type="pmid">34147145</pub-id><pub-id pub-id-type="pmcid">PMC8494620</pub-id></mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Twohey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>K</given-names></string-name></person-group>. <year>2020</year>. <article-title>With first dibs on vaccines, rich countries have &#8216;cleared the shelves.&#8217;</article-title><publisher-name>The New York Times</publisher-name>, <publisher-loc>New York, NY</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nytimes.com/2020/12/15/us/coronavirus-vaccine-doses-reserved.html" ext-link-type="uri">https://www.nytimes.com/2020/12/15/us/coronavirus-vaccine-doses-reserved.html</ext-link>.</mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Obinna</surname><given-names>DN</given-names></string-name></person-group>. <year>2022</year>. <article-title>Solidarity across borders: a pragmatic need for global COVID-19 vaccine equity</article-title>. <source>Int J Health Plann Manage</source><volume>37</volume>:<fpage>21</fpage>&#8211;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hpm.3341</pub-id>.<pub-id pub-id-type="pmid">34585430</pub-id><pub-id pub-id-type="pmcid">PMC8653338</pub-id></mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Mwai</surname><given-names>P</given-names></string-name></person-group>. <day>31</day><month>December</month><year>2021</year>. <article-title>Covid-19 vaccinations: African nations miss WHO target</article-title>. <publisher-name>BBC News</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bbc.com/news/56100076" ext-link-type="uri">https://www.bbc.com/news/56100076</ext-link>.</mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Herzog</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Norheim</surname><given-names>OF</given-names></string-name>, <string-name name-style="western"><surname>Emanuel</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>McCoy</surname><given-names>MS</given-names></string-name></person-group>. <year>2021</year>. <article-title>Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access</article-title>. <source>BMJ</source><volume>372</volume>:<fpage>m4853</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.m4853</pub-id>.<pub-id pub-id-type="pmid">33402340</pub-id></mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <article-title>COVAX. Working toward for global equitable access to COVID-19 vaccines</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/initiatives/act-accelerator/covax" ext-link-type="uri">https://www.who.int/initiatives/act-accelerator/covax</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="webpage">Gavi. <article-title>COVAX vaccine roll-out</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gavi.org/covax-vaccine-roll-out" ext-link-type="uri">https://www.gavi.org/covax-vaccine-roll-out</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Cohen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kupferschmidt</surname><given-names>K</given-names></string-name></person-group>. <day>9</day><month>March</month><year>2021</year>. <article-title>Countries now scrambling for COVID-19 vaccines may soon have surpluses to donate</article-title>. <publisher-name>American Association for the Advancement of Science (AAAS)</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.science.org/content/article/countries-now-scrambling-covid-19-vaccines-may-soon-have-surpluses-donate" ext-link-type="uri">https://www.science.org/content/article/countries-now-scrambling-covid-19-vaccines-may-soon-have-surpluses-donate</ext-link>.</mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bubar</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Reinholt</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kissler</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cobey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grad</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Larremore</surname><given-names>DB</given-names></string-name></person-group>. <year>2021</year>. <article-title>Model-informed COVID-19 vaccine prioritization strategies by age and serostatus</article-title>. <source>Science</source><volume>371</volume>:<fpage>916</fpage>&#8211;<lpage>921</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abe6959</pub-id>.<pub-id pub-id-type="pmid">33479118</pub-id><pub-id pub-id-type="pmcid">PMC7963218</pub-id></mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grauer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>L&#246;wen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liebchen</surname><given-names>B</given-names></string-name></person-group>. <year>2020</year>. <article-title>Strategic spatiotemporal vaccine distribution increases the survival rate in an infectious disease like Covid-19</article-title>. <source>Sci Rep</source><volume>10</volume>:<fpage>21594</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-78447-3</pub-id>.<pub-id pub-id-type="pmid">33299029</pub-id><pub-id pub-id-type="pmcid">PMC7726577</pub-id></mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Williams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Degeling</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McVernon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>How should we conduct pandemic vaccination?</article-title><source>Vaccine</source><volume>39</volume>:<fpage>994</fpage>&#8211;<lpage>999</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2020.12.059</pub-id>.<pub-id pub-id-type="pmid">33423839</pub-id><pub-id pub-id-type="pmcid">PMC7792561</pub-id></mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jecker</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Wightman</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Diekema</surname><given-names>DS</given-names></string-name></person-group>. <year>2021</year>. <article-title>Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines</article-title>. <source>J Med Ethics</source><volume>47</volume>:<fpage>308</fpage>&#8211;<lpage>317</lpage>. doi:<pub-id pub-id-type="doi">10.1136/medethics-2020-107036</pub-id>.<pub-id pub-id-type="pmid">33593876</pub-id></mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tran</surname><given-names>TN-A</given-names></string-name>, <string-name name-style="western"><surname>Wikle</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Inam</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Strong</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Brinda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Leighow</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hossain</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pritchard</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hanage</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Hanks</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Boni</surname><given-names>MF</given-names></string-name></person-group>. <day>15</day><month>January</month><year>2021</year>. <article-title>Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts</article-title>. <source>medRxiv</source>. doi:<pub-id pub-id-type="doi">10.1101/2021.01.12.21249694</pub-id>.<pub-id pub-id-type="pmcid">PMC8275456</pub-id><pub-id pub-id-type="pmid">34253200</pub-id></mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Ferran</surname><given-names>M</given-names></string-name></person-group>. <day>19</day><month>January</month><year>2022</year>. <article-title>CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally</article-title>. <publisher-name>The Conversation</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672" ext-link-type="uri">http://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker. Biological E Limited: Corbevax</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/54/" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/54/</ext-link>. <date-in-citation content-type="access-date">Retrieved 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>James</surname><given-names>ER</given-names></string-name></person-group>. <year>2021</year>. <article-title>Disrupting vaccine logistics</article-title>. <source>Int Health</source><volume>13</volume>:<fpage>211</fpage>&#8211;<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1093/inthealth/ihab010</pub-id>.<pub-id pub-id-type="pmid">33709112</pub-id><pub-id pub-id-type="pmcid">PMC8079314</pub-id></mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>AboulFotouh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>RO</given-names>, <suffix>III.</suffix></string-name></person-group><year>2021</year>. <article-title>Next-generation COVID-19 vaccines should take efficiency of distribution into consideration</article-title>. <source>AAPS PharmSciTech</source><volume>22</volume>:<fpage>126</fpage>. doi:<pub-id pub-id-type="doi">10.1208/s12249-021-01974-3</pub-id>.<pub-id pub-id-type="pmid">33835300</pub-id><pub-id pub-id-type="pmcid">PMC8034273</pub-id></mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Sguazzin</surname><given-names>A</given-names></string-name></person-group>. <day>3</day><month>January</month><year>2021</year>. <article-title>Africa left with few options for vaccines, South Africa says</article-title>. <publisher-name>Bloomberg</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bloomberg.com/news/articles/2021-01-03/pfizer-to-supply-african-health-care-workers-with-vaccines" ext-link-type="uri">https://www.bloomberg.com/news/articles/2021-01-03/pfizer-to-supply-african-health-care-workers-with-vaccines</ext-link>. <date-in-citation content-type="access-date">Accessed 13 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="webpage"><collab>UNICEF</collab>. <article-title>COVAX: ensuring global equitable access to COVID-19 vaccines</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines" ext-link-type="uri">https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bajaj</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Maki</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Stanford</surname><given-names>FC</given-names></string-name></person-group>. <year>2022</year>. <article-title>Vaccine apartheid: global cooperation and equity</article-title>. <source>Lancet</source><volume>399</volume>:<fpage>1452</fpage>&#8211;<lpage>1453</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(22)00328-2</pub-id>.<pub-id pub-id-type="pmid">35218695</pub-id><pub-id pub-id-type="pmcid">PMC8865875</pub-id></mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sparke</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>O</given-names></string-name></person-group>. <year>2022</year>. <article-title>Competing responses to global inequalities in access to COVID vaccines: vaccine diplomacy and vaccine charity versus vaccine liberty</article-title>. <source>Clin Infect Dis</source><volume>75</volume>:<fpage>S86</fpage>&#8211;<lpage>S92</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciac361</pub-id>.<pub-id pub-id-type="pmid">35535787</pub-id><pub-id pub-id-type="pmcid">PMC9376271</pub-id></mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grenfell</surname><given-names>RFQ</given-names></string-name>, <string-name name-style="western"><surname>Oyeyemi</surname><given-names>OT</given-names></string-name></person-group>. <day>29</day><month>June</month><year>2022</year>. <article-title>Access to COVID-19 vaccines and testing in Africa: the importance of COVAX&#8212;Nigeria as a case study</article-title>. <source>Pathog Glob Health</source> doi:<pub-id pub-id-type="doi">10.1080/20477724.2022.2091862</pub-id>.<pub-id pub-id-type="pmcid">PMC9970234</pub-id><pub-id pub-id-type="pmid">35770309</pub-id></mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Taylor</surname><given-names>A</given-names></string-name></person-group>. <day>10</day><month>December</month><year>2021</year>. <article-title>Covax promised 2 billion vaccine doses to help the world&#8217;s neediest in 2021. It won&#8217;t deliver even half that</article-title>. <publisher-name>Washington Post</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.washingtonpost.com/world/2021/12/10/covax-doses-delivered/" ext-link-type="uri">https://www.washingtonpost.com/world/2021/12/10/covax-doses-delivered/</ext-link>.</mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <article-title>Ten threats to global health in 2019</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019" ext-link-type="uri">https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Hamel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kirzinger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lopes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kearney</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sparks</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Brodie</surname><given-names>M</given-names></string-name></person-group>. <day>22</day><month>January</month><year>2021</year>. <article-title>KFF COVID-19 vaccine monitor: January 2021</article-title>. <publisher-name>KFF</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-january-2021/" ext-link-type="uri">https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-january-2021/</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosenbaum</surname><given-names>L</given-names></string-name></person-group>. <year>2021</year>. <article-title>Escaping catch-22&#8212;overcoming Covid vaccine hesitancy</article-title>. <source>N Engl J Med</source><volume>384</volume>:<fpage>1367</fpage>&#8211;<lpage>1371</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMms2101220</pub-id>.<pub-id pub-id-type="pmid">33577150</pub-id></mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Unroe</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rusyniak</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Blackburn</surname><given-names>J</given-names></string-name></person-group>. <year>2021</year>. <article-title>Willingness of long-term care staff to receive a COVID-19 vaccine: a single state survey</article-title>. <source>J Am Geriatr Soc</source><volume>69</volume>:<fpage>593</fpage>&#8211;<lpage>599</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jgs.17022</pub-id>.<pub-id pub-id-type="pmid">33370448</pub-id></mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ruiz</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>RA</given-names></string-name></person-group>. <year>2022</year>. <article-title>Parental COVID-19 vaccine hesitancy in the United States</article-title>. <source>Public Health Rep</source><volume>137</volume>:<fpage>1162</fpage>&#8211;<lpage>1169</lpage>. doi:<pub-id pub-id-type="doi">10.1177/00333549221114346</pub-id>.<pub-id pub-id-type="pmid">35915993</pub-id><pub-id pub-id-type="pmcid">PMC9574308</pub-id></mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>C&#233;nat</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Noorishad</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moshirian Farahi</surname><given-names>SMM</given-names></string-name>, <string-name name-style="western"><surname>Darius</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Mesbahi El Aouame</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Onesi</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Broussard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Furyk</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Yaya</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Caulley</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Chomienne</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Etowa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Labelle</surname><given-names>PR</given-names></string-name></person-group>. <year>2022</year>. <article-title>Prevalence and factors related to COVID-19 vaccine hesitancy and unwillingness in Canada: a systematic review and meta-analysis</article-title>. <source>J Med Virol</source><volume>95</volume>:<elocation-id>e28156</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/jmv.28156</pub-id>.<pub-id pub-id-type="pmid">36114154</pub-id><pub-id pub-id-type="pmcid">PMC9538578</pub-id></mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Steinert</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Sternberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Prince</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fasolo</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Galizzi</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>B&#252;the</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Veltri</surname><given-names>GA</given-names></string-name></person-group>. <year>2022</year>. <article-title>COVID-19 vaccine hesitancy in eight European countries: prevalence, determinants, and heterogeneity</article-title>. <source>Sci Adv</source><volume>8</volume>:<elocation-id>eabm9825</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/sciadv.abm9825</pub-id>.<pub-id pub-id-type="pmid">35476432</pub-id><pub-id pub-id-type="pmcid">PMC9045608</pub-id></mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ackah</surname><given-names>BBB</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stallwood</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fazal</surname><given-names>ZA</given-names></string-name>, <string-name name-style="western"><surname>Okpani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ukah</surname><given-names>UV</given-names></string-name>, <string-name name-style="western"><surname>Adu</surname><given-names>PA</given-names></string-name></person-group>. <year>2022</year>. <article-title>COVID-19 vaccine hesitancy in Africa: a scoping review</article-title>. <source>Glob Health Res Policy</source><volume>7</volume>:<fpage>21</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s41256-022-00255-1</pub-id>.<pub-id pub-id-type="pmid">35850783</pub-id><pub-id pub-id-type="pmcid">PMC9294808</pub-id></mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Harapan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Anwar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yufika</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sharun</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gachabayov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fahriani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Husnah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Raad</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Abdalla</surname><given-names>RY</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>RY</given-names></string-name>, <string-name name-style="western"><surname>Khiri</surname><given-names>NME</given-names></string-name>, <string-name name-style="western"><surname>Ismaeil</surname><given-names>MIH</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Kacem</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Dahman</surname><given-names>NBH</given-names></string-name>, <string-name name-style="western"><surname>Teyeb</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Aloui</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hafsi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferjani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Deeb</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Emad</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Monib</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Sami</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Subramaniam</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Panchawagh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Anandu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Haque</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Ferreto</surname><given-names>LED</given-names></string-name>, <string-name name-style="western"><surname>Briones</surname><given-names>MFC</given-names></string-name>, <string-name name-style="western"><surname>Morales</surname><given-names>RBI</given-names></string-name>, <string-name name-style="western"><surname>D&#237;az</surname><given-names>SAL</given-names></string-name>, <string-name name-style="western"><surname>Aburto</surname><given-names>JTO</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>JET</given-names></string-name>, <string-name name-style="western"><surname>Balogun</surname><given-names>EO</given-names></string-name>, <string-name name-style="western"><surname>Enitan</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Yomi</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Durosinmi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ezigbo</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Adejumo</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Babadi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kakemam</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Malik</surname><given-names>NI</given-names></string-name>, <string-name name-style="western"><surname>Ullah</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Rosiello</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Emran</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Wendt</surname><given-names>GW</given-names></string-name>, <string-name name-style="western"><surname>Arab-Zozani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Mudatsir</surname><given-names>M</given-names></string-name></person-group>. <year>2022</year>. <article-title>Vaccine hesitancy among communities in ten countries in Asia, Africa, and South America during the COVID-19 pandemic</article-title>. <source>Pathog Glob Health</source><volume>116</volume>:<fpage>236</fpage>&#8211;<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1080/20477724.2021.2011580</pub-id>.<pub-id pub-id-type="pmid">34928187</pub-id><pub-id pub-id-type="pmcid">PMC9132408</pub-id></mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dereje</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tesfaye</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tamene</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Alemeshet</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Abe</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tesfa</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gedion</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Biruk</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lakew</surname><given-names>Y</given-names></string-name></person-group>. <year>2022</year>. <article-title>COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: a mixed-method study</article-title>. <source>BMJ Open</source><volume>12</volume>:<elocation-id>e052432</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2021-052432</pub-id>.<pub-id pub-id-type="pmcid">PMC9152622</pub-id><pub-id pub-id-type="pmid">35636790</pub-id></mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rathje</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Roozenbeek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Van Bavel</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>van der Linden</surname><given-names>S</given-names></string-name></person-group>. <year>2022</year>. <article-title>Social media behavior is associated with vaccine hesitancy</article-title>. <source>PNAS Nexus</source><volume>1</volume>:<fpage>pgac207</fpage>. doi:<pub-id pub-id-type="doi">10.1093/pnasnexus/pgac207</pub-id>.<pub-id pub-id-type="pmid">36714849</pub-id><pub-id pub-id-type="pmcid">PMC9802475</pub-id></mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pertwee</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Simas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Larson</surname><given-names>HJ</given-names></string-name></person-group>. <year>2022</year>. <article-title>An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy</article-title>. <source>Nat Med</source><volume>28</volume>:<fpage>456</fpage>&#8211;<lpage>459</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-01728-z</pub-id>.<pub-id pub-id-type="pmid">35273403</pub-id></mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>JWJ</given-names></string-name>, <string-name name-style="western"><surname>Vaithilingam</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nair</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>L-A</given-names></string-name>, <string-name name-style="western"><surname>Musa</surname><given-names>KI</given-names></string-name></person-group>. <year>2022</year>. <article-title>Key predictors of COVID-19 vaccine hesitancy in Malaysia: an integrated framework</article-title>. <source>PLoS One</source><volume>17</volume>:<elocation-id>e0268926</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0268926</pub-id>.<pub-id pub-id-type="pmid">35604921</pub-id><pub-id pub-id-type="pmcid">PMC9126375</pub-id></mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schernhammer</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Weitzer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Laubichler</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Birmann</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Bertau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zenk</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Caniglia</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>J&#228;ger</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Steiner</surname><given-names>G</given-names></string-name></person-group>. <year>2022</year>. <article-title>Correlates of COVID-19 vaccine hesitancy in Austria: trust and the government</article-title>. <source>J Public Health (Oxf)</source><volume>44</volume>:<fpage>e106</fpage>&#8211;<lpage>e116</lpage>. doi:<pub-id pub-id-type="doi">10.1093/pubmed/fdab122</pub-id>.<pub-id pub-id-type="pmid">33948665</pub-id><pub-id pub-id-type="pmcid">PMC8135852</pub-id></mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Head</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Kasting</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Sturm</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Hartsock</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Zimet</surname><given-names>GD</given-names></string-name></person-group>. <year>2020</year>. <article-title>A national survey assessing SARS-CoV-2 vaccination intentions: implications for future public health communication efforts</article-title>. <source>Sci Commun</source><volume>42</volume>:<fpage>698</fpage>&#8211;<lpage>723</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1075547020960463</pub-id>.<pub-id pub-id-type="pmcid">PMC7520657</pub-id><pub-id pub-id-type="pmid">38602991</pub-id></mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salmon</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Opel</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Dudley</surname><given-names>MZ</given-names></string-name>, <string-name name-style="western"><surname>Brewer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Breiman</surname><given-names>R</given-names></string-name></person-group>. <year>2021</year>. <article-title>Reflections on governance, communication, and equity: challenges and opportunities in COVID-19 vaccination</article-title>. <source>Health Aff (Millwood)</source><volume>40</volume>:<fpage>419</fpage>&#8211;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2020.02254</pub-id>.<pub-id pub-id-type="pmid">33539178</pub-id></mixed-citation></ref><ref id="B294"><label>294</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anand</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Stahel</surname><given-names>VP</given-names></string-name></person-group>. <year>2021</year>. <article-title>The safety of Covid-19 mRNA vaccines: a review</article-title>. <source>Patient Saf Surg</source><volume>15</volume>:<fpage>20</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13037-021-00291-9</pub-id>.<pub-id pub-id-type="pmid">33933145</pub-id><pub-id pub-id-type="pmcid">PMC8087878</pub-id></mixed-citation></ref><ref id="B295"><label>295</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Salmon</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Dudley</surname><given-names>MZ</given-names></string-name>, <string-name name-style="western"><surname>Glanz</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Omer</surname><given-names>SB</given-names></string-name></person-group>. <year>2015</year>. <article-title>Vaccine hesitancy: causes, consequences, and a call to action</article-title>. <source>Vaccine</source><volume>33</volume>:<fpage>D66</fpage>&#8211;<lpage>D71</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.035</pub-id>.<pub-id pub-id-type="pmid">26615171</pub-id></mixed-citation></ref><ref id="B296"><label>296</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jacobson</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>St Sauver</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Finney Rutten</surname><given-names>LJ</given-names></string-name></person-group>. <year>2015</year>. <article-title>Vaccine hesitancy</article-title>. <source>Mayo Clin Proc</source><volume>90</volume>:<fpage>1562</fpage>&#8211;<lpage>1568</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mayocp.2015.09.006</pub-id>.<pub-id pub-id-type="pmid">26541249</pub-id></mixed-citation></ref><ref id="B297"><label>297</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Berg</surname><given-names>S</given-names></string-name></person-group>. <day>20</day><month>July</month><year>2022</year>. <article-title>What sets apart Novavax option from other COVID-19 vaccines</article-title>. <publisher-name>American Medical Association</publisher-name>, <publisher-loc>Philadelphia, PA</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ama-assn.org/delivering-care/public-health/what-sets-apart-novavax-option-other-covid-19-vaccines" ext-link-type="uri">https://www.ama-assn.org/delivering-care/public-health/what-sets-apart-novavax-option-other-covid-19-vaccines</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B298"><label>298</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Berman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rupp</surname><given-names>R</given-names></string-name></person-group>. <day>3</day><month>August</month><year>2022</year>. <article-title>Novavax COVID vaccine is for those hesitant to get vaccinated</article-title>. <publisher-name>The Daily News</publisher-name>, <publisher-loc>Galveston, TX</publisher-loc>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.galvnews.com/health/free/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html" ext-link-type="uri">https://www.galvnews.com/health/free/novavax-covid-vaccine-is-for-those-hesitant-to-get-vaccinated/article_8ddebef4-1db0-579a-b0d2-852f2031d881.html</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B299"><label>299</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rubin</surname><given-names>R</given-names></string-name></person-group>. <year>2022</year>. <article-title>Despite its fan base, newly authorized &#8220;traditional&#8221; Novavax COVID-19 vaccine is having trouble gaining a foothold in the US</article-title>. <source>JAMA</source><volume>328</volume>:<fpage>1026</fpage>&#8211;<lpage>1028</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.13661</pub-id>.<pub-id pub-id-type="pmid">36001324</pub-id></mixed-citation></ref><ref id="B300"><label>300</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Constantino</surname><given-names>AK</given-names></string-name></person-group>. <day>15</day><month>July</month><year>2022</year>. <article-title>Novavax&#8217;s new Covid vaccine is perfect for people scared of mRNA tech&#8212;but it won&#8217;t win over the unvaccinated</article-title>. <publisher-name>CNBC</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cnbc.com/2022/07/15/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html" ext-link-type="uri">https://www.cnbc.com/2022/07/15/why-new-novavax-covid-vaccine-wont-win-over-unvaccinated-americans.html</ext-link>. <date-in-citation content-type="access-date">Accessed 16 January 2023</date-in-citation>.</mixed-citation></ref><ref id="B301"><label>301</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Bergeri</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Bresee</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Cowling</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Crowcroft</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Fahmy</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hirve</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Katz</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Lanata</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>L&#8217;Azou Jackson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mwenda</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Nogareda</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Orenstein</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Ortiz</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Pebody</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schrag</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>PG</given-names></string-name>, <string-name name-style="western"><surname>Srikantiah</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Subissi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Valenciano</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vaughn</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Verani</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Wilder-Smith</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Feikin</surname><given-names>DR</given-names></string-name></person-group>. <year>2021</year>. <article-title>Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization</article-title>. <source>Vaccine</source><volume>39</volume>:<fpage>4013</fpage>&#8211;<lpage>4024</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.099</pub-id>.<pub-id pub-id-type="pmid">34119350</pub-id><pub-id pub-id-type="pmcid">PMC8166525</pub-id></mixed-citation></ref><ref id="B302"><label>302</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name></person-group>. <year>2005</year>. <article-title>SARS vaccine development</article-title>. <source>Emerg Infect Dis</source><volume>11</volume>:<fpage>1016</fpage>&#8211;<lpage>1020</lpage>. doi:<pub-id pub-id-type="doi">10.3201/1107.050219</pub-id>.<pub-id pub-id-type="pmid">16022774</pub-id><pub-id pub-id-type="pmcid">PMC3371787</pub-id></mixed-citation></ref><ref id="B303"><label>303</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Graham</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Donaldson</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Baric</surname><given-names>RS</given-names></string-name></person-group>. <year>2013</year>. <article-title>A decade after SARS: strategies for controlling emerging coronaviruses</article-title>. <source>Nat Rev Microbiol</source><volume>11</volume>:<fpage>836</fpage>&#8211;<lpage>848</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro3143</pub-id>.<pub-id pub-id-type="pmid">24217413</pub-id><pub-id pub-id-type="pmcid">PMC5147543</pub-id></mixed-citation></ref><ref id="B304"><label>304</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lurie</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Saville</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Halton</surname><given-names>J</given-names></string-name></person-group>. <year>2020</year>. <article-title>Developing Covid-19 vaccines at pandemic speed</article-title>. <source>N Engl J Med</source><volume>382</volume>:<fpage>1969</fpage>&#8211;<lpage>1973</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id>.<pub-id pub-id-type="pmid">32227757</pub-id></mixed-citation></ref><ref id="B305"><label>305</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maslow</surname><given-names>JN</given-names></string-name></person-group>. <year>2017</year>. <article-title>Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus</article-title>. <source>Hum Vaccin Immunother</source><volume>13</volume>:<fpage>2918</fpage>&#8211;<lpage>2930</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2017.1358325</pub-id>.<pub-id pub-id-type="pmid">28846484</pub-id><pub-id pub-id-type="pmcid">PMC5718785</pub-id></mixed-citation></ref><ref id="B306"><label>306</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Jordahl</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Van Den Bossche</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fleischmann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McBride</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wasserman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Badaracco</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Gerard</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Snow</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Tratner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Farmer</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hjelle</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Cochran</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gillies</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Culbertson</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bartos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Caria</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Taves</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eubank</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sangarshanan</surname></string-name>, <string-name name-style="western"><surname>Flavin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Richards</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Maxalbert</surname></string-name>, <string-name name-style="western"><surname>Bilogur</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Arribas-Bel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mesejo-Le&#243;n</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wasser</surname><given-names>L</given-names></string-name></person-group>. <day>16</day><month>October</month><year>2021</year>. <article-title>geopandas/geopandas: v0.10.2</article-title>. <publisher-name>Zenodo</publisher-name>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/gqkzpv" ext-link-type="uri">https://doi.org/gqkzpv</ext-link>.</mixed-citation></ref><ref id="B307"><label>307</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Kibirige</surname><given-names>H</given-names></string-name></person-group>. <year>2022</year>. <article-title>plotnine</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/has2k1/plotnine" ext-link-type="uri">https://github.com/has2k1/plotnine</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B308"><label>308</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name name-style="western"><surname>Wickham</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Henry</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pedersen</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wilke</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yutani</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dunnington</surname><given-names>D</given-names></string-name>, <collab>R Studio</collab></person-group>. <article-title>Smoothed conditional means&#8212;geom_smooth</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ggplot2.tidyverse.org/reference/geom_smooth.html" ext-link-type="uri">https://ggplot2.tidyverse.org/reference/geom_smooth.html</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B309"><label>309</label><mixed-citation publication-type="webpage"><collab>Our World in Data</collab>. <year>2022</year>. <article-title>COVID-19 dataset by Our World in Data</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/owid/covid-19-data/blob/9e0b8314da28f155a88bbaf7617390c01c1c26da/public/data/vaccinations/locations.csv" ext-link-type="uri">https://github.com/owid/covid-19-data/blob/9e0b8314da28f155a88bbaf7617390c01c1c26da/public/data/vaccinations/locations.csv</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B310"><label>310</label><mixed-citation publication-type="webpage"><collab>VIPER Group COVID19 Vaccine Tracker Team</collab>. <article-title>COVID19 Vaccine Tracker. Types of vaccines</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/types-of-vaccines/" ext-link-type="uri">https://covid19.trackvaccines.org/types-of-vaccines/</ext-link>. <date-in-citation content-type="access-date">Accessed 5 December 2022</date-in-citation>.</mixed-citation></ref><ref id="B311"><label>311</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dong</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gardner</surname><given-names>L</given-names></string-name></person-group>. <year>2020</year>. <article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title>. <source>Lancet Infect Dis</source><volume>20</volume>:<fpage>533</fpage>&#8211;<lpage>534</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30120-1</pub-id>.<pub-id pub-id-type="pmid">32087114</pub-id><pub-id pub-id-type="pmcid">PMC7159018</pub-id></mixed-citation></ref><ref id="B312"><label>312</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Omma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Batirel</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Aydin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yilmaz Karadag</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Erden</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kucuksahin</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Armagan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>G&#252;ven</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Karakas</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Gokdemir</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Altunal</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Buber</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Gemcioglu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zengin</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Inan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Sahiner</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Korukluoglu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sezer</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ozdarendeli</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ates</surname><given-names>I</given-names></string-name></person-group>. <year>2022</year>. <article-title>Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in T&#252;rkiye: a randomized trial</article-title>. <source>Hum Vaccin Immunother</source><volume>18</volume>:<fpage>2122503</fpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2022.2122503</pub-id>.<pub-id pub-id-type="pmid">36315843</pub-id><pub-id pub-id-type="pmcid">PMC9746394</pub-id></mixed-citation></ref><ref id="B313"><label>313</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hamidi Farahani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Basiri</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Karimi RahJerdi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sheidaei</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gohari</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rahimi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gholami</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Moradi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ghafoori Naeeni</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Saffar</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Ghasemi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barati</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Moradi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Monazah</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pouranvari</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Forooghizadeh</surname><given-names>M</given-names></string-name></person-group>. <year>2022</year>. <article-title>Comparison of the safety and immunogenicity of FAKHRAVAC and BBIBP-CorV vaccines when administrated as booster dose: a parallel two arms, randomized, double blind clinical trial</article-title>. <source>Vaccines</source><volume>10</volume>:<fpage>1800</fpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines10111800</pub-id>.<pub-id pub-id-type="pmid">36366308</pub-id><pub-id pub-id-type="pmcid">PMC9695457</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>